


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:52:13Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406204" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406204</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" id="c733542758" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Chem</journal-id><journal-id journal-id-type="iso-abbrev">J Med Chem</journal-id><journal-id journal-id-type="pmc-domain-id">822</journal-id><journal-id journal-id-type="pmc-domain">acssd</journal-id><journal-id journal-id-type="publisher-id">jm</journal-id><journal-title-group><journal-title>Journal of Medicinal Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0022-2623</issn><issn pub-type="epub">1520-4804</issn><self-uri>pubs.acs.org/jmc</self-uri><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>ACS AuthorChoice</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406204</article-id><article-id pub-id-type="pmcid-ver">PMC12406204.1</article-id><article-id pub-id-type="pmcaid">12406204</article-id><article-id pub-id-type="pmcaiid">12406204</article-id><article-id pub-id-type="pmid">40796509</article-id><article-id pub-id-type="doi">10.1021/acs.jmedchem.5c00604</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Conformational
Restriction of Designer Drugs Reveals
Subtype-Selective and Biased CB<sub>2</sub> Agonists with Neuroprotective
Effects</article-title></title-group><contrib-group id="CONTRIB-GROUP-d14e25-autogenerated"><contrib id="ath1" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5630850</contrib-id><name name-style="western"><surname>Gio&#233;-Gallo</surname><given-names initials="C">Claudia</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath2" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7503473</contrib-id><name name-style="western"><surname>Ortigueira</surname><given-names initials="S">Sandra</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath3" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">4966033</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2539-3106</contrib-id><name name-style="western"><surname>Prieto-D&#237;az</surname><given-names initials="R">Rub&#233;n</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath4" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1754113</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0713-3151</contrib-id><name name-style="western"><surname>Contino</surname><given-names initials="M">Marialessandra</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath5" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2423617</contrib-id><name name-style="western"><surname>Azuaje</surname><given-names initials="J">Jhonny</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath6" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">521637</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4195-5228</contrib-id><name name-style="western"><surname>Perrone</surname><given-names initials="MG">Maria Grazia</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath7" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">131103</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9787-4836</contrib-id><name name-style="western"><surname>Riganti</surname><given-names initials="C">Chiara</given-names></name><xref rid="aff3" ref-type="aff"/></contrib><contrib id="ath8" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2071824</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9475-9602</contrib-id><name name-style="western"><surname>Alberga</surname><given-names initials="D">Domenico</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath9" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2572754</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4042-2841</contrib-id><name name-style="western"><surname>Mangiatordi</surname><given-names initials="GF">Giuseppe Felice</given-names></name><xref rid="aff4" ref-type="aff"/></contrib><contrib id="ath10" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6253978</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9922-3543</contrib-id><name name-style="western"><surname>And&#250;jar-Arias</surname><given-names initials="A">Antonio</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath11" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5853050</contrib-id><name name-style="western"><surname>Garc&#237;a-Rey</surname><given-names initials="A">Aitor</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath12" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6265802</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5575-3240</contrib-id><name name-style="western"><surname>Graziano</surname><given-names initials="G">Giovanni</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath13" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">2314214</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9430-7972</contrib-id><name name-style="western"><surname>Stefanachi</surname><given-names initials="A">Angela</given-names></name><xref rid="aff2" ref-type="aff"/></contrib><contrib id="ath14" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5258121</contrib-id><name name-style="western"><surname>Val</surname><given-names initials="C">Cristina</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath15" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">5388039</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1595-3459</contrib-id><name name-style="western"><surname>Mart&#237;nez</surname><given-names initials="AL">Ant&#243;n Leandro</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath16" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7503484</contrib-id><name name-style="western"><surname>Rebassa</surname><given-names initials="JB">Joan Biel</given-names></name><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath17" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7503491</contrib-id><name name-style="western"><surname>Reza</surname><given-names initials="D">David</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath18" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7705523</contrib-id><name name-style="western"><surname>Selas</surname><given-names initials="A">Asier</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath19" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">6607677</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-3921-7597</contrib-id><name name-style="western"><surname>Francavilla</surname><given-names initials="F">Fabio</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath20" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">250296</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0095-3931</contrib-id><name name-style="western"><surname>Paleo</surname><given-names initials="MR">M. Rita</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath21" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1985268</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5218-6351</contrib-id><name name-style="western"><surname>Garc&#237;a-Mera</surname><given-names initials="X">Xerardo</given-names></name><xref rid="aff1" ref-type="aff"/></contrib><contrib id="ath22" contrib-type="author"><contrib-id contrib-id-type="paragon-plus" authenticated="true">370435</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4730-0863</contrib-id><name name-style="western"><surname>Loza</surname><given-names initials="MI">M. Isabel</given-names></name><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath23" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">7503486</contrib-id><name name-style="western"><surname>Navarro</surname><given-names initials="G">Gemma</given-names></name><xref rid="cor1" ref-type="corresp"/><xref rid="aff6" ref-type="aff"/></contrib><contrib id="ath24" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">1043626</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5523-1979</contrib-id><name name-style="western"><surname>Brea</surname><given-names initials="J">Jos&#233;</given-names></name><xref rid="cor2" ref-type="corresp"/><xref rid="aff5" ref-type="aff"/></contrib><contrib id="ath25" contrib-type="author" corresp="yes"><contrib-id contrib-id-type="paragon-plus" authenticated="true">248501</contrib-id><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5571-2812</contrib-id><name name-style="western"><surname>Sotelo</surname><given-names initials="E">Eddy</given-names></name><xref rid="cor3" ref-type="corresp"/><xref rid="aff1" ref-type="aff"/></contrib><aff id="aff1">
<label>&#8224;</label>
<institution content-type="dept">Centro
Singular de Investigaci&#243;n en Qu&#237;mica Biol&#243;xica
y Materiais Moleculares (CIQUS)</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">16780</institution-id><institution>Universidade
de Santiago de Compostela</institution></institution-wrap>, <postal-code>15782</postal-code>
<city>Santiago de Compostela</city>, <country country="ES">Spain</country>
</aff><aff id="aff2">
<label>&#8225;</label>
<institution content-type="dept">Dipartimento
di Farmacia-Scienze del Farmaco</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9295</institution-id><institution>Universit&#224;
degli Studi di Bari ALDO MORO</institution></institution-wrap>, <addr-line>via Orabona 4</addr-line>, <postal-code>70125</postal-code>
<city>Bari</city>, <country country="IT">Italy</country>
</aff><aff id="aff3">
<label>&#167;</label>
<institution content-type="dept">Dipartimento
di Oncologia</institution>, <institution-wrap><institution-id institution-id-type="Ringgold" specific-use="source:pplus">9314</institution-id><institution>Universit&#224; degli Studi
di Torino</institution></institution-wrap>, <addr-line>piazza Nizza 44</addr-line>, <postal-code>10126</postal-code>
<city>Torino</city>, <country country="IT">Italy</country>
</aff><aff id="aff4">
<label>&#8741;</label>
<institution>CNR
&#8722; Institute of Crystallography</institution>, <addr-line>Via Giovanni Amendola, 122/O</addr-line>, <postal-code>70126</postal-code>
<city>Bari</city>, <country country="IT">Italy</country>
</aff><aff id="aff5">
<label>&#8869;</label>
<institution content-type="dept">Centro
Singular de Investigaci&#243;n en Medicina Molecular y Enfermedades
Cr&#243;nicas (CIMUS)</institution>, <institution>Universidade de
Santiago de Compostela</institution>, <postal-code>15782</postal-code>
<city>Santiago de Compostela</city>, <country country="ES">Spain</country>
</aff><aff id="aff6">
<label>#</label>
<institution content-type="dept">Department
of Biochemistry and Physiology, School of Pharmacy and Food Science</institution>, <institution>Universitat de Barcelona, Institut de Neurosci&#232;ncies
UB</institution>, <city>Barcelona</city>
<postal-code>08028</postal-code>, <country country="ES">Spain</country>
</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>Email: <email>g.navarro@ub.edu</email>, Phone: <phone>+34 934024505</phone>.</corresp><corresp id="cor2"><label>*</label>Email: <email>pepo.brea@usc.es</email>, Phone: <phone>+34 881815459</phone>.</corresp><corresp id="cor3"><label>*</label>Email: <email>e.sotelo@usc.es</email>, Phone: <phone>+34 881815732</phone>.</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>12</day><month>8</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><day>28</day><month>8</month><year>2025</year></pub-date><volume>68</volume><issue>16</issue><issue-id pub-id-type="pmc-issue-id">496131</issue-id><fpage>17103</fpage><lpage>17129</lpage><history><date date-type="received"><day>28</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>08</day><month>8</month><year>2025</year></date><date date-type="rev-recd"><day>06</day><month>8</month><year>2025</year></date><date date-type="online"><day>12</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 00:25:59.930"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Authors. Published by American Chemical Society</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Authors</copyright-holder><ali:free_to_read content-type="AuthorChoicev2" start_date="2025-08-12"/><license><ali:license_ref specific-use="textmining" content-type="ccbylicense" start_date="2025-08-12">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is licensed under CC-BY 4.0</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="jm5c00604.pdf"/><abstract><p>This study presents the design, synthesis, and characterization
of a novel series of structurally simple, selective, and functionally
biased CB<sub>2</sub> receptor (CB<sub>2</sub>R) agonists with potent
anti-inflammatory and neuroprotective properties. These compounds
were developed using a conformational restriction strategy to abolish
CB<sub>1</sub>R binding, thereby enhancing CB<sub>2</sub>R selectivity.
Pharmacological profiling identified ligands with distinct bias toward
&#946;-arrestin, MAPK, and G-protein signaling pathways. The series
exhibits favorable drug-like properties, including high BBB permeability,
low P-glycoprotein interaction, and microsomal stability. Representative
compounds demonstrated neuroprotective activity in mouse primary neuronal
assays and significantly reduced ROS and caspase levels <italic toggle="yes">in
vitro</italic>, indicating mitigation of oxidative stress and apoptosis.
In a neuron-like SH-SY5Y model expressing pathogenic mutations, they
preserved neurite complexity in a CB<sub>2</sub>R-dependent manner.
Collectively, these findings highlight the advantages of conformational
restriction in transforming abused promiscuous, neurotoxic ligands
into highly selective and efficacious agents for the treatment of
neurodegenerative disorders, without CB<sub>1</sub>R-mediated psychoactive
effects.</p></abstract><abstract abstract-type="graphical"><graphic id="agr1" position="float" orientation="portrait" xlink:href="jm5c00604_0020.jpg"/></abstract><abstract abstract-type="toc-graphic"><graphic position="float" orientation="portrait" xlink:href="jm5c00604_0018.jpg"/></abstract><funding-group><award-group id="fnd-1"><funding-source><institution-wrap><institution>European Cooperation in Science and Technology</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100000921</institution-id></institution-wrap></funding-source><award-id>CA 18133</award-id></award-group></funding-group><funding-group><award-group id="fnd-2"><funding-source><institution-wrap><institution>Conseller&#237;a de Cultura, Educaci&#243;n e Ordenaci&#243;n Universitaria, Xunta de Galicia</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100008425</institution-id></institution-wrap></funding-source><award-id>ED431B 2020/43</award-id></award-group></funding-group><funding-group><award-group id="fnd-3"><funding-source><institution-wrap><institution>European Regional Development Fund</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100008530</institution-id></institution-wrap></funding-source><award-id>NA</award-id></award-group></funding-group><funding-group><award-group id="fnd-4"><funding-source><institution-wrap><institution>Xunta de Galicia</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100010801</institution-id></institution-wrap></funding-source><award-id>ED431C 2018/21</award-id></award-group></funding-group><funding-group><award-group id="fnd-5"><funding-source><institution-wrap><institution>Xunta de Galicia</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100010801</institution-id></institution-wrap></funding-source><award-id>ED431C 2022/20</award-id></award-group></funding-group><funding-group><award-group id="fnd-6"><funding-source><institution-wrap><institution>Xunta de Galicia</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100010801</institution-id></institution-wrap></funding-source><award-id>ED431G 2019/02</award-id></award-group></funding-group><funding-group><award-group id="fnd-7"><funding-source><institution-wrap><institution>Agencia Estatal de Investigaci&#243;n</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100011033</institution-id></institution-wrap></funding-source><award-id>PID2020-113430RB-I00</award-id></award-group></funding-group><funding-group><award-group id="fnd-8"><funding-source><institution-wrap><institution>Agencia Estatal de Investigaci&#243;n</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100011033</institution-id></institution-wrap></funding-source><award-id>PID2020-118511RB-I00</award-id></award-group></funding-group><funding-group><award-group id="fnd-9"><funding-source><institution-wrap><institution>Agencia Estatal de Investigaci&#243;n</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100011033</institution-id></institution-wrap></funding-source><award-id>PID2021-124010OB-100</award-id></award-group></funding-group><funding-group><award-group id="fnd-10"><funding-source><institution-wrap><institution>Agencia Estatal de Investigaci&#243;n</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100011033</institution-id></institution-wrap></funding-source><award-id>PID2023-146870OB-I00</award-id></award-group></funding-group><funding-group><award-group id="fnd-11"><funding-source><institution-wrap><institution>Centro Singular de Investigaci&#243;n de Galicia</institution><institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100018942</institution-id></institution-wrap></funding-source><award-id>ED431G 2023/03</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>jm5c00604</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>jm5c00604</meta-value></custom-meta><custom-meta><meta-name>production-flag-MathML-config-version</meta-name><meta-value>3</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-citation-display-style</meta-name><meta-value>acs-titles</meta-value></custom-meta><custom-meta><meta-name>production-flag-journal-date-display-style</meta-name><meta-value>dates-used-rcd-rvd-acc</meta-value></custom-meta><custom-meta><meta-name>production-flag-si-avail</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>document-id-alt-64</meta-name><meta-value>eb5f2829168366b12117db6ef721c0d8d19c2443632265fbe0048f37085be063</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="sec1"><title>Introduction</title><p>The endocannabinoid system (ECS) is a
crucial regulatory network
responsible for maintaining homeostasis in diverse physiological processes
within the human body.<named-content content-type="bibref-group">
<xref rid="ref1" ref-type="bibr"/>,<xref rid="ref2" ref-type="bibr"/>
</named-content> The ECS comprises endogenous cannabinoids,
cannabinoid receptors (CBRs: CB<sub>1</sub>R and CB<sub>2</sub>R),
and approximately 20 associated enzymes involved in the biosynthesis
and degradation of endocannabinoids, as well as hundreds of lipid
mediators. It modulates a wide range of physiological functions, including
appetite, pain sensation, immune responses, mood, and memory.<named-content content-type="bibref-group">
<xref rid="ref3" ref-type="bibr"/>,<xref rid="ref4" ref-type="bibr"/>
</named-content> CB<sub>1</sub>R and CB<sub>2</sub>R, both class A GPCRs with high
transmembrane sequence similarity,<named-content content-type="bibref-group">
<xref rid="ref5" ref-type="bibr"/>,<xref rid="ref6" ref-type="bibr"/>
</named-content> have distinct
distributions and physiological roles, making them key regulators
of the endocannabinoid system.<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>&#8722;<xref rid="ref8" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref9" ref-type="bibr"/>
</named-content> Since the discovery and cloning
of CBRs, interest in understanding their signaling mechanisms, pharmacology,
and therapeutic potential has grown significantly.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref11" ref-type="bibr"/>
</named-content>
</p><p>The CB<sub>2</sub>R, initially dubbed as the peripheral cannabinoid
receptor, due to its early discovery and abundance in immune system
cells, plays a crucial role in regulating immune response and inflammation.<named-content content-type="bibref-group">
<xref rid="ref5" ref-type="bibr"/>,<xref rid="ref9" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/>
</named-content> More recently, high levels of
CB<sub>2</sub>R expression have been confirmed in different brain
regions, including the cortex, striatum, amygdala, cerebellum, and
microglia.<named-content content-type="bibref-group">
<xref rid="ref13" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/>
</named-content> Notably, under conditions of
inflammation or glial activation, CB<sub>2</sub>R expression undergoes
a significant upregulation. This widespread expression pattern suggests
the involvement of CB<sub>2</sub>R in a multitude of neurological
functions within the brain.<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>,<xref rid="ref12" ref-type="bibr"/>
</named-content> Emerging evidence supports
a critical role for CB<sub>2</sub>R in mediating neuroprotection and
neuroinflammation.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref16" ref-type="bibr"/>
</named-content> Dysregulation of the CB<sub>2</sub>R produces immunomodulatory effects, influencing cytokine release,
cell migration, and immune cell proliferation and, has been implicated
in various pathological conditions, highlighting its involvement in
chronic inflammation and autoimmune disorders.<named-content content-type="bibref-group">
<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref14" ref-type="bibr"/>
</named-content>
</p><p>The CB<sub>2</sub>R&#8242;s involvement in neuronal damage
and
neuroinflammation underscores its potential as a therapeutic target
for neuroprotection and the management of central nervous system pathologies
with an inflammatory basis.<xref rid="ref17" ref-type="bibr"/> Indeed, by
modulating the activity of microglia, the primary immune cells in
the brain, CB<sub>2</sub>R agonists can suppress the production of
pro-inflammatory cytokines and enhance the clearance of toxic protein
aggregates implicated in neurodegenerative processes, promoting neurogenesis
and neuroplasticity, facilitating neuronal repair and regeneration.<named-content content-type="bibref-group">
<xref rid="ref18" ref-type="bibr"/>&#8722;<xref rid="ref19" ref-type="bibr" specific-use="suppress-in-print"/>
<xref rid="ref20" ref-type="bibr"/>
</named-content> Additionally, preclinical data and clinical studies have demonstrated
the efficacy of CB<sub>2</sub>R agonists in ameliorating autoimmune
responses, reducing inflammation, and alleviating chronic pain without
the psychoactive effects associated with CB<sub>1</sub>R receptor
activation.<xref rid="ref21" ref-type="bibr"/> Despite their promise, CB<sub>2</sub>R agonists have not performed well in clinical trials.<named-content content-type="bibref-group">
<xref rid="ref9" ref-type="bibr"/>,<xref rid="ref22" ref-type="bibr"/>
</named-content> Several factors may account for the discrepancy between preclinical
and clinical efficacy, including interspecies differences in receptors
and signaling pathways, insufficient receptor subtype selectivity
and issues with functional behavior. Consequently, there is a pressing
need to develop novel potent, subtype selective and effective CB<sub>2</sub>R agonists to address challenging medical needs.<named-content content-type="bibref-group">
<xref rid="ref12" ref-type="bibr"/>,<xref rid="ref23" ref-type="bibr"/>,<xref rid="ref24" ref-type="bibr"/>
</named-content>
</p><p>Indole and indazole derivatives
are among the earliest identified
and most studied synthetic CBR ligands.<xref rid="ref25" ref-type="bibr"/> While these ligands inspired the early development of CBR agonists,
a significant number of derivatives based on these scaffolds have
emerged as designer drugs of abuse since the 2000s, under the misleading
claim of being synthetic, legal and safe alternatives to marijuana
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>).<named-content content-type="bibref-group">
<xref rid="ref25" ref-type="bibr"/>,<xref rid="ref26" ref-type="bibr"/>
</named-content> In addition to their promiscuous effects on CB<sub>1</sub>R and
CB<sub>2</sub>R, abused synthetic cannabinoid receptor agonists (SCRAs)
demonstrate exceptional potency and efficacy (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>), making them archetypal models for developing
pharmacomodulation strategies to identify CB<sub>2</sub>R-selective
agonists.<named-content content-type="bibref-group">
<xref rid="ref27" ref-type="bibr"/>,<xref rid="ref28" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig1" fig-type="figure" orientation="portrait"><label>1</label><caption><p>Structure and binding data of representative
abused indole and
indazole SCRAs used as models in this study.<xref rid="ref29" ref-type="bibr"/>
</p></caption><graphic id="gr2" position="float" orientation="portrait" xlink:href="jm5c00604_0001.jpg"/></fig><p>Recent reports have highlighted medicinal chemistry
efforts aimed
at dissociating the intrinsically promiscuous cannabinomimetic profiles
of designer drugs to develop selective CB<sub>2</sub>R agonists.<xref rid="ref30" ref-type="bibr"/> Despite important advances in structural biology
of cannabinoid receptors,<named-content content-type="bibref-group">
<xref rid="ref7" ref-type="bibr"/>,<xref rid="ref8" ref-type="bibr"/>,<xref rid="ref10" ref-type="bibr"/>
</named-content> the high homology between these receptors continues to pose significant
challenges, making this goal elusive. We recently reported the synthesis
and detailed pharmacological characterization of a large collection
of indole- and indazole-based abused SCRAs.<xref rid="ref29" ref-type="bibr"/> This study revealed key structure&#8211;activity relationship trends
that inspired the design of new series. Building upon these findings,
we herein investigated the impact of introducing conformational constraints
on prototypical indole- and indazole-based designer drugs of abuse
(<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>). This conformational
lock strategy effectively eliminated CB<sub>1</sub>R binding, resulting
in the discovery of structurally novel, potent, efficacious, and highly
selective CB<sub>2</sub>R agonists. The new ligands exhibit diverse
functional selectivity profiles, excellent CNS permeability, and demonstrate
remarkable anti-inflammatory and neuroprotective properties.</p></sec><sec id="sec2"><title>Results and Discussion</title><sec id="sec2.1"><title>Design</title><p>Understanding the thermodynamics of molecular
recognition events is essential in drug design.<xref rid="ref31" ref-type="bibr"/> When a ligand binds to its receptor, it undergoes a conformational
energy loss, which increases entropy in the surroundings, often weakening
the interaction between the ligand and receptor.<xref rid="ref32" ref-type="bibr"/> To mitigate these entropic penalties and enhance the potency
of the ligand, a thoughtful strategy is to limit its conformational
flexibility through rigidification.<xref rid="ref33" ref-type="bibr"/> This
method has become a well-established approach in rational drug design,<xref rid="ref31" ref-type="bibr"/> as it can significantly improve both pharmacodynamic
and pharmacokinetic profiles, leading to better clinical outcomes.
By locking a ligand into a specific conformation optimal for binding,
rigidification can improve affinity and selectivity profiles, thus
reducing off-target interactions. In the development of kinase inhibitors,
for example, scaffold rigidification enhances selectivity by reducing
interactions with related kinases, minimizing adverse effects, and
improving therapeutic efficacy.<xref rid="ref34" ref-type="bibr"/> Similarly,
in the design of HIV protease inhibitors, rigidification boosts metabolic
stability and bioavailability by stabilizing the peptide backbone.<xref rid="ref35" ref-type="bibr"/>
</p><p>The accepted pharmacophoric model of synthetic
cannabinoid receptor agonists (SCRAs) comprises four key structural
elements (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>):
the tail (purple), the heterocyclic core (green), the linker (blue),
and the head (brown). Our early study on the pharmacological profiles
of abused indole and indazole-based SCRAs<xref rid="ref29" ref-type="bibr"/> revealed that methylation at the amide group near the heterocyclic
core led to a significant reduction in cannabinoid receptor (CBR)
affinity, compared to their unmethylated counterparts (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>, compare the binding data
for compounds <bold>11</bold> vs <bold>12</bold> and <bold>13</bold> vs <bold>14</bold>).<xref rid="ref29" ref-type="bibr"/> This effect was
significantly more pronounced for CB<sub>1</sub>R than CB<sub>2</sub>R (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>), thus
suggesting an opportunity to develop CB<sub>2</sub>R-selective agonists.
This observation guided the design of herein documented conformationally
restricted analogues (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>), in which a five- or six-membered ring was created (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref> bottom left, red
dotted lines) to connect the nitrogen atom of the amide group in the
linker fragment (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>, blue) to the central carbon of the amino acid (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>, Series <bold>I</bold>&#8211;<bold>IV</bold>). This structural modification, aimed at limiting the flexibility
of the molecules, was expected to retain CB<sub>2</sub>R affinity
while drastically reducing CB<sub>1</sub>R binding, thus improving
the selectivity and therapeutic profile. In practice, the proposed
strategy involved replacing the classical amino acids present in abused
SCRAs (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>, e.g.,
valine and <italic toggle="yes">tert</italic>-leucine) with proline and homoproline
derivatives (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>). It was hypothesized that the reduced rotational freedom conferred
by this bridging would induce a conformational lock in the bioactive
form of the ligands, thereby diminishing CB<sub>1</sub>R binding while
preserving the critical interactions with the orthosteric pocket of
CB<sub>2</sub>R.</p><fig position="float" id="fig2" fig-type="figure" orientation="portrait"><label>2</label><caption><p>Design strategy followed within the project and general
structure
of the new series.</p></caption><graphic id="gr3" position="float" orientation="portrait" xlink:href="jm5c00604_0002.jpg"/></fig></sec><sec id="sec2.2"><title>Prediction and Comparative Analysis of Molecular Descriptors
Impacting Drug-Like Properties</title><p>Assessing physicochemical
properties early in drug discovery is crucial, as they influence ADME-Tox
profiles.<xref rid="ref36" ref-type="bibr"/> Molecular descriptors like
Log&#8239;<italic toggle="yes">P</italic>, Log&#8239;<italic toggle="yes">D</italic>, and
tPSA help predict a compound&#8217;s biological behavior, such as
membrane permeability and blood-brain barrier (BBB) crossing.<named-content content-type="bibref-group">
<xref rid="ref37" ref-type="bibr"/>,<xref rid="ref38" ref-type="bibr"/>
</named-content> Cannabinoid receptor ligands often exhibit high lipophilicity, challenging
drug-likeness criteria and pharmacokinetics.<named-content content-type="bibref-group">
<xref rid="ref39" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content> This high lipophilicity can contribute to adverse effects and pharmacokinetic
challenges.<xref rid="ref40" ref-type="bibr"/> To address this, we conducted
an <italic toggle="yes">in silico</italic> evaluation of molecular descriptors
for newly designed cyclic amides compared to abused SCRAs (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>).<xref rid="ref29" ref-type="bibr"/> This study was conducted during the library design phase
to compare the new series with abused SCRAs and to anticipate issues
that could affect the drug-likeness and ADME properties of the novel
series. For this assessment, 64 representative compounds were selected
from the abused SCRAs series [including the two central scaffolds
(indole and indazole), four representative R<sup>1</sup> (pentyl,
5-fluoropentyl, cyclohexylmethyl and 4-fluorobenzyl), and two R<sup>2</sup> groups (isopropyl and <italic toggle="yes">tert</italic>-butyl), as well
as their (<italic toggle="yes">R</italic>) and (<italic toggle="yes">S</italic>) enantiomers].
The same scaffolds and R<sup>1</sup> groups were introduced to the
new cyclic amides, substituting the R<sup>2</sup> group with either
a 5- or 6-membered ring.</p><fig position="float" id="fig3" fig-type="figure" orientation="portrait"><label>3</label><caption><p>Comparative analysis of molecular descriptors.
(A) Radar-type molecular
descriptors analysis, (B) BOILED-egg, (c) CNS-MPO.</p></caption><graphic id="gr4" position="float" orientation="portrait" xlink:href="jm5c00604_0003.jpg"/></fig><p>Six molecular descriptors were selected and calculated
to identify
key differences between the two series (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>). The predicted Log&#8239;<italic toggle="yes">P</italic> values of the conformationally restricted ligands (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>, Compounds <bold>15</bold>&#8211;<bold>18</bold>) typically ranged from 2 to 3.5, which is
1.5 to 3 points lower than those calculated for abused SCRAs,<xref rid="ref41" ref-type="bibr"/> remaining well within the range compatible with
efficient blood-brain barrier (BBB) permeability. The results, presented
in <xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A, demonstrate
that the introduction of the cyclic structure (conformational restriction)
leads to significant changes in representative molecular descriptors.
As observed (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>A), the new series show improved parameters, particularly with marked
reductions in lipophilicity (Log&#8239;<italic toggle="yes">P</italic>), polar
surface area (TPSA) and flexibility (number of rotatable bonds).</p><p>To complement the predictive analysis of how structural rigidification
would affects physicochemical properties of the new ligands (<bold>15</bold>&#8211;<bold>18</bold>) and its comparison with abused
SCRAs (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>), two
additional computational approaches were employed: the CNS MPO criteria
and the BOILED-egg model (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>).<named-content content-type="bibref-group">
<xref rid="ref42" ref-type="bibr"/>,<xref rid="ref43" ref-type="bibr"/>
</named-content> A CNS-MPO score above 4 is generally
considered a strong indicator of effective BBB permeability.<xref rid="ref43" ref-type="bibr"/> The BOILED-egg model offers a simple yet effective
method for predicting both blood-brain barrier (BBB) penetration and
gastrointestinal absorption, improving early stage drug evaluation
by classifying compounds based on their potential to reach the CNS
or other target tissues.<xref rid="ref42" ref-type="bibr"/> Finally, a screening
was performed to identify any potential Pan-Assay Interference Structures
(PAINS), using the PAINS filters,<xref rid="ref44" ref-type="bibr"/> which
could otherwise lead to false positives in biological assays. The
studies were conducted for six representative new ligands (<bold>16b</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, and <bold>18p</bold>) and a selection of structural analogs of
abused SCRAs. As observed (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>), the computational predictions for CNS-MPO and BOILED-egg
parameters yielded excellent results, suggesting that the conformationally
restricted ligands possess favorable profiles as potential CNS-targeted
therapeutics. The CNS-MPO scores (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>C), generally above 4, suggest that new ligands
are well-suited for crossing the blood-brain barrier (BBB) and maintaining
efficacy within the CNS. Similarly, the BOILED-egg model (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>B) supports these
findings, with most ligands positioned in the yellow region, indicating
favorable BBB permeability and optimal CNS exposure. Finally, all
tested ligands passed the PAINS filter (see <xref rid="sec4" ref-type="sec">Experimental
Section</xref>), ruling out the possibility of false positives in
biological assays and suggesting they are robust drug candidates.</p></sec><sec id="sec2.3"><title>Chemistry</title><p>Eight carboxylic acids (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>, Compounds <bold>19a</bold>&#8211;<bold>h</bold>), obtained via alkylation and saponification,<xref rid="ref29" ref-type="bibr"/> were selected to systematically explore the
effects of rigidification of the linker region (<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>) on the cannabinomimetic profile. Carboxylic
acids <bold>19</bold> incorporate both indole and indazole cores and
the most common tail residues (R<sup>1</sup>) found in abused SCRAs: <italic toggle="yes">n</italic>-pentyl, 5-fluoropentyl, cyclohexylmethyl, and 4-fluorobenzyl
(<xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>). Four cyclic
amino acid methyl esters (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>, Compounds <bold>20a</bold>&#8211;<bold>d</bold>),
with both (<italic toggle="yes">R</italic>) and (<italic toggle="yes">S</italic>) configurations,
were chosen as precursors. The library was synthesized using an efficient
two-step approach (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>). First, the amide coupling of compounds <bold>19</bold> with
commercially available enantiopure methyl prolinates or homoprolinates
(<bold>20a</bold>&#8211;<bold>d</bold>) yielded the targeted ester
derivatives (<bold>15</bold> and <bold>16</bold>) with high efficiency
(72 to 98%). In the second step, mild ammonolysis of <bold>15</bold> and <bold>16</bold> afforded the final amides (<bold>17</bold> and <bold>18</bold>) in nearly quantitative yields. The structure and diversity
of the 64-member library are shown in <xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>.</p><fig position="float" id="sch1" fig-type="scheme" orientation="portrait"><label>1</label><caption><title>Synthetic Pathway Employed for the Synthesis
of the New Series of
CBR Ligands<xref rid="s1fn1" ref-type="fn"/>
</title></caption><graphic id="gr1" position="float" orientation="portrait" xlink:href="jm5c00604_0012.jpg"/><p>
<fn id="s1fn1"><label>a</label><p>Method (a) HATU, DIPEA,
CH<sub>2</sub>Cl<sub>2</sub>, rt, 24 h. Method (b) NH<sub>3</sub> in
MeOH,
rt, 4 h.</p></fn>
</p></fig><p>Although racemization is unlikely
under the utilized experimental
conditions,<xref rid="ref45" ref-type="bibr"/> it was standard practice
to analyze all library members using analytical chiral HPLC to verify
the preservation of the configuration at the stereocenter (ee &#8805;
98%) in the final compounds. A selection of the HPLC traces obtained
for representative enantiomeric pairs and the characterization through
Circular Dichroism (CD) is presented in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Figure S1</ext-link>. A detailed description of the synthetic methods and the
complete structural, spectroscopic, and analytical data for all compounds
as well as HPLC traces for representative enantiomeric pairs is provided
in the experimental part and <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>.</p></sec><sec id="sec2.4"><title>Biological Evaluation</title><p>The cannabimimetic binding profile
of the 64 newly synthesized ligands was first studied <italic toggle="yes">in vitro</italic> by evaluating their affinity (<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub>) for human CB<sub>1</sub>R and CB<sub>2</sub>R following established
experimental protocols.<xref rid="ref29" ref-type="bibr"/> Competitive radioligand
binding assays were conducted using membrane preparations from human
CB<sub>1</sub>R transfected in CHO C3 cells and from human CB<sub>2</sub>R transfected in HEK-293T cells. A well-characterized tritiated
ligand ([<sup>3</sup>H]&#173;CP55,940) was used for these assays. The binding
affinity data obtained are reported in <xref rid="tbl1" ref-type="table">Tables <xref rid="tbl1" ref-type="table"/>
</xref>&#8211;<xref rid="tbl4" ref-type="table"/>. For comparative
purposes, binding data for representative CBR ligands (Surinabant,
CP55,940, and <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="GW405833">GW405833</ext-link>) were also determined using the reported experimental
protocols. These data are also included in the tables. Representative
dose&#8211;response curves obtained for selected ligands during the
binding affinity determinations at CB<sub>2</sub>R are presented in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Figure S2</ext-link>. A detailed description of the employed
protocols is reported in the experimental part and the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>.</p><table-wrap position="float" id="tbl1" orientation="portrait"><label>1</label><caption><title>Structure and Binding Data Obtained
for the Esters <bold>15a</bold>&#8211;<bold>p</bold> and <bold>16a</bold>&#8211;<bold>p</bold>
</title></caption><graphic id="fx1" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00604_0013.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="2" align="center" rowspan="1">CB<sub>1</sub>R<hr/></th><th colspan="2" align="center" rowspan="1">CB<sub>2</sub>R<hr/></th><th align="center" colspan="1" rowspan="1">&#160;</th></tr><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">X</th><th align="center" colspan="1" rowspan="1">*(<italic toggle="yes">R</italic>/<italic toggle="yes">S</italic>)</th><th align="center" colspan="1" rowspan="1">R<sup>1</sup>
</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> (nM) or % at 1 &#956;M<xref rid="t1fn1" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">p<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub>
</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> (nM) or % at 1 &#956;M<xref rid="t1fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">p<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub>
</th><th align="center" colspan="1" rowspan="1">SI <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> CB<sub>1</sub>R/ <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> CB<sub>2</sub>R</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>15a</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">121&#160;&#177;&#160;6</td><td align="left" colspan="1" rowspan="1">6.92</td><td align="left" colspan="1" rowspan="1">189&#160;&#177;&#160;10</td><td align="left" colspan="1" rowspan="1">6.72</td><td align="left" colspan="1" rowspan="1">0.6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15b</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">4%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">25%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15c</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">55.9&#160;&#177;&#160;2.7</td><td align="left" colspan="1" rowspan="1">7.25</td><td align="left" colspan="1" rowspan="1">71.7&#160;&#177;&#160;2.0</td><td align="left" colspan="1" rowspan="1">7.14</td><td align="left" colspan="1" rowspan="1">0.8</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15d</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">26%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15e</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">11.3&#160;&#177;&#160;0.5</td><td align="left" colspan="1" rowspan="1">7.95</td><td align="left" colspan="1" rowspan="1">38.3&#160;&#177;&#160;2.1</td><td align="left" colspan="1" rowspan="1">7.42</td><td align="left" colspan="1" rowspan="1">0.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15f</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">32%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">463&#160;&#177;&#160;11</td><td align="left" colspan="1" rowspan="1">6.33</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15g</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">14.4&#160;&#177;&#160;0.6</td><td align="left" colspan="1" rowspan="1">7.84</td><td align="left" colspan="1" rowspan="1">47.7&#160;&#177;&#160;1.9</td><td align="left" colspan="1" rowspan="1">7.32</td><td align="left" colspan="1" rowspan="1">0.3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15h</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">10%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">599&#160;&#177;&#160;13</td><td align="left" colspan="1" rowspan="1">6.22</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15i</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">337&#160;&#177;&#160;9</td><td align="left" colspan="1" rowspan="1">6.47</td><td align="left" colspan="1" rowspan="1">75.9&#160;&#177;&#160;2.2</td><td align="left" colspan="1" rowspan="1">7.12</td><td align="left" colspan="1" rowspan="1">4</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15j</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">4%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">208&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.68</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15k</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">173&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.76</td><td align="left" colspan="1" rowspan="1">41.9&#160;&#177;&#160;2.1</td><td align="left" colspan="1" rowspan="1">7.38</td><td align="left" colspan="1" rowspan="1">4</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15l</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">1%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">513&#160;&#177;&#160;3</td><td align="left" colspan="1" rowspan="1">6.29</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15m</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">73.4&#160;&#177;&#160;2.9</td><td align="left" colspan="1" rowspan="1">7.13</td><td align="left" colspan="1" rowspan="1">20.7&#160;&#177;&#160;0.6</td><td align="left" colspan="1" rowspan="1">7.68</td><td align="left" colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15n</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">99.3&#160;&#177;&#160;2.8</td><td align="left" colspan="1" rowspan="1">7.00</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15o</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">46.2&#160;&#177;&#160;2.3</td><td align="left" colspan="1" rowspan="1">7.34</td><td align="left" colspan="1" rowspan="1">16.5&#160;&#177;&#160;1.1</td><td align="left" colspan="1" rowspan="1">7.78</td><td align="left" colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>15p</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">5%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">157&#160;&#177;&#160;4</td><td align="left" colspan="1" rowspan="1">6.80</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16a</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">644&#160;&#177;&#160;13</td><td align="left" colspan="1" rowspan="1">6.19</td><td align="left" colspan="1" rowspan="1">114&#160;&#177;&#160;6</td><td align="left" colspan="1" rowspan="1">6.94</td><td align="left" colspan="1" rowspan="1">6</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16b</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">18%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">273&#160;&#177;&#160;4</td><td align="left" colspan="1" rowspan="1">6.56</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16c</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">716&#160;&#177;&#160;16</td><td align="left" colspan="1" rowspan="1">6.15</td><td align="left" colspan="1" rowspan="1">84.1&#160;&#177;&#160;1.9</td><td align="left" colspan="1" rowspan="1">7.08</td><td align="left" colspan="1" rowspan="1">8</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16d</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">24%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">251&#160;&#177;&#160;7</td><td align="left" colspan="1" rowspan="1">6.60</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16e</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">122&#160;&#177;&#160;8</td><td align="left" colspan="1" rowspan="1">6.91</td><td align="left" colspan="1" rowspan="1">45.1&#160;&#177;&#160;1.7</td><td align="left" colspan="1" rowspan="1">7.35</td><td align="left" colspan="1" rowspan="1">3</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16f</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">37%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">93.1&#160;&#177;&#160;3.3</td><td align="left" colspan="1" rowspan="1">7.03</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16g</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">90.3&#160;&#177;&#160;2.3</td><td align="left" colspan="1" rowspan="1">7.04</td><td align="left" colspan="1" rowspan="1">22.5&#160;&#177;&#160;1.1</td><td align="left" colspan="1" rowspan="1">7.65</td><td align="left" colspan="1" rowspan="1">4</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16h</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">35%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">109&#160;&#177;&#160;4</td><td align="left" colspan="1" rowspan="1">6.96</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16i (ISAM-CG538)</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">685&#160;&#177;&#160;21</td><td align="left" colspan="1" rowspan="1">6.16</td><td align="left" colspan="1" rowspan="1">10.9&#160;&#177;&#160;0.5</td><td align="left" colspan="1" rowspan="1">7.96</td><td align="left" colspan="1" rowspan="1">62</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16j (ISAM-CG528)</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">89.1&#160;&#177;&#160;3.1</td><td align="left" colspan="1" rowspan="1">7.05</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16k</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">392&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.41</td><td align="left" colspan="1" rowspan="1">10.6&#160;&#177;&#160;0.7</td><td align="left" colspan="1" rowspan="1">7.97</td><td align="left" colspan="1" rowspan="1">37</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16l</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">5%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">127&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.90</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16m</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">162&#160;&#177;&#160;3</td><td align="left" colspan="1" rowspan="1">6.79</td><td align="left" colspan="1" rowspan="1">5.20&#160;&#177;&#160;0.4</td><td align="left" colspan="1" rowspan="1">8.28</td><td align="left" colspan="1" rowspan="1">31</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16n</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">164&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.79</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16o</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">65.4&#160;&#177;&#160;2.4</td><td align="left" colspan="1" rowspan="1">7.18</td><td align="left" colspan="1" rowspan="1">4.10&#160;&#177;&#160;0.12</td><td align="left" colspan="1" rowspan="1">8.39</td><td align="left" colspan="1" rowspan="1">16</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16p</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">5%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">48.4&#160;&#177;&#160;1.8</td><td align="left" colspan="1" rowspan="1">7.32</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Surinabant</bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">3.00&#160;&#177;&#160;0.2</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">400&#160;&#177;&#160;6</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">0.0075</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold><ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="GW405833">GW405833</ext-link></bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">4772&#160;&#177;&#160;110</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">5.80&#160;&#177;&#160;0.4</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">822</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>CP55</bold>,<bold>940</bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1.01&#160;&#177;&#160;0.08</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">0.13&#160;&#177;&#160;0.08</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">7.76</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Displacement of specific [<sup>3</sup>H]&#173;CP 55,940 binding in membrane preparations of human CB<sub>1</sub>R transfected in CHO&#8211;CB1 C3 cell line expressed as <italic toggle="yes">K</italic>
<sub>i</sub> in nM (<italic toggle="yes">n</italic> = 3) or percentage
displacement of specific binding at 1 &#956;M (<italic toggle="yes">n</italic> = 2).</p></fn><fn id="t1fn2"><label>b</label><p>Displacement of
specific [<sup>3</sup>H]&#173;CP 55,940 binding in membrane preparations
of human CB<sub>2</sub>R transfected in HEK-293T cells expressed as <italic toggle="yes">K</italic>
<sub>i</sub> in nM (<italic toggle="yes">n</italic> = 3) or percentage
displacement
of specific binding at 1 &#956;M (<italic toggle="yes">n</italic> = 2).</p></fn></table-wrap-foot></table-wrap><p>The compounds are grouped into four series (<bold>I</bold>&#8211;<bold>IV</bold>, <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig"/>
</xref>). <xref rid="tbl1" ref-type="table">Tables <xref rid="tbl1" ref-type="table"/>
</xref> and <xref rid="tbl2" ref-type="table"/> show the data for ester
derivatives (Series <bold>I and II</bold>), while <xref rid="tbl3" ref-type="table">Tables <xref rid="tbl3" ref-type="table"/>
</xref> and <xref rid="tbl4" ref-type="table"/> report the data for
amides (Series <bold>III</bold> and <bold>IV</bold>). To help in identifying
the most promising ligands and rapidly
analyzing structure-selectivity relationships across the series, the
selectivity index (SI), calculated as the affinity ratio (<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> CB<sub>1</sub>R/<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> CB<sub>2</sub>R), is also reported
alongside the tables.</p><table-wrap position="float" id="tbl2" orientation="portrait"><label>2</label><caption><title>Structure and Binding Data Obtained
for the Amides <bold>17a</bold>&#8211;<bold>p</bold> and <bold>18a</bold>&#8211;<bold>p</bold>
</title></caption><graphic id="fx2" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00604_0014.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">CB<sub>1</sub>R<hr/></th><th colspan="2" align="center" rowspan="1">CB<sub>2</sub>R<hr/></th><th align="center" colspan="1" rowspan="1">&#160;</th></tr><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">X</th><th align="center" colspan="1" rowspan="1">*(<italic toggle="yes">R</italic>/<italic toggle="yes">S</italic>)</th><th align="center" colspan="1" rowspan="1">R<sup>1</sup>
</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> (nM) or % at 1 &#956;M<xref rid="t2fn1" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> (nM)
or % at 1 &#956;M<xref rid="t2fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">p<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub>
</th><th align="center" colspan="1" rowspan="1">SI <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> CB<sub>1</sub>R/ <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> CB<sub>2</sub>R</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>17a</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">24%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17b</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">17%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17c</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">1%</td><td align="left" colspan="1" rowspan="1">15%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17d</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">5%</td><td align="left" colspan="1" rowspan="1">16%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17e</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">6%</td><td align="left" colspan="1" rowspan="1">288 &#177; 7</td><td align="left" colspan="1" rowspan="1">6.54</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17f</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">411 &#177; 16</td><td align="left" colspan="1" rowspan="1">6.39</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17g</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">20%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17h</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">4%</td><td align="left" colspan="1" rowspan="1">7%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17i</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">31%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17j</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">28%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17k</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">17%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17l</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">4%</td><td align="left" colspan="1" rowspan="1">25%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17m</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">1%</td><td align="left" colspan="1" rowspan="1">27%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17n</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">28%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17o</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">4%</td><td align="left" colspan="1" rowspan="1">628 &#177; 21</td><td align="left" colspan="1" rowspan="1">6.20</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>17p</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">4%</td><td align="left" colspan="1" rowspan="1">12%</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18a</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">111&#160;&#177;&#160;6</td><td align="left" colspan="1" rowspan="1">6.95</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18b</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">10%</td><td align="left" colspan="1" rowspan="1">136&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.87</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18c</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">7%</td><td align="left" colspan="1" rowspan="1">132&#160;&#177;&#160;4</td><td align="left" colspan="1" rowspan="1">6.88</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18d</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">15%</td><td align="left" colspan="1" rowspan="1">169&#160;&#177;&#160;6</td><td align="left" colspan="1" rowspan="1">6.77</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18e (ISAM-CG585)</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">22%</td><td align="left" colspan="1" rowspan="1">30.2&#160;&#177;&#160;1.2</td><td align="left" colspan="1" rowspan="1">7.52</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18f
(ISAM-CG586)</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">11%</td><td align="left" colspan="1" rowspan="1">96.8&#160;&#177;&#160;2.6</td><td align="left" colspan="1" rowspan="1">7.01</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18g</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">21%</td><td align="left" colspan="1" rowspan="1">115&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.94</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18h</bold>
</td><td align="left" colspan="1" rowspan="1">CH</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">207&#160;&#177;&#160;9</td><td align="left" colspan="1" rowspan="1">6.68</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18i</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">91.8&#160;&#177;&#160;4.9</td><td align="left" colspan="1" rowspan="1">7.04</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18j</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">Pentyl</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">145&#160;&#177;&#160;6</td><td align="left" colspan="1" rowspan="1">6.84</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18k</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">151&#160;&#177;&#160;6</td><td align="left" colspan="1" rowspan="1">6.82</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18l</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">5-F-Pentyl</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">143&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.84</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18m
(ISAM-CG558)</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">21%</td><td align="left" colspan="1" rowspan="1">59.5&#160;&#177;&#160;2.8</td><td align="left" colspan="1" rowspan="1">7.23</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18n</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">CH<sub>2</sub>&#8211;Cy</td><td align="left" colspan="1" rowspan="1">26%</td><td align="left" colspan="1" rowspan="1">112&#160;&#177;&#160;4</td><td align="left" colspan="1" rowspan="1">6.95</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18o (ISAM-CG557)</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(S)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">54.6&#160;&#177;&#160;1.1</td><td align="left" colspan="1" rowspan="1">7.26</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18p (ISAM-CG549)</bold>
</td><td align="left" colspan="1" rowspan="1">N</td><td align="left" colspan="1" rowspan="1">
<italic toggle="yes">(R)</italic>
</td><td align="left" colspan="1" rowspan="1">4-F-Bn</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">120&#160;&#177;&#160;5</td><td align="left" colspan="1" rowspan="1">6.92</td><td align="left" colspan="1" rowspan="1">&gt;100</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Surinabant</bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">3.00&#160;&#177;&#160;0.2</td><td align="left" colspan="1" rowspan="1">400&#160;&#177;&#160;6</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">0.0075</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold><ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="GW405833">GW405833</ext-link></bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">4772&#160;&#177;&#160;110</td><td align="left" colspan="1" rowspan="1">5.80&#160;&#177;&#160;0.4</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">822</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>CP55</bold>,<bold>940</bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1.01&#160;&#177;&#160;0.08</td><td align="left" colspan="1" rowspan="1">0.13&#160;&#177;&#160;0.08</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">7.76</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Displacement of specific [<sup>3</sup>H]&#173;CP 55,940 binding in membrane preparations of human CB<sub>1</sub>R transfected in CHO&#8211;CB1 C3 cell line expressed as <italic toggle="yes">K</italic>
<sub>i</sub> in nM (<italic toggle="yes">n</italic> = 3) or percentage
displacement of specific binding at 1 &#956;M (<italic toggle="yes">n</italic> = 2).</p></fn><fn id="t2fn2"><label>b</label><p>Displacement of
specific [<sup>3</sup>H]&#173;CP 55,940 binding in membrane preparations
of human CB<sub>2</sub>R transfected in HEK-293T cells expressed as <italic toggle="yes">K</italic>
<sub>i</sub> in nM (<italic toggle="yes">n</italic> = 3) or percentage
displacement
of specific binding at 1 &#956;M (<italic toggle="yes">n</italic> = 2).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl3" orientation="landscape"><label>3</label><caption><title>Structure, Affinity, and Functional
Data of Selected Derivatives</title></caption><graphic id="fx3" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00604_0015.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th rowspan="2" align="center" colspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="4" align="center" rowspan="1">CB<sub>2</sub>R<hr/></th><th rowspan="2" colspan="2" align="center">Bias factor &#946;-arrestin &#8211; cAMP<xref rid="t3fn5" ref-type="table-fn"/>
<hr/></th><th rowspan="2" colspan="2" align="center">Bias factor MAPK &#8211;
cAMP<xref rid="t3fn5" ref-type="table-fn"/>
<hr/></th><th rowspan="2" colspan="2" align="center">Bias factor &#946;-arrestin
&#8211; MAPK<xref rid="t3fn5" ref-type="table-fn"/>
<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">CB<sub>1</sub>R<hr/></th><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="3" align="center" rowspan="1">EC<sub>50</sub> nM<xref rid="t3fn3" ref-type="table-fn"/> (<italic toggle="yes">E</italic>
<sub>max</sub>)<xref rid="t3fn4" ref-type="table-fn"/>
<hr/></th></tr><tr><th align="center" colspan="1" rowspan="1">Cpds</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> or % at 1 &#956;M<xref rid="t3fn1" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> (nM)<xref rid="t3fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">AMPc</th><th align="center" colspan="1" rowspan="1">&#946;-arrestin</th><th align="center" colspan="1" rowspan="1">MAPK</th><th align="center" colspan="1" rowspan="1">
<inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00604_m002.jpg"/><mml:math id="d1e3341" display="inline"><mml:mi>&#916;&#916;</mml:mi><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives>
</inline-formula>
</th><th align="center" colspan="1" rowspan="1">
<inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00604_m003.jpg"/><mml:math id="d1e3366" display="inline"><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo stretchy="true">|</mml:mo><mml:mrow><mml:mi>&#916;&#916;log</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">|</mml:mo></mml:mrow></mml:msup></mml:math></alternatives>
</inline-formula>
</th><th align="center" colspan="1" rowspan="1">
<inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00604_m004.jpg"/><mml:math id="d1e3397" display="inline"><mml:mi>&#916;&#916;</mml:mi><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives>
</inline-formula>
</th><th align="center" colspan="1" rowspan="1">
<inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00604_m005.jpg"/><mml:math id="d1e3422" display="inline"><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo stretchy="true">|</mml:mo><mml:mrow><mml:mi>&#916;&#916;log</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">|</mml:mo></mml:mrow></mml:msup></mml:math></alternatives>
</inline-formula>
</th><th align="center" colspan="1" rowspan="1">
<inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00604_m006.jpg"/><mml:math id="d1e3453" display="inline"><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mrow><mml:mi>log</mml:mi><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></alternatives>
</inline-formula>
</th><th align="center" colspan="1" rowspan="1">
<inline-formula>
<alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00604_m007.jpg"/><mml:math id="d1e3482" display="inline"><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo stretchy="true">|</mml:mo><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mrow><mml:mi mathvariant="normal">&#916;</mml:mi><mml:mo>&#8290;</mml:mo><mml:mi>log</mml:mi><mml:mo linebreak="nobreak" lspace="0em" rspace="0.25em">&#8289;</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:msub><mml:mi>E</mml:mi><mml:mi>max</mml:mi></mml:msub><mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mn>50</mml:mn></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:mrow><mml:mo stretchy="true">|</mml:mo></mml:mrow></mml:msup></mml:math></alternatives>
</inline-formula>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>16i</bold>
</td><td align="left" colspan="1" rowspan="1">685&#160;nM</td><td align="left" colspan="1" rowspan="1">10.9</td><td align="left" colspan="1" rowspan="1">0.03&#160;&#177;&#160;0.01 (64%)</td><td align="left" colspan="1" rowspan="1">1.09&#160;&#177;&#160;0.01 (48%)</td><td align="left" colspan="1" rowspan="1">0.38&#160;&#177;&#160;0.09 (88%)</td><td align="left" colspan="1" rowspan="1">&#8211;2.36 (G protein)</td><td align="left" colspan="1" rowspan="1">231 (G
protein)</td><td align="left" colspan="1" rowspan="1">&#8211;1.36 (G protein)</td><td align="left" colspan="1" rowspan="1">23 (G
protein)</td><td align="left" colspan="1" rowspan="1">&#8211;1.00 (MAPK)</td><td align="left" colspan="1" rowspan="1">10 (MAPK)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>16j</bold>
</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">89.1</td><td align="left" colspan="1" rowspan="1">0.09 &#177; 0.01 (53%)</td><td align="left" colspan="1" rowspan="1">0.28 &#177;
0.02 (65%)</td><td align="left" colspan="1" rowspan="1">0.09 &#177; 0.003 (89%)</td><td align="left" colspan="1" rowspan="1">&#8211;1.08
(G protein)</td><td align="left" colspan="1" rowspan="1">12 (G protein)</td><td align="left" colspan="1" rowspan="1">&#8211;0.17
(No bias)</td><td align="left" colspan="1" rowspan="1">1 (No bias)</td><td align="left" colspan="1" rowspan="1">&#8211;0.91 (MAPK)</td><td align="left" colspan="1" rowspan="1">8 (MAPK)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18e</bold>
</td><td align="left" colspan="1" rowspan="1">22%</td><td align="left" colspan="1" rowspan="1">30.2</td><td align="left" colspan="1" rowspan="1">1701 &#177; 12 (82%)</td><td align="left" colspan="1" rowspan="1">0.40 &#177; 0.08 (120%)</td><td align="left" colspan="1" rowspan="1">0.09 &#177; 0.002 (74%)</td><td align="left" colspan="1" rowspan="1">3.12 (&#946;-arrestin)</td><td align="left" colspan="1" rowspan="1">1306 (&#946;-arrestin)</td><td align="left" colspan="1" rowspan="1">3.84 (MAPK)</td><td align="left" colspan="1" rowspan="1">6843 (MAPK)</td><td align="left" colspan="1" rowspan="1">&#8211;0.72
(MAPK)</td><td align="left" colspan="1" rowspan="1">5 (MAPK)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18f</bold>
</td><td align="left" colspan="1" rowspan="1">11%</td><td align="left" colspan="1" rowspan="1">96.8</td><td align="left" colspan="1" rowspan="1">118 &#177; 4
(55%)</td><td align="left" colspan="1" rowspan="1">0.08 &#177; 0.01 (88%)</td><td align="left" colspan="1" rowspan="1">0.07 &#177;
0.007 (94%)</td><td align="left" colspan="1" rowspan="1">2.69 (&#946;-arrestin)</td><td align="left" colspan="1" rowspan="1">495
(&#946;-arrestin)</td><td align="left" colspan="1" rowspan="1">3.06 (MAPK)</td><td align="left" colspan="1" rowspan="1">1156 (MAPK)</td><td align="left" colspan="1" rowspan="1">&#8211;0.37 (MAPK)</td><td align="left" colspan="1" rowspan="1">2 (MAPK)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18o</bold>
</td><td align="left" colspan="1" rowspan="1">3%</td><td align="left" colspan="1" rowspan="1">54.6</td><td align="left" colspan="1" rowspan="1">0.60 &#177; 0.09 (60%)</td><td align="left" colspan="1" rowspan="1">60.9 &#177; 2.5 (148%)</td><td align="left" colspan="1" rowspan="1">0.03 &#177; 0.003 (68%)</td><td align="left" colspan="1" rowspan="1">&#8211;2.29 (G protein)</td><td align="left" colspan="1" rowspan="1">196 (G protein)</td><td align="left" colspan="1" rowspan="1">0.96 (MAPK)</td><td align="left" colspan="1" rowspan="1">9 (MAPK)</td><td align="left" colspan="1" rowspan="1">&#8211;3.25 (MAPK)</td><td align="left" colspan="1" rowspan="1">1783 (MAPK)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18p</bold>
</td><td align="left" colspan="1" rowspan="1">2%</td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1">6.80 &#177; 0.3 (58%)</td><td align="left" colspan="1" rowspan="1">326 &#177; 4 (77%)</td><td align="left" colspan="1" rowspan="1">0.40 &#177; 0.02 (79%)</td><td align="left" colspan="1" rowspan="1">&#8211;2.24 (G protein)</td><td align="left" colspan="1" rowspan="1">172 (G protein)</td><td align="left" colspan="1" rowspan="1">0.97 (MAPK)</td><td align="left" colspan="1" rowspan="1">9 (MAPK)</td><td align="left" colspan="1" rowspan="1">&#8211;3.20 (MAPK)</td><td align="left" colspan="1" rowspan="1">1599 (MAPK)</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>JWH-133</bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">6.73 &#177; 0.5 (98%)</td><td align="left" colspan="1" rowspan="1">1.34 &#177; 0.05 (93%)</td><td align="left" colspan="1" rowspan="1">2.70 &#177; 0.19 (98%)</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>Displacement of specific [3H]&#173;CP
55,940 binding in membrane preparations of human CB1R transfected
in CHO&#8211;CB<sub>1</sub>R C3 cell line expressed as <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> in nM (<italic toggle="yes">n</italic> = 3) or percentage
displacement of specific binding at a concentration of 1 &#956;M
(<italic toggle="yes">n</italic> = 2).</p></fn><fn id="t3fn2"><label>b</label><p>Displacement of specific [3H]&#173;CP
55,940 binding in membrane preparations of human CB<sub>2</sub>R transfected
in HEK-293T cells expressed as <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> in nM (<italic toggle="yes">n</italic> = 3) or percentage displacement
of specific binding at a concentration of 1 &#956;M (<italic toggle="yes">n</italic> = 2).</p></fn><fn id="t3fn3"><label>c</label><p>Functional activity
assessed in
transfected HEK-293T cells by determining cAMP levels after forskolin
stimulation.</p></fn><fn id="t3fn4"><label>d</label><p>
<italic toggle="yes">E</italic>
<sub>max</sub> values were normalized to a maximal efficacious concentration
of
CP 55,940.</p></fn><fn id="t3fn5"><label>e</label><p>Bias factors
were quantified by
the relative activity model using JWH-133 as a reference ligand (see
the <xref rid="sec4" ref-type="sec">Experimental Section</xref>). The preferred (biased)
pathway is indicated in parentheses.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl4" orientation="portrait"><label>4</label><caption><title>Solubility, Plasma Protein Binding
and Metabolic Stability of Selected Ligands</title></caption><graphic id="fx4" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00604_0016.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th><th colspan="4" align="center" rowspan="1">microsomal
stability<hr/></th><th align="center" colspan="1" rowspan="1">&#160;</th><th align="center" colspan="1" rowspan="1">&#160;</th></tr><tr><th align="center" colspan="1" rowspan="1">compound</th><th align="center" colspan="1" rowspan="1">solubility (&#956;M)<xref rid="t4fn1" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">specie</th><th align="center" colspan="1" rowspan="1">%<xref rid="t4fn2" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">t</italic>
<sub>1/2</sub>
<xref rid="t4fn3" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">Cl<sub>int</sub>
<xref rid="t4fn4" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">h</italic>CB<sub>2</sub>R <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> (nM)<xref rid="t4fn5" ref-type="table-fn"/>
</th><th align="center" colspan="1" rowspan="1">
<italic toggle="yes">h</italic>CB<sub>1</sub>R % at 1 &#956;M<xref rid="t4fn6" ref-type="table-fn"/>
</th></tr></thead><tbody><tr><td rowspan="2" align="left" colspan="1">
<bold>18o</bold>
</td><td rowspan="2" align="left" colspan="1">43.7</td><td align="left" colspan="1" rowspan="1">Human</td><td align="left" colspan="1" rowspan="1">59.6</td><td align="left" colspan="1" rowspan="1">50.9</td><td align="left" colspan="1" rowspan="1">11.8</td><td align="left" colspan="1" rowspan="1">54.6</td><td align="left" colspan="1" rowspan="1">21%</td></tr><tr><td align="left" colspan="1" rowspan="1">Mouse</td><td align="left" colspan="1" rowspan="1">28.4</td><td align="left" colspan="1" rowspan="1">28.0</td><td align="left" colspan="1" rowspan="1">26.1</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td rowspan="2" align="left" colspan="1">
<bold>18e</bold>
</td><td rowspan="2" align="left" colspan="1">40.1</td><td align="left" colspan="1" rowspan="1">Human</td><td align="left" colspan="1" rowspan="1">15.9</td><td align="left" colspan="1" rowspan="1">19.4</td><td align="left" colspan="1" rowspan="1">67.3</td><td align="left" colspan="1" rowspan="1">30.2</td><td align="left" colspan="1" rowspan="1">19%</td></tr><tr><td align="left" colspan="1" rowspan="1">Mouse</td><td align="left" colspan="1" rowspan="1">22.3</td><td align="left" colspan="1" rowspan="1">21.8</td><td align="left" colspan="1" rowspan="1">54.3</td><td align="left" colspan="1" rowspan="1">&#160;</td><td align="left" colspan="1" rowspan="1">&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Progesterone</bold>
</td><td align="left" colspan="1" rowspan="1">6.7</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Prazosin</bold>
</td><td align="left" colspan="1" rowspan="1">31.3</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>Testosterone</bold>
</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">Human</td><td align="left" colspan="1" rowspan="1">7.11</td><td align="left" colspan="1" rowspan="1">16.13</td><td align="left" colspan="1" rowspan="1">32.44</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td></tr></tbody></table><table-wrap-foot><fn id="t4fn1"><label>a</label><p>Solubility in 1:99 DMSO/PSB buffer.</p></fn><fn id="t4fn2"><label>b</label><p>Percentage remanent (sampling
time
60 min).</p></fn><fn id="t4fn3"><label>c</label><p>
<italic toggle="yes">t</italic>
<sub>1/2</sub> in min.</p></fn><fn id="t4fn4"><label>d</label><p>Intrinsic clearance in &#956;L&#183;min<sup>&#8211;1</sup>&#183;mg<sub>prot</sub>
<sup>&#8211;1</sup>.</p></fn><fn id="t4fn5"><label>e</label><p>Displacement of specific [<sup>3</sup>H]&#173;CP 55,940 binding in membrane
preparations of human CB<sub>1</sub>R transfected in CHO&#8211;CB<sub>1</sub>RC3 cell line expressed
as <italic toggle="yes">K</italic>
<sub>i</sub> in nM (<italic toggle="yes">n</italic> = 3).</p></fn><fn id="t4fn6"><label>f</label><p>Displacement of specific [<sup>3</sup>H]&#173;CP55,940 binding in membrane preparations of human CB<sub>2</sub>R transfected in HEK-293T cells expressed as percentage displacement
of specific binding at a concentration of 1 &#956;M (<italic toggle="yes">n</italic> = 2).</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2.5"><title>Structure&#8211;Activity and Structure-Selectivity Relationship
Analyses</title><p>In this section, we review the binding data (<xref rid="tbl1" ref-type="table">Tables <xref rid="tbl1" ref-type="table"/>
</xref>, <xref rid="tbl2" ref-type="table"/>) and discuss key aspects of the structure-affinity (SAR)
and structure-selectivity (SSR) relationships within the series. These
findings are further supported by molecular modeling studies using
a refined 3D model of CB<sub>2</sub>R. As previously indicated, all
ligands were tested as enantiopure compounds. For clarity, the collection
was organized into four series, each containing 16 derivatives and
exploring five points of diversity: the tail group (R<sup>1</sup>),
the central scaffold (indole or indazole), the conformationally restricted
amino acid linker (proline or homoproline), the functional group (ester
or amide), and the stereochemistry [(<italic toggle="yes">S</italic>) and (<italic toggle="yes">R</italic>) enantiomers].</p><p>The cannabinomimetic affinity profiles
of the conformationally constrained, analogues of abused SCRAs, obtained
in this study are presented in the <xref rid="tbl1" ref-type="table">Tables <xref rid="tbl1" ref-type="table"/>
</xref>, <xref rid="tbl2" ref-type="table"/>. As observed,
nine ligands combine attractive CB<sub>2</sub>R affinity (<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> &lt; 100 nM) and high subtype
selectivity [e.g., compounds <bold>15n</bold>, <bold>16f</bold>, <bold>16j</bold>, <bold>16p</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18i</bold>, <bold>18m</bold>, <bold>18o</bold>]. In addition to uncovering
interesting structural diversity and SAR trends, the obtained data
emphasize the benefits of pharmacophore rigidification as an effective
strategy to achieving selective CB<sub>2</sub>R ligands starting from
highly promiscuous (CB<sub>1</sub>R &amp; CB<sub>2</sub>R) abused
SCRAs (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>), probably
by capturing bioactive conformation. Among the four subsets (<xref rid="tbl1" ref-type="table">Tables <xref rid="tbl1" ref-type="table"/>
</xref>, <xref rid="tbl2" ref-type="table"/>), derivatives containing the piperidine core and amide functional
group (Series <bold>IV</bold>, <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) collectively emerge as the most appealing CB<sub>2</sub>R agonists. All derivatives in this subset exhibit high affinity
and excellent subtype selectivity (&gt;100-fold), regardless of the
tail
group at R<sup>1</sup>, the central bicyclic heterocycle, or the configuration
at the piperidine nuclei. Compounds <bold>18e</bold> (<bold>ISAM-CG585</bold>), <bold>18m</bold> (<bold>ISAM-CG558</bold>), and <bold>18o</bold> (<bold>ISAM-CG557</bold>) stand out, exhibiting <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> values of 30.2, 59.5, and 54.6 nM,
respectively, with almost negligible binding (&#8764;20%) at CB<sub>1</sub>R (at a concentration of 1 &#956;M).</p><p>To analyze the
structure&#8211;activity and structure-selectivity
relationships, the binding data from <xref rid="tbl1" ref-type="table">Tables <xref rid="tbl1" ref-type="table"/>
</xref>, <xref rid="tbl2" ref-type="table"/> were examined.
For clearer visualization of both affinity and selectivity variations,
the binding data (p<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> values) were graphically represented by plotting p<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> CB<sub>1</sub>R (Y axis) against p<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> CB<sub>2</sub>R (X axis),
using an identical scale for both axes (<xref rid="fig6" ref-type="fig">Figures <xref rid="fig6" ref-type="fig"/>
</xref> and <xref rid="fig7" ref-type="fig"/>). Compounds
with equal binding affinities to CB<sub>1</sub>R and CB<sub>2</sub>R will align along the diagonal (Y = X), while those with selective
affinity toward CB<sub>1</sub>R or CB<sub>2</sub>R will appear below
or above the diagonal, respectively. The distance of each compound
from this diagonal serves as a direct indicator of its degree of selectivity.</p><p>A rapid understanding of the significant improvement in selectivity
between the novel conformationally restricted derivatives (Compounds <bold>15</bold>&#8211;<bold>18</bold>) and the reference library of structurally
analogous abused SCRAs (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>) can be obtained by analyzing the data in <xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref>. As observed in the graphs,
the majority of the classical abused SCRAs cluster near the diagonal
(<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref> left), indicating
their nonselective agonist profile. In contrast, many of the newly
synthesized cyclic compounds (<xref rid="fig4" ref-type="fig">Figure <xref rid="fig4" ref-type="fig"/>
</xref> right) are positioned in the lower right region of
the plot, demonstrating a clear shift toward greater selectivity for
CB<sub>2</sub>R, thereby minimizing CB<sub>1</sub>R-related side effects
while improving their therapeutic potential.</p><fig position="float" id="fig4" fig-type="figure" orientation="portrait"><label>4</label><caption><p>Affinity-selectivity
plot for 64 classical abused SCRAs (left)
and the 64 new derivatives (right) herein documented.</p></caption><graphic id="gr5" position="float" orientation="portrait" xlink:href="jm5c00604_0004.jpg"/></fig><p>Although the esters reported here (Series <bold>I</bold> and <bold>II</bold>) were originally conceived as synthetic
intermediates for
the preparation of the targeted amides (<xref rid="sch1" ref-type="fig">Scheme <xref rid="sch1" ref-type="fig"/>
</xref>), they were ultimately included in the pharmacological
evaluation. While esters are generally not considered optimal drug
candidates, their evaluation in this context provides valuable data
for comparing the effects of rigidification on binding profiles in
two functionally distinct series (esters and amides). This comparison
is further supported by available binding data on structurally analogous
abused ester SCRAs (<xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig"/>
</xref>), offering deeper insights into structure&#8211;activity
relationships. Additionally, the affinity data for esters contributed
to identify key SAR trends, both within this group and in relation
to their amide counterparts.</p><p>The analysis of the binding data
for the ester series (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>) shows remarkably
similar structure activity/selectivity relationship (SAR) patterns.
Both subsets&#58872;prolinates [<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> and <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref> (left)] and homoprolinates [<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref> and <xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref> (right)]&#58872;exhibit promiscuous binding profiles
for the (<italic toggle="yes">S</italic>) stereoisomers (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>A squares), consistent with the nonselective
behavior characteristic of both enantiomers in abused synthetic cannabinoids
(SCRAs). The nonselective binding profile observed for (<italic toggle="yes">S</italic>) stereoisomers is largely independent of the R<sup>1</sup> group,
the central core (whether indole or indazole), or the size of the
amino acid residue (proline or homoproline). Despite this promiscuity,
subtle differences in binding affinity can be discerned. For prolinate
derivatives (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), compounds in the indole series generally show higher affinity
for CB<sub>1</sub>R than for CB<sub>2</sub>R, whereas the opposite
trend is noted in the indazole series. Additionally, ligands featuring
cyclohexylmethyl or 4-fluorobenzyl groups at R<sup>1</sup> tend to
display superior binding affinities across both receptor types. A
comparative analysis of the cannabimimetic binding profiles of the
(<italic toggle="yes">R</italic>) stereoisomers from the ester series reveals marked
differences compared to their (<italic toggle="yes">S</italic>) counterparts. The
(<italic toggle="yes">R</italic>) stereoisomers generally exhibit high selectivity
for CB<sub>2</sub>R across both ester series (<xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>). This selectivity is primarily achieved
through a reduction in overall affinity, with the (<italic toggle="yes">R</italic>) derivatives displaying a 3- to 12-fold lower CB<sub>2</sub>R affinity
(<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> = 99.3&#8211;599
nM) compared to the (<italic toggle="yes">S</italic>) stereoisomers. The most potent
ligands in the series often feature cyclohexylmethyl or 4-fluorobenzyl
groups at R<sup>1</sup>, with indazole derivatives generally displaying
superior CB<sub>2</sub>R affinity. Notably, the piperidine derivative <bold>16p</bold> stands out, showing high affinity for CB<sub>2</sub>R
(<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> = 48.4 nM) and negligible
binding to CB<sub>1</sub>R at 1 &#956;M.</p><fig position="float" id="fig5" fig-type="figure" orientation="portrait"><label>5</label><caption><p>Affinity-selectivity
plot for the 64 new derivatives herein documented
clustered according to (A) their functional group or (B) ring size.</p></caption><graphic id="gr6" position="float" orientation="portrait" xlink:href="jm5c00604_0005.jpg"/></fig><p>In sharp contrast to the consistent binding profiles
and SAR trends
seen in the ester series (<bold>I</bold> and <bold>II</bold>, <xref rid="tbl1" ref-type="table">Table <xref rid="tbl1" ref-type="table"/>
</xref>), the affinity data
obtained for the amide subsets (<bold>III</bold> and <bold>IV</bold>, <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) reveal
markedly different binding characteristics. The conversion of esters
in series <bold>I</bold> to its amide analogues (Series <bold>III</bold>) triggers a substantial shift in cannabimimetic binding effect (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref>). Notably, amides
with a five-membered central amino acid residue (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) largely lose their ability
to bind either CB<sub>2</sub>R or CB<sub>1</sub>R. The few exceptions
to this trend include indole derivatives <bold>17e</bold> and <bold>17f</bold>, and indazole-based amide <bold>17o</bold>, which display <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> values of 288, 411, and 628
nM, respectively, with no significant CB<sub>1</sub>R binding. It
is also worth noting that enantiomers <bold>17e</bold> and <bold>17f</bold> both demonstrate moderate CB<sub>2</sub>R affinity, although the
(<italic toggle="yes">S</italic>) stereoisomer shows slightly higher CB<sub>2</sub>R affinity.</p><p>The homoproline amides (series <bold>IV</bold>, <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) represent the most
promising
CB<sub>2</sub>R ligands identified in this study. In stark contrast
to the previously discussed derivatives, particularly their ester
counterparts (series <bold>II</bold>) and their inferior homologues
pyrrolidine-based amides (series <bold>III</bold>), piperidine-based
amides (series <bold>IV</bold>) display a significantly different
cannabimimetic binding profile, both in terms of affinity and selectivity.
As shown in <xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>, all members of this subset demonstrate moderate to high CB<sub>2</sub>R affinity while exhibiting negligible binding to CB<sub>1</sub>R. Notably, the expansion of the central cyclic nitrogenated core
plays a crucial role, transforming inactive pyrrolidine derivatives
(series <bold>III</bold>) into potent, highly selective CB<sub>2</sub>R ligands. A direct comparison between amides <bold>IV</bold> and
their ester analogues (series <bold>II</bold>) further underscores
the importance of the amide functional group in enhancing potency
and selectivity. As observed (<xref rid="fig5" ref-type="fig">Figure <xref rid="fig5" ref-type="fig"/>
</xref> right bottom), transformation of the ester into an
amide group produces an even more a significant loss of affinity for
the CB<sub>1</sub>R receptor, particularly in the (<italic toggle="yes">S</italic>) enantiomers. The potency and selectivity profiles observed are
consistent across the series, showing minimal influence from stereochemistry
or the presence of a second nitrogen atom in the core structure (indole
vs indazole). Changes in R<sup>1</sup> similarly have a slight impact,
except for the cyclohexylmethyl group, which generates the ligands
with the highest affinity. A comparison of the CB<sub>2</sub>R affinity
between (<italic toggle="yes">R</italic>) and (<italic toggle="yes">S</italic>) enantiomers
throughout series <bold>IV</bold> indicates that they are generally
equipotent, though (<italic toggle="yes">S</italic>) enantiomers occasionally demonstrate
slightly higher affinity. The most notable differences (2&#8211;3-fold)
in enantiomeric binding is observed for ligands bearing cyclohexylmethyl
or 4-fluorobenzyl groups at R<sup>1</sup>, being consistently the
(<italic toggle="yes">S</italic>) stereoisomers more potent than its (<italic toggle="yes">R</italic>) counterparts (e.g., compare <bold>18e</bold> and <bold>18f</bold>, <bold>18m</bold> and <bold>18n</bold>, <bold>18g</bold> and <bold>18h</bold>, <bold>18o</bold> and <bold>18p</bold>).</p><p>Since amide
series <bold>IV</bold> (<xref rid="tbl2" ref-type="table">Table <xref rid="tbl2" ref-type="table"/>
</xref>) led to the identification of the most potent
(<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> &lt; 100 nM) and
selective CB<sub>2</sub>R ligands identified in this study (e.g., <bold>18e</bold>, <bold>18m</bold>, <bold>18o</bold>), these compounds,
along with other structurally and functionally diverse analogs, were
selected for in-depth analysis through computational tools and advanced
pharmacological studies. The exploration encompassed their functional
behavior, preferred signaling pathways, preliminary pharmacokinetic
profiles, as well as their anti-inflammatory and neuroprotective effects.</p></sec><sec id="sec2.6"><title>Molecular Docking</title><p>To provide a molecular basis for
the obtained affinity data, we conducted docking simulations within
the orthosteric binding site of the CB<sub>2</sub>R. As the starting
protein structure, we employed the recently published X-ray data of
the receptor complexed with an agonist (PDB code: <ext-link xlink:href="6KPC" ext-link-type="PDB">6KPC</ext-link>, released in 2020<xref rid="ref46" ref-type="bibr"/>). Notice that given the structural differences
of the studied molecules with respect to the cocrystallized ligand
(i.e., AM12033), flexibility was allowed for all protein cavity atoms
during postdocking Molecular Mechanics energies combined with the
Generalized Born and Surface Area continuum solvation (MM-GBSA) calculations.<xref rid="ref47" ref-type="bibr"/> For the sake of clarity, we present below the
molecular insights derived from the docking simulations for each SAR
clue obtained from the experimental data. <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref> shows the complexes obtained after performing postdocking
MM-GBSA calculations on the top-scored pose of ligands <bold>11</bold> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>A) and <bold>12</bold> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>B). Notably, compound <bold>11</bold> is predicted to establish a
T-shaped &#960;-&#960; stacking interaction with F183. Additionally,
its amide group interacts with F106 (aromatic H-bond) and H95 (H-bond
interaction). Interestingly, methylation of this amide group disrupts
these interactions, providing a possible explanation for the observed
reduced CB<sub>2</sub>R affinity as indicated by the measured <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> (125 nM vs 540 nM returned
by <bold>11</bold> and <bold>12</bold>, respectively). However, this
substitution does not significantly alter the predicted binding mode,
as the newly introduced methyl group engages in hydrophobic interactions
with F91. The picture emerging from the analysis of the binding poses
is consistent with the MM-GBSA free binding energy values, which are
&#8722;63.79 kcal/mol and &#8722;56.19 kcal/mol for compounds <bold>11</bold> and <bold>12</bold>, respectively. In summary, the study
provides a robust binding mode hypothesis for these compounds and
offers a rational explanation of how methylation, although detrimental,
does not result in a dramatic loss of CB<sub>2</sub>R affinity.</p><fig position="float" id="fig6" fig-type="figure" orientation="portrait"><label>6</label><caption><p>Protein&#8211;ligand
complexes returned by MMGBSA calculations
performed on the top-scored docking poses of: (A) <bold>11</bold>,
(B) <bold>12</bold>, (C) <bold>17e</bold>, (D) <bold>18e</bold>, (E) <bold>18f</bold>, and (F) <bold>18o</bold>. &#960;&#8211;&#960; stacking
interactions are shown as blue dashed lines, hydrogen bonds as black
dashed lines, aromatic hydrogen bonds as red dashed lines, and hydrophobic
interactions are indicated by yellow lines.</p></caption><graphic id="gr7" position="float" orientation="portrait" xlink:href="jm5c00604_0006.jpg"/></fig><p>The effect of conformational restriction, as well
as ring contraction,
was studied using compounds <bold>17e</bold> (pentagonal amide, <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> = 288 nM) and <bold>18e</bold> (hexagonal amide, <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> = 30.2 nM) as model ligands [both (<italic toggle="yes">S</italic>) stereoisomers].
The top-scored poses obtained after MM-GBSA calculations are shown
in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>C (<bold>17e</bold>) and <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>D (<bold>18e</bold>). Remarkably, compound <bold>17e</bold> is predicted
to interact with the receptor pocket through a binding mode very similar
to that observed for compound <bold>11</bold> (<xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>A). Specifically, it establishes a T-shaped
&#960;-&#960; interaction with F183, an aromatic H-bond with F106,
and a hydrogen bond with H95. The substitution of a pyrrolidine (series <bold>III</bold>) with a piperidine (series <bold>IV</bold>) results in
a significant change in binding mode. The amide group, instead of
interacting with H95, establishes a strong interaction with the backbone
of L182. Consistent with the experimental data, this different binding
mode translates into a distinct MMGBSA energy, estimated to be &#8722;64.03
kcal/mol (<bold>17e</bold>) and &#8722;71.65 kcal/mol (<bold>18e</bold>). Notably, the importance of the interaction with L182 is highlighted
by a more detailed analysis of the individual contributions to the
free binding energy. The difference, indeed, is primarily attributed
to the electrostatic contribution (i.e., MM-GBSA dG Bind Coulomb),
which increases from &#8722;1.77 kcal/mol (17e) to &#8722;12.48
kcal/mol (<bold>18e</bold>).</p><p>Since some of the enantiomeric
pairs of the most intriguing series
(series <bold>IV</bold>&#58872;piperidine derivatives) exhibits noticeable
enantioselectivity, we aimed to investigate its underlying reasons
by analyzing two enantiomers, namely <bold>18e</bold> (<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> = 30.2 nM) and <bold>18f</bold> (<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> = 96.8 nM). The complexes
obtained after MM-GBSA calculations are shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>D (<bold>18e</bold>-(<italic toggle="yes">S</italic>) enantiomer) and <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>E (<bold>18f</bold>-(<italic toggle="yes">R</italic>) enantiomer).
As evident from the figures, the change in chirality results in a
different orientation of the amide moiety within the pocket. Specifically,
this moiety, which establishes a strong interaction with L182 in the
(<italic toggle="yes">S</italic>) enantiomer, reorients in the (<italic toggle="yes">R</italic>) enantiomer to form an interaction with the side chain of S90. This
altered orientation seems to be the responsible for the differing
free binding energy values, consistent with the experimental data:
&#8722;71.65 kcal/mol for <bold>18e</bold> and &#8722;63.65 kcal/mol
for <bold>18f</bold>. Notably, this conformational adaptation within
the pocket leads to a reduced contribution to the free energy in terms
of Coulombic interactions (&#8722;9.57 kcal/mol vs &#8722;12.48
kcal/mol). Given that compound <bold>18o</bold> is one of the most
promising candidates, the same protocol was applied to it. The complex
obtained from the MM-GBSA calculations is shown in <xref rid="fig6" ref-type="fig">Figure <xref rid="fig6" ref-type="fig"/>
</xref>F. Consistent with the previously
observed trends and experimental data, <bold>18o</bold> is predicted
to interact with CB<sub>2</sub>R in the same manner as <bold>18e</bold>, with its terminal amide forming a strong interaction with the backbone
of L182. The binding free energy values support this finding, with
a predicted value of &#8722;83.50 kcal/mol. Finally, as observed
across the binding data analysis (<xref rid="tbl1" ref-type="table">Tables <xref rid="tbl1" ref-type="table"/>
</xref>, <xref rid="tbl2" ref-type="table"/>), the similar
binding modes obtained for <bold>18o</bold> and <bold>18e</bold> support
the noncritical role of the second nitrogen atom and the residue at
R<sup>1</sup> for CB<sub>2</sub>R binding.</p><p>It is worth noting
that, to gain molecular insights into the effect
of the conformational restriction on CB<sub>1</sub>R affinity, <bold>13</bold> (<italic toggle="yes">K<sub>i</sub>
</italic> = 268 nM) and <bold>18e</bold> (19% displacement at 1 &#956;M) were docked into the CB<sub>1</sub>R binding site. The docking results indicate that the applied conformational
restriction prevents <bold>18e</bold> from efficiently binding CB<sub>1</sub>R due to a steric hindrance with F177 (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Figure S3</ext-link>).</p></sec><sec id="sec2.7"><title>Intrinsic Activity Assays and Signaling Bias Evaluation</title><p>To gain deeper insight into the functional effects of the identified
CB<sub>2</sub>R ligands, a subset of six ligands (<bold>16i</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, and <bold>18p</bold>) was selected based on their affinity, selectivity,
and structural diversity</p><p>Initially we tested their ability to
modify CB<sub>2</sub>R-mediated cAMP accumulation, providing insights
into their functional behavior as either agonists or antagonists (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>). Moreover, the signaling
profiles of selected ligands were investigated through their impact
on &#946;-arrestin recruitment and Mitogen-Activated Protein Kinase
(MAPK) phosphorylation pathway, enabling a more comprehensive evaluation
of their intracellular signaling profiles (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>).</p><p>A detailed description of the protocols
employed is reported in
the experimental part. An initial observation from the data (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>) reveals the identification
of some ligands with EC<sub>50</sub> values in the low picomolar range
across various signaling pathways, accompanied by <italic toggle="yes">E</italic>
<sub>max</sub> values indicative of either partial or full agonist
profiles. The dose&#8211;response curves for each ligand, evaluated
across the different signaling pathways, are presented in <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>. The cAMP assay data presented in <xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref> and <xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>, expressed as the maximal effect achieved by JWH-133,
provide unequivocal evidence that tested ligands behave as CB<sub>2</sub>R agonists. A dose-dependent reduction in cAMP levels was
observed for all evaluated compounds. As observed (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>), except for <bold>18e</bold>, most compounds exhibited EC<sub>50</sub> values in the low nanomolar
(e.g., <bold>18p</bold>, <bold>18f</bold>) or picomolar (e.g., <bold>16i</bold>, <bold>16j</bold>, and <bold>18o</bold>) range. It should
be highlighted that marked EC<sub>50</sub> differences (&gt;10-fold)
were observed (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>) for two enantiomer pairs (<bold>18e</bold>/<bold>18f</bold> and <bold>18o</bold>/<bold>18p</bold>) of the evaluated subset. For ligands <bold>16i</bold>, <bold>16j</bold>, and <bold>18o</bold>, the observed
EC<sub>50</sub> values indicated significantly greater functional
activity compared to the reference agonist JWH-133. As observed, in
this pathway (cAMP), all compounds behave as partial or full agonists,
with <italic toggle="yes">E</italic>
<sub>max</sub> values ranging from 53 to 82%.</p><fig position="float" id="fig7" fig-type="figure" orientation="portrait"><label>7</label><caption><p>Dose&#8211;response
curves (expressed as the percentage of the
maximum decrease of forskolin-induced cAMP levels elicited by JWH-133)
obtained for selected ligands across the different signaling pathways
to assess its biased signaling profile at CB<sub>2</sub>R.</p></caption><graphic id="gr8" position="float" orientation="portrait" xlink:href="jm5c00604_0007.jpg"/></fig><p>Biased agonists are ligands that exhibit preferential
activation
of certain signaling pathways over others, thereby offering the possibility
of fine-tuning receptor-mediated responses. Accordingly, the study
of signaling bias has gained great attention due to its potential
to develop safer and more efficacious drugs.<xref rid="ref48" ref-type="bibr"/> Although several CB<sub>2</sub>R-biased agonists have been identified,<xref rid="ref49" ref-type="bibr"/> most of these agonists, to the best of our knowledge,
exhibit limited subtype selectivity (e.g., CB<sub>1</sub>R vs CB<sub>2</sub>R).<xref rid="ref49" ref-type="bibr"/> Because of this lack of subtype
selectivity, it is difficult to precisely investigate and interpret
biased signaling effects in complex cellular systems (i.e., where
both receptors are coexpressed). Given the enormous therapeutic potential
of CB<sub>2</sub>R agonists, particularly for treating challenging
diseases and conditions such as neuroinflammation, pain, and immune
disorders,<named-content content-type="bibref-group">
<xref rid="ref17" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>
</named-content> it is essential to assess the
signaling profiles of new subtype selective CB<sub>2</sub>R ligands
to determine whether they exhibit significant bias toward intracellular
pathways.<xref rid="ref49" ref-type="bibr"/>
</p><p>To investigate the biased
signaling of selected ligands (<bold>16b</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, and <bold>18p</bold>), we focused on three key pathways:
cAMP modulation, &#946;-arrestin recruitment, and MAPK phosphorylation,
each associated with distinct downstream physiological outcomes.<named-content content-type="bibref-group">
<xref rid="ref10" ref-type="bibr"/>,<xref rid="ref50" ref-type="bibr"/>
</named-content> The compounds were assessed for their ability to engage these pathways
by determining their EC<sub>50</sub> values and efficacy (<italic toggle="yes">E</italic>
<sub>max</sub>) in each assay (<xref rid="fig7" ref-type="fig">Figure <xref rid="fig7" ref-type="fig"/>
</xref>). JWH-133, a well-known nonbiased (balanced)
agonist,<xref rid="ref49" ref-type="bibr"/> was employed as the reference
for comparing the signaling profiles of the tested compounds. An operational
model analysis<xref rid="ref51" ref-type="bibr"/> was applied to quantify
the functional bias of each CB<sub>2</sub>R-selective agonist. This
involved calculating the bias factor by comparing the signaling pathways:
&#946;-arrestin versus cAMP, MAPK versus cAMP, and &#946;-arrestin
versus MAPK. By calculating the bias factors relative to JWH-133,
nonbiased reference, it was possible to identify pathway-selective
preferences of the compounds. The results, summarized in <xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>, highlight the distinct
signaling preferences of each compound, allowing us to better understand
their selectivity and potential for biased agonism.</p><p>Enantiomers <bold>16i</bold> and <bold>16j</bold> demonstrated
a marked bias for G-protein pathway (<xref rid="tbl3" ref-type="table">Table <xref rid="tbl3" ref-type="table"/>
</xref>), as evidenced by negative &#916;&#916;log&#173;(<italic toggle="yes">E</italic>
<sub>max</sub>/EC<sub>50</sub>) values in &#946;-arrestin&#8211;cAMP
and MAPK&#8211;cAMP comparisons. This suggests that these ligands
preferentially activate G-protein signaling while minimizing &#946;-arrestin
and MAPK signaling. On the other hand, enantiomers <bold>18e</bold> and <bold>18f</bold> show a strong bias toward &#946;-arrestin
and MAPK pathways, with exceptionally high values in &#946;-arrestin&#8211;cAMP
and MAPK&#8211;cAMP comparisons, highlighting the predominant activation
of the &#946;-arrestin pathway among the evaluated compounds. Finally,
compounds <bold>18o</bold> and <bold>18p</bold> display notable bias
toward MAPK, especially in &#946;-arrestin&#8211;MAPK signaling,
indicating a selective MAPK pathway activation.</p><p>Understanding
functional bias is crucial for designing drugs that
selectively modulate CB<sub>2</sub>R signaling to meet specific therapeutic
needs, while minimizing side effects linked to unwanted signaling.
In this context, our newly identified compounds demonstrate both high
subtype selectivity (most of them with negligible CB<sub>1</sub>R
binding) and attractive biased profiles. This analysis demonstrates
that each ligand&#8217;s specific bias profile could support tailored
therapeutic applications, with <bold>16i</bold> and <bold>16j</bold> favoring G-protein pathways, while <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, and <bold>18p</bold> offer potential for therapies
leveraging &#946;-arrestin and MAPK pathway activation selectively.
This differential signaling highlights their versatility and potential
of these candidates for pathway-specific modulation in targeted therapeutic
settings.</p></sec><sec id="sec2.8"><title>Solubility and Microsomal Stability Exploration</title><p>As
part of the profiling of selected ligands, and to complement the computational
studies outlined in the previous sections (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>), two CB<sub>2</sub>R agonists (<bold>18o</bold> and <bold>18e</bold>) were selected for preliminary pharmacokinetic
characterization to assess their kinetic solubility and liver microsomal
stability. These data provide preliminary insights into their <italic toggle="yes">in vitro</italic> ADMET profiles. As shown (<xref rid="tbl4" ref-type="table">Table <xref rid="tbl4" ref-type="table"/>
</xref>), both ligands display moderate to satisfactory
solubility (40&#8211;55 &#956;M) in PBS at pH 7, indicating that
structural rigidification did not significantly impact this property.
These results are encouraging, as maintaining adequate solubility
while introducing molecular rigidity is often challenging.</p><p>The
microsomal stability study for compounds <bold>18o</bold> and <bold>18e</bold> reveals differences in metabolic stability between species
and across compounds (<xref rid="tbl4" ref-type="table">Table <xref rid="tbl4" ref-type="table"/>
</xref>). Compound <bold>18o</bold> stands out for its favorable
stability in human microsomes, with 59.6% of the compound remaining
after 60 min, a half-life of 50.9 min, and a low clearance rate of
11.8 &#956;L&#183;min<sup>&#8211;1</sup>&#183;mgprot<sup>&#8211;1</sup>. These metrics suggest that <bold>18o</bold> is metabolically stable,
making it a strong candidate for further development. However, in
mouse microsomes, <bold>18o</bold> shows a faster metabolism, with
only 28.4% remaining and a shorter half-life of 28 min, highlighting
the species-specific metabolic differences often observed in preclinical
models.<xref rid="ref52" ref-type="bibr"/> Compound <bold>18e</bold>, on
the other hand, exhibits poor stability in both human and mouse microsomes,
with significantly lower remaining percentage (15.9% in humans and
22.3% in mice), shorter half-lives (19.4 min in humans and 21.8 min
in mice), and much higher clearance rates (67.3 &#956;L&#183;min<sup>&#8211;1</sup>&#183;mgprot<sup>&#8211;1</sup> in humans), suggesting
rapid metabolism that could limit its therapeutic potential.</p><p>It is important to highlight the structural differences between
compounds <bold>18o</bold> and <bold>18e</bold>, which likely contribute
to their distinct metabolic profiles. The key variations lie in the
presence of a nitrogen atom at position 2 of the central scaffold
(indole vs indazole) and the substituent at the R<sup>1</sup> position
(4-fluorobenzyl in <bold>18o</bold> vs cyclohexylmethyl in <bold>18e</bold>). Among these structural features, it is reasonable to hypothesize
that the R<sup>1</sup> group would have the most significant impact
on their metabolic stability. The 4-fluorobenzyl group in <bold>18o</bold> may contribute to its superior microsomal stability, especially
in human liver microsomes, by reducing susceptibility to metabolic
degradation. In contrast, the cyclohexylmethyl group in <bold>18e</bold> could be more prone to metabolic transformations, accounting for
the much higher clearance and shorter half-life observed across both
human and mouse microsomes. This structural insight aligns with the
superior pharmacokinetic profile of <bold>18o</bold> and underscores
the importance of R<sup>1</sup> group selection when designing metabolically
stable drug candidates in these subsets.</p></sec><sec id="sec2.9"><title>BBB Permeability and P-Glycoprotein Interaction Investigation</title><p>The therapeutic potential of CB<sub>2</sub>R agonists in treating
neurodegenerative diseases, hinges critically on their ability to
cross the blood-brain barrier (BBB) and evade active efflux mechanisms,
such as that mediated by P-glycoprotein (P-gP). The BBB is a highly
selective barrier that regulates the passage of substances into the
central nervous system (CNS), making it essential to evaluate drug
candidates&#8217; permeability across this barrier.<xref rid="ref53" ref-type="bibr"/> Furthermore, P-gP, a transporter protein expressed in the
BBB, often actively pumps foreign substances out of the brain, limiting
drug efficacy in CNS applications.<xref rid="ref54" ref-type="bibr"/> Therefore,
understanding both BBB permeability and P-gp interaction is crucial
for developing CNS-acting agents, as effective compounds must exhibit
both good brain penetration and minimal efflux to ensure sustained
therapeutic concentrations within the CNS.<xref rid="ref55" ref-type="bibr"/>
</p><p>To validate the early predictions from the CNS-MPO and BOILED-egg
models (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig"/>
</xref>),
we experimentally assessed the BBB permeability and P-gp interaction
of the selected CB<sub>2</sub>R agonists. For these studies, two pairs
of amide enantiomers (<bold>18p</bold> and <bold>18o</bold>, <bold>18e</bold>, and <bold>18f</bold>) were selected, and the evaluations
were conducted using established protocols previously published by
our group.<xref rid="ref20" ref-type="bibr"/> Key parameters measured included
the permeability coefficients (<italic toggle="yes">P</italic>
<sub>app</sub>BA
and <italic toggle="yes">P</italic>
<sub>app</sub>AB), the bidirectional permeability
ratio (BA/AB), and the degree of interaction with P-gP, as detailed
in <xref rid="tbl5" ref-type="table">Table <xref rid="tbl5" ref-type="table"/>
</xref>.</p><table-wrap position="float" id="tbl5" orientation="portrait"><label>5</label><caption><title>Evaluation of the BBB Permeability
and P-gp Interaction of Selected CB<sub>2</sub>R</title></caption><graphic id="fx5" content-type="header" position="float" orientation="portrait" xlink:href="jm5c00604_0017.jpg"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="center" colspan="1" rowspan="1">ligand</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
<sub>app</sub>BA (nm/sec)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
<sub>app</sub>AB (nm/sec)</th><th align="center" char="." colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
<sub>app</sub> (BA/AB)</th><th align="center" colspan="1" rowspan="1">P-gp interaction
EC<sub>50</sub> (&#956;M)
or % at 100&#160;&#956;M</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">
<bold>18o (ISAM-CG557)</bold>
</td><td align="char" char="." colspan="1" rowspan="1">290</td><td align="char" char="." colspan="1" rowspan="1">727</td><td align="char" char="." colspan="1" rowspan="1">0.39</td><td align="left" colspan="1" rowspan="1">49%</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18p (ISAM-CG549)</bold>
</td><td align="char" char="." colspan="1" rowspan="1">219</td><td align="char" char="." colspan="1" rowspan="1">632</td><td align="char" char="." colspan="1" rowspan="1">0.35</td><td align="left" colspan="1" rowspan="1">56.9&#160;&#956;M</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18e (ISAM-CG585)</bold>
</td><td align="char" char="." colspan="1" rowspan="1">506</td><td align="char" char="." colspan="1" rowspan="1">995</td><td align="char" char="." colspan="1" rowspan="1">0.51</td><td align="left" colspan="1" rowspan="1">30%</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>18f (ISAM-CG586)</bold>
</td><td align="char" char="." colspan="1" rowspan="1">393</td><td align="char" char="." colspan="1" rowspan="1">792</td><td align="char" char="." colspan="1" rowspan="1">0.49</td><td align="left" colspan="1" rowspan="1">61.8 &#956;M</td></tr></tbody></table></table-wrap><p>The overall analysis of the experimental data (<xref rid="tbl5" ref-type="table">Table <xref rid="tbl5" ref-type="table"/>
</xref>) reveals that the
four tested
compounds&#58872;<bold>18p</bold>, <bold>18o</bold>, <bold>18e</bold>, and <bold>18f</bold>&#58872;demonstrate good potential as CNS-targeted
therapeutics based on their BBB permeability and P-glycoprotein (P-gp)
interactions. All four compounds showed a noticeable ability to cross
membranes, with particularly rapid transport from the apical compartment,
where efflux pumps are expressed following polarization, to the basolateral
compartment (<italic toggle="yes">P</italic>
<sub>app</sub>AB). Because these derivatives
exhibit low (EC<sub>50</sub> ranging from 56.9 to 61.8 &#956;M) or
negligible (30 and 49% inhibition at 100 &#956;M) interaction with
P-gp, they are expected to readily cross the BBB and reach their CNS
target, avoiding P-gp-mediated efflux. In the permeability assay, <bold>18e</bold> exhibited the most promising profile, with high <italic toggle="yes">P</italic>
<sub>app</sub>BA (506 nm/sec) and <italic toggle="yes">P</italic>
<sub>app</sub>AB (995 nm/sec) values and minimal P-gp interaction (30%
inhibition at 1 &#956;M), indicating strong BBB penetration and minimal
efflux from the brain. This is further supported by its BA/AB ratio
(0.51), indicative of balanced bidirectional permeability, thereby
positioning it as a promising candidate for CNS applications, such
as in neuroinflammation and neurodegenerative diseases. <bold>18f</bold> also performed well, exhibiting a slightly lower <italic toggle="yes">P</italic>
<sub>app</sub>BA value of 393 nm/sec and a high <italic toggle="yes">P</italic>
<sub>app</sub>AB value of 792 nm/sec, along with low P-gp interaction
(61.8 &#956;M). Compounds <bold>18e</bold>, <bold>18p</bold>, and <bold>18o</bold> all demonstrated predicted ability to cross the blood&#8211;brain
barrier, with varying degrees of permeability and P-gp interaction.
While <bold>18e</bold> showed higher passive influx, <bold>18p</bold> and <bold>18o</bold> also exhibited acceptable permeability profiles
and moderate P-gp-mediated efflux. These results support the potential
of all three compounds as viable candidates for CNS applications.</p></sec><sec id="sec2.10"><title>Assessment of CB<sub>1</sub>R Activity to Evaluate Central Safety
of CB<sub>2</sub>R-Selective Ligands</title><p>Given their excellent
CB<sub>2</sub>R functional activity and ability to cross the blood&#8211;brain
barrier, compounds <bold>18p</bold> and <bold>18o</bold> were selected
for CB<sub>1</sub>R functional evaluation to assess potential risks
of CB<sub>1</sub>R-mediated central effects. In a Gi protein&#8211;mediated
cAMP inhibition assay, performed according to our previously described
protocol,<xref rid="ref29" ref-type="bibr"/> both compounds showed weak
CB<sub>1</sub>R activation. Compound <bold>18p</bold> showed an EC<sub>50</sub> of 755 &#177; 31 nM and <italic toggle="yes">E</italic>
<sub>max</sub> of 45%, while <bold>18o</bold> displayed even lower efficacy (36%)
and potency (EC<sub>50</sub> = 1071 &#177; 57 nM). In contrast, both
ligands demonstrated markedly superior CB<sub>2</sub>R activity, with <bold>18p</bold> showing EC<sub>50</sub> = 6.80 &#177; 0.3 nM and <italic toggle="yes">E</italic>
<sub>max</sub> = 58%, and <bold>18o</bold> achieving EC<sub>50</sub> = 0.60 &#177; 0.09 nM and <italic toggle="yes">E</italic>
<sub>max</sub> = 60%, resulting in functional selectivity ratios of 111 (<bold>18p</bold>) and &gt;1780 (<bold>18o</bold>). Full CB<sub>1</sub>R
dose&#8211;response
curves are provided in the Supporting Information (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Figure S6</ext-link>). These results confirm that both compounds exhibit
limited CB<sub>1</sub>R activity and are unlikely to trigger CB<sub>1</sub>R-mediated psychotropic effects at therapeutically relevant
concentrations. Notably, compound <bold>18o</bold> stands out for
its exceptional CB<sub>2</sub>R potency and functional selectivity,
reinforcing its profile as a highly promising CB<sub>2</sub>R agonist
with minimal risk of central side effects despite effective CNS penetration.</p></sec><sec id="sec2.11"><title>Anti-Inflammatory Profiling of CB<sub>2</sub>R Agonists: Insights
into Cytokine Production</title><p>The CB<sub>2</sub>R plays a crucial
role in regulating immune and inflammatory responses.<xref rid="ref17" ref-type="bibr"/> Unlike CB<sub>1</sub>R, which is predominantly expressed
in the CNS system and associated with psychoactive effects, CB<sub>2</sub>R is primarily found in peripheral tissues, including immune
cells (e.g., monocytes, macrophages, and microglia). Its activation
has been linked to anti-inflammatory and immunomodulatory effects,
making it a promising target in conditions where chronic inflammation
plays a central role in disease progression, including cancer, neurodegenerative
diseases, autoimmune diseases, and obesity.<named-content content-type="bibref-group">
<xref rid="ref15" ref-type="bibr"/>,<xref rid="ref40" ref-type="bibr"/>,<xref rid="ref56" ref-type="bibr"/>
</named-content> Some selective CB<sub>2</sub>R agonists
have shown promise as therapeutic agents due to their ability to modulate
cytokine profiles and reduce inflammation.<named-content content-type="bibref-group">
<xref rid="ref19" ref-type="bibr"/>,<xref rid="ref20" ref-type="bibr"/>
</named-content>
</p><p>Six representative CB<sub>2</sub>R agonists (<bold>16i</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, and <bold>18p</bold>) were evaluated for their ability to modulate
the production of key pro- (e.g., TNF-&#945;, IFN-&#947;, IL-1&#946;,
IL-6) and anti-inflammatory (e.g., IL-4, IL-10) cytokines in human
monocytes and macrophages, where CB<sub>2</sub>R is abundantly expressed.<xref rid="ref12" ref-type="bibr"/> The experiments were performed both in basal
and LPS-activated states and would allow to gain insight into how
these compounds affect circulating leukocytes (monocytes) and tissue-resident
cells (macrophages). To mimic an inflammatory environment, both cell
types were also treated with LPS, enabling an assessment of the anti-inflammatory
potential of the compounds in both resting and activated states. Alongside
the selected ligands, the study included HU308,<xref rid="ref57" ref-type="bibr"/> a well-established CB<sub>2</sub>R-selective agonist known
for its anti-inflammatory properties, and SR144528,<xref rid="ref58" ref-type="bibr"/> a CB<sub>2</sub>R-selective antagonist. SR144528 was used
alone and in combination with the test compounds to confirm that the
observed effects were specifically mediated through CB<sub>2</sub>R activation.</p><p>As illustrated in <xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>, all tested compounds (<bold>16i</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>,
and <bold>18p</bold>) significantly reduced the production of pro-inflammatory
cytokines (TNF-&#945;, IFN-&#947;, IL-1&#946;, and IL-6) in unstimulated
monocytes and macrophages, demonstrating comparable or even superior
efficacy to the reference CB<sub>2</sub>R agonist HU308 (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>, panel A and C,
respectively). Consistently, selected ligands also enhanced the production
of anti-inflammatory cytokines (IL-4 and IL-10) to levels like those
observed with HU308 (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>, panel A and C). The effects were even more pronounced in
LPS-activated monocytes (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>, panel B) and macrophages (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>, panel D), where a greater modulation of
both pro- and anti-inflammatory cytokine levels was detected. As expected,
the CB<sub>2</sub>R antagonist SR144528 reversed these effects across
most tested conditions, confirming CB<sub>2</sub>R-mediated activity.</p><fig position="float" id="fig8" fig-type="figure" orientation="portrait"><label>8</label><caption><p>Cytokines
levels in human monocytes (A, B) and macrophages (C,
D) treated with CB<sub>2</sub>R ligands. THP-1 cells either untreated
(A-B) or treated (C, D) with 0.01 &#956;M PMA for 48 h to differentiate
them into macrophages, were incubated for additional 24 h in the absence
(A, C) or presence of 10 &#956;g/mL LPS (B, D), without (Ctrl) or
with the CB<sub>2</sub>R reference agonist HU308, the reference antagonist
SR144528 and the CB<sub>2</sub>R ligands <bold>16i</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, <bold>18p</bold> at 100 nM. All the compounds were tested alone (solid bars) and
in the presence of the CB<sub>2</sub>R antagonist SR144528 (striped
bars). Cytokine levels were measured by ELISA coupled with qRT-PCR.
Data are means &#177; SD (<italic toggle="yes">n</italic> = 3). Two-way ANOVA followed
by Tukey&#8217;s posthoc test was applied. *<italic toggle="yes">p</italic> &lt;
0.05; **<italic toggle="yes">p</italic> &lt; 0.01; ***<italic toggle="yes">p</italic> &lt; 0.001;
****<italic toggle="yes">p</italic> &lt; 0.0001; * indicates vs Ctrl.</p></caption><graphic id="gr9" position="float" orientation="portrait" xlink:href="jm5c00604_0008.jpg"/></fig><p>To further investigate the efficacy of our tested
compounds, we
conducted dose&#8211;response experiments on macrophages stimulated
with LPS, comparing their effects to the known agonist HU308. The
compounds were evaluated at concentrations of 1, 10, and 100 nM (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Figure S4</ext-link>), showing a clear dose&#8211;response
effect in all cases.</p><p>These findings collectively highlight the
anti-inflammatory properties
of the selected CB<sub>2</sub>R agonists. As observed (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>, panel B and D), the maximum
decrease in pro-inflammatory cytokines and the enhanced release of
anti-inflammatory cytokines in LPS-stimulated cells indicate that
these compounds are more effective in managing strong inflammatory
responses, both in circulating immune cells (monocytes) and tissue-resident
cells (macrophages). The cytokine modulation profiles observed (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>) support the hypothesis
that these ligands promote a shift toward an anti-inflammatory immune
response, reducing the detrimental effects of chronic inflammation.
This makes them promising candidates for the development of new therapies
addressing severe inflammatory conditions, such as systemic infections,
sepsis, neuroinflammation, and certain types of cancer or scenarios
where conventional anti-inflammatory treatments are insufficient.
Moreover, the selective targeting of CB<sub>2</sub>R without activating
CB<sub>1</sub>R ensures a favorable safety profile, minimizing the
risk of psychoactive side effects, and positioning these ligands as
promising candidates for neurodegenerative and oncological therapies.
To ensure the safety and viability of our tested compounds, we evaluated
their cytotoxic effects on monocytes and macrophages under the same
conditions as those used for assessing anti-inflammatory activity
(<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>). Each compound
was tested at a concentration of 100 nM. The cytotoxicity assays confirmed
that the compounds did not adversely affect cell viability, supporting
their potential as therapeutic agents (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Figure S5</ext-link>).</p><p>Among the six evaluated CB<sub>2</sub>R ligands,
distinct cytokine
modulation profiles were observed, possibly reflecting their unique
signaling bias. <bold>16i</bold> and <bold>16j</bold>, with a pronounced
bias toward cAMP-mediated G-protein signaling, and <bold>18o</bold> and <bold>18p</bold>, strongly biased toward MAPK signaling, demonstrated
a significant reduction in pro-inflammatory cytokines such as TNF-&#945;,
IFN-&#947;, and IL-1&#946;, while also increasing anti-inflammatory
cytokines like IL-10 and IL-4 (<xref rid="fig8" ref-type="fig">Figure <xref rid="fig8" ref-type="fig"/>
</xref>). In contrast, <bold>18e</bold> and <bold>18f</bold>, which are predominantly biased toward &#946;-arrestin, showed
limited efficacy in reducing pro-inflammatory cytokines and promoting
anti-inflammatory ones. The stronger recruitment of &#946;-arrestin
may underlie this suboptimal profile, as it appears less effective
in shifting the immune balance toward an anti-inflammatory state.
These findings suggest that excessive &#946;-arrestin signaling might
not be ideal for resolving inflammatory responses and could contribute
to pro-inflammatory conditions under certain circumstances, as previously
reported in studies exploring the impact of &#946;-arrestin-biased
ligands at CB<sub>2</sub>R.<named-content content-type="bibref-group">
<xref rid="ref59" ref-type="bibr"/>,<xref rid="ref60" ref-type="bibr"/>
</named-content>
</p><p>Given the subtype
selectivity and biased signaling profiles of
the herein developed CB<sub>2</sub>R agonists, we investigated how
their &#916;&#916;log&#173;(<italic toggle="yes">E</italic>
<sub>max</sub>/EC<sub>50</sub>) values relative to &#946;-arrestin correlate with cytokine modulation.
Given the complex nature of biased signaling, we selected cAMP vs
&#946;-arrestin as a representative comparison to simplify the interpretation
of the data. This approach allows us to clearly delineate the pro-
and anti-inflammatory profiles of the biased ligands without introducing
additional layers of complexity inherent to three-way comparisons.
Additional analyses, including cAMP vs MAPK and &#946;-arrestin vs
MAPK, are provided in <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Figure S6</ext-link> for further
exploration of these signaling axes. As shown in <xref rid="fig9" ref-type="fig">Figure <xref rid="fig9" ref-type="fig"/>
</xref>, the cytokine expression profiles
for both pro-inflammatory (TNF-&#945;, IFN-&#947;, IL-1&#946;,
IL-6) and anti-inflammatory (IL-10, IL-4) cytokines vary distinctly
along the bias axis from cAMP to &#946;-arrestin. Ligands with a
stronger bias toward &#946;-arrestin [positive &#916;&#916;log&#173;(<italic toggle="yes">E</italic>
<sub>max</sub>/EC<sub>50</sub>) values] are associated
with an increase in pro-inflammatory cytokines (TNF-&#945;, IFN-&#947;)
and a reduction in anti-inflammatory cytokines (IL-10, IL-4). Conversely,
ligands biased toward cAMP [negative &#916;&#916;log&#173;(<italic toggle="yes">E</italic>
<sub>max</sub>/EC<sub>50</sub>) values] show a decrease in pro-inflammatory
cytokines and an increase in anti-inflammatory cytokines, highlighting
the beneficial effects of cAMP signaling in suppressing inflammation
and promoting resolution. This trend is consistent across both monocyte
and macrophage populations, under basal and LPS-stimulated conditions.</p><fig position="float" id="fig9" fig-type="figure" orientation="portrait"><label>9</label><caption><p>(A) Linear
correlation between &#916;log&#173;(<italic toggle="yes">E</italic>
<sub>max</sub>/EC<sub>50</sub>) for cAMP and &#946;-arrestin pathways
and cytokine expression (TNF-&#945;, IFN-&#947;, IL-1&#946;, IL-6,
IL-10, IL-4) for <bold>16i</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold> and <bold>18p</bold> in (A)
monocytes and (B) macrophages. Slopes are significantly different
from 0 (<italic toggle="yes">p</italic> &lt; 0.005) except those marked as ns.
Data are presented as mean &#177; SEM.</p></caption><graphic id="gr10" position="float" orientation="portrait" xlink:href="jm5c00604_0009.jpg"/></fig><p>These results suggest that &#946;-arrestin-biased
CB<sub>2</sub>R agonists exhibit a less favorable anti-inflammatory
cytokine profile,
thereby limiting their effectiveness in promoting an anti-inflammatory
response. In contrast, CB<sub>2</sub>R agonists biased toward cAMP-mediated
signaling demonstrate a more favorable profile in reducing inflammation.
The key challenge seems to lie in mitigating &#946;-arrestin dominance.
This effect may be attributed to enhanced internalization and desensitization
of CB<sub>2</sub>R, resulting in reduced signaling activity and diminished
surface receptor levels.<xref rid="ref61" ref-type="bibr"/> Thus, the development
of cAMP-biased CB<sub>2</sub>R agonists, characterized by minimal
&#946;-arrestin recruitment, may represent a more effective strategy
for achieving robust and sustained anti-inflammatory effects.</p></sec><sec id="sec2.12"><title>Evaluation of the Neuroprotective Effect of Selected CB<sub>2</sub>R Agonists</title><p>Activation of the CB<sub>2</sub>R by selective
small molecules offers significant neuroprotective potential, particularly
for neurodegenerative diseases.<xref rid="ref62" ref-type="bibr"/> Primarily
expressed in immune cells and microglia in the CNS, CB<sub>2</sub>R activation reduces neuroinflammation by lowering pro-inflammatory
cytokines and promoting an anti-inflammatory state.<xref rid="ref63" ref-type="bibr"/> This effect is critical in pathologies such as Alzheimer&#8217;s,
Parkinson&#8217;s, and Multiple Sclerosis, where inflammation plays
a key role.<named-content content-type="bibref-group">
<xref rid="ref16" ref-type="bibr"/>,<xref rid="ref64" ref-type="bibr"/>
</named-content> Additionally, CB<sub>2</sub>R
activation has been shown to decrease oxidative stress and apoptosis
in neurons, supporting cell survival. Unlike CB<sub>1</sub>R, CB<sub>2</sub>R modulation avoids psychoactive effects, making it an attractive
target for neuroprotective therapies.</p><p>A mouse primary cell experiment
was performed to examine the neuroprotective effects of CB<sub>2</sub>R agonists selected for in-depth study (<bold>16i</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, and <bold>18p</bold>). First, to exclude any intrinsic toxicity of the selected
candidates, their potential effects on primary cell cultures were
assessed. The results (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>A, colored bars) unequivocally confirmed that the selected
CB<sub>2</sub>R agonists did not affect primary cell survival. This
finding is particularly noteworthy, and not self-evident, given the
significant neurotoxicity observed during our earlier study with structurally
related, classical abused [CB<sub>1</sub>R/CB<sub>2</sub>R promiscuous]
synthetic cannabinoids (SCRAs).<xref rid="ref29" ref-type="bibr"/> For comparative
purposes, <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>A also depicts cell viability data obtained for some abused SCRAs
(<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>A, gray
bars) under identical conditions. These data underscore that the conformational
restriction strategy employed here successfully achieves a complete
reversal of the neurotoxicity signatures associated with promiscuous
(CB<sub>1</sub>R and CB<sub>2</sub>R) abused SCRAs, which exhibited
reductions in cell viability of up to 70%.<xref rid="ref29" ref-type="bibr"/> Notably, the strikingly different toxicological profiles observed
between these two subsets (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>A), despite their high structural similarity, strongly
suggest that the neurotoxicity associated with abused SCRAs is predominantly
driven by CB<sub>1</sub>R activation rather than being an intrinsic
property of the molecular scaffold.</p><fig position="float" id="fig10" fig-type="figure" orientation="portrait"><label>10</label><caption><p>Neuroprotective effects of compounds <bold>16i</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, and <bold>18p</bold> in primary cultures in (A) basal
conditions compared to
previously reported SCRAs<xref rid="ref30" ref-type="bibr"/> (gray bars)
and (B) following LPS + IFN-&#947; stimulation. Asterisks (*) indicate
statistical significance vs the respective control group. (C) The
CB<sub>2</sub> receptor antagonist SR144528 reversed the protective
effect of <bold>18o</bold>. Data represent mean &#177; SEM (<italic toggle="yes">n</italic> = 9 per group). Statistical analysis was performed using
Two-Way ANOVA followed by Sidak&#8217;s multiple comparisons test.
Asterisks (*) indicate statistical significance vs basal conditions.
(D) Reduction in ROS levels in both basal and LPS-stimulated conditions.
Asterisks (*) indicate statistical significance vs LPS treatment.
(E) Decrease in caspase activity under the same conditions. Asterisks
(*) indicate statistical significance vs LPS treatment. (F) Representative
immunofluorescence images showing cellular morphology changes. Data
represent mean &#177; SEM (<italic toggle="yes">n</italic> = 9 per group). Statistical
analysis was performed using Two-Way ANOVA followed by Sidak&#8217;s
multiple comparisons test.</p></caption><graphic id="gr11" position="float" orientation="portrait" xlink:href="jm5c00604_0010.jpg"/></fig><p>Following the examination of the neuroprotective
effects of herein
developed CB<sub>2</sub>R agonists (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>), the selected derivatives (<bold>16i</bold>, <bold>16j</bold>, <bold>18e</bold>, <bold>18f</bold>, <bold>18o</bold>, and <bold>18p</bold>) were evaluated in primary cultures exposed
to LPS + IFN-&#947;, which caused a significant reduction (approximately
50%) in cell viability due to the induced inflammatory conditions.
As shown in <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>B, the addition of the studied compounds produced a marked recovery
in cell viability (ranging from 77 to 93%), indicating their strong
neuroprotective properties. Among the tested compounds, ligand <bold>18o</bold> emerged as the most promising neuroprotective candidate,
demonstrating an exceptional ability to nearly fully restore cell
viability. These findings demonstrate the potential of these novel
CB<sub>2</sub>R agonists as promising therapeutic candidates for neuroinflammatory
conditions. To unequivocally confirm that the observed neuroprotective
effect was indeed mediated by CB<sub>2</sub>R activation, an additional
experiment was conducted (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>C). In this experiment, primary cultures treated with
LPS + IFN-&#947;, which exhibited reduced cell viability, were treated
with compound <bold>18o</bold> in one set and with <bold>18o</bold> alongside the selective CB<sub>2</sub>R antagonist SR144528 in another.
As illustrated in <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>C, the addition of ligand <bold>18o</bold> almost fully restored
cell viability to near 100%. However, the presence of the antagonist
(SR144528) effectively blocked the neuroprotective action of <bold>18o</bold>, preserving the reduced viability (&#8764;60%) observed
with LPS + IFN-&#947; treatment alone. These results unequivocally
demonstrate the significant neuroprotective effects of the CB<sub>2</sub>R agonists are mediated through CB<sub>2</sub>R activation.
Taken together, these results exemplify the beneficial outcomes of
applying conformational restriction design criteria, transforming
promiscuous, neurotoxic ligands into highly selective and promising
neuroprotective agents.</p><p>To further elucidate the mechanisms
underlying these effects, we
assessed markers of oxidative stress and apoptosis, two central pathways
involved in neurodegeneration. Excessive production of reactive oxygen
species (ROS) is a hallmark of neuroinflammatory and neurodegenerative
conditions, contributing to cellular damage by promoting lipid peroxidation,
protein oxidation, and mitochondrial dysfunction. Additionally, activation
of executioner caspases such as caspase-3 plays a pivotal role in
the progression of apoptosis, ultimately leading to neuronal loss.
As shown in <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>D, treatment with the compounds resulted in a significant reduction
in intracellular ROS levels under both basal and LPS-stimulated conditions,
indicating a potent antioxidant effect. Furthermore, as illustrated
in <xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>E,F, a
marked decrease in caspase activity was observed, consistent with
an attenuation of apoptotic signaling. Together, these findings confirm
the compounds&#8217; capacity to mitigate oxidative damage and prevent
programmed cell death, supporting their neuroprotective potential
through dual modulation of redox balance and apoptosis.</p><p>Finally,
to further validate these effects, a neuron-like <italic toggle="yes">in vitro</italic> model using differentiated SH-SY5Y cells was employed
(<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig"/>
</xref>). This
model reproduces key features of neuronal dysfunction, most notably
neurite shortening, by recapitulating cellular stress pathways relevant
to neurodegeneration. The SH-SY5Y cells were sequentially differentiated
with retinoic acid and GLP-1 to induce a mature neuronal phenotype
exhibiting dopaminergic and glutamatergic traits.<xref rid="ref65" ref-type="bibr"/> To simulate neurodegenerative conditions, cells were transiently
transfected with expression plasmids encoding the MAPT P301L and APP
V717I mutations. The MAPT P301L mutation promotes pathological tau
hyperphosphorylation and aggregation, leading to microtubule destabilization,
impaired axonal transport, and neurite retraction.<named-content content-type="bibref-group">
<xref rid="ref66" ref-type="bibr"/>,<xref rid="ref67" ref-type="bibr"/>
</named-content> Meanwhile, the APP V717I mutation increases the production of long,
aggregation-prone amyloidogenic peptides, disrupting cellular homeostasis
through oxidative stress and cytoskeletal disorganization.<named-content content-type="bibref-group">
<xref rid="ref68" ref-type="bibr"/>,<xref rid="ref69" ref-type="bibr"/>
</named-content>
</p><fig position="float" id="fig11" fig-type="figure" orientation="portrait"><label>11</label><caption><p>
<bold>18o</bold> and <bold>18e</bold> elicit a concentration-dependent
neuroprotective effect on neurite length in transfected SH-SY5Y cells.
(A) Bar graph showing mean neurite length in nontransfected cells,
transfected cells (<italic toggle="yes">MAPT</italic> P301L + <italic toggle="yes">APP</italic> V717I), and transfected cells treated with <bold>18o</bold> or <bold>18e</bold> at concentrations ranging from 1&#8239;nM to 1 &#956;M.
Each data point represents the mean of technical replicates from an
independent biological experiment (<italic toggle="yes">N</italic> = 3). Bars represent
mean &#177; SEM across experiments. ***<italic toggle="yes">p</italic> &lt; 0.001,
**<italic toggle="yes">p</italic> &lt; 0.01 (two-way ANOVA followed by Sidak&#8217;s
post hoc test). (B) Representative images of each condition acquired
with a 20&#215; objective. Scale bar = 100 &#956;m. (C) Bar graph
showing neurite length in SH-SY5Y cells transfected with <italic toggle="yes">MAPT</italic> P301L and <italic toggle="yes">APP</italic> V717I, treated with 18o (1&#8239;&#956;M)
or 18e (100&#8239; and 10&#8239;nM), in the presence or absence
of the CB<sub>2</sub>R antagonist SR144528 (1 &#956;M). Each data
point represents the mean of technical replicates from an independent
biological experiment (<italic toggle="yes">n</italic> = 3). Bars represent mean
&#177; SEM across experiments. Bars represent mean &#177; SEM across
experiments. <italic toggle="yes">p</italic>&#8239;&lt;&#8239;0.001 (two-way
ANOVA followed by Sidak&#8217;s post hoc test). (D) Representative
images of each condition acquired with a 20&#215; objective. Scale
bar = 100 &#956;m.</p></caption><graphic id="gr12" position="float" orientation="portrait" xlink:href="jm5c00604_0011.jpg"/></fig><p>The combined expression of these mutations in differentiated
SH-SY5Y
cells results in a reduction in neurite complexity, which is quantifiable
through high-content imaging of neurite length and arborization, thereby
establishing a phenotypic readout for compound screening. This model
has been validated using well-known neuroprotective agents such as
melatonin and resveratrol.<xref rid="ref70" ref-type="bibr"/> In our study,
a significant concentration-dependent protective effect against neurite
shortening induced by plasmid transfection was observed for both <bold>18o</bold> and <bold>18e</bold> at concentrations ranging from 10&#8239;nM
to 1 &#956;M (<xref rid="fig10" ref-type="fig">Figure <xref rid="fig10" ref-type="fig"/>
</xref>A,B). At 1&#8239;nM, neither compound produced a statistically significant
effect. Notably, the neuroprotective effect of <bold>18o</bold> and <bold>18e</bold> at both 100 and 10 nM was reversed by the CB<sub>2</sub>R antagonist SR144528 (<xref rid="fig11" ref-type="fig">Figure <xref rid="fig11" ref-type="fig"/>
</xref>C,D), reinforcing that the neuroprotection is mediated
through CB<sub>2</sub>R activation.</p></sec></sec><sec id="sec3"><title>Conclusions</title><p>Herein, we documented the development of
a new series of structurally
simple, potent, subtype-selective and biased CB<sub>2</sub>R agonists
with notable anti-inflammatory and neuroprotective effect. Building
on the promiscuous (CB<sub>1</sub>R &amp; CB<sub>2</sub>R) profiles
of abused synthetic cannabinoid receptor agonists (SCRAs), a conformational
restriction approach was applied to effectively eliminate CB<sub>1</sub>R binding. Affinity and functional data of the newly synthesized
library highlighted key structure&#8211;activity relationships and
identified specific signaling pathway biases, either favoring &#946;-arrestin
and MAPK or G-protein pathways, likely contributing to the compounds&#8217;
robust anti-inflammatory and neuroprotective effects. The neuroprotective
profile was further supported by functional data showing that representative
compounds significantly reduced intracellular ROS levels and caspase
activation, mitigating oxidative stress and apoptosis in neuroinflammatory
settings. In a physiologically relevant neuron-like model using differentiated
SH-SY5Y cells expressing MAPT and APP mutations, the compounds effectively
prevented neurite shortening&#58872;a hallmark of early neuronal dysfunction&#58872;in
a CB<sub>2</sub>R-dependent manner. These cellular and phenotypic
findings corroborate the compounds&#8217; ability to preserve neuronal
integrity in pathologically relevant contexts. Moreover, this series
demonstrated favorable pharmacokinetic properties, including solubility,
strong blood&#8211;brain barrier (BBB) permeability, low P-glycoprotein
interaction, and microsomal stability, reinforcing their potential
for CNS-targeted applications. Altogether, these results support the
therapeutic promise of these CB2R agonists as safer, targeted treatments
for neuroinflammatory and neurodegenerative diseases, devoid of CB<sub>1</sub>R-mediated psychoactive side effects.</p></sec><sec id="sec4"><title>Experimental Section</title><sec id="sec4.1"><title>Chemistry</title><p>All starting materials, reagents and solvents
were purchased and used without further purification. After extraction
from aqueous phases, the organic solvents were dried over anhydrous
magnesium sulfate. Unless stated otherwise, UV light and/or iodine
vapor were used to detect compounds. The amide couplings and the ammonolysis
reactions were performed in coated Kimble vials on a PLS (6 &#215;
4) Organic Synthesizer with orbital stirring. The purity and identity
of all tested compounds were established by a combination of HPLC,
mass spectrometry and NMR spectroscopy. Purification of isolated products
was carried out by column chromatography (Kieselgel 0.040&#8211;0.063
mm, E. Merck) or medium pressure liquid chromatography (MPLC) on a
Combi Flash Companion (Teledyne ISCO) with RediSep prepacked normal-phase
silica gel (35&#8211;60 &#956;m) columns. The NMR spectra were recorded
on Bruker AM300 and XM500 spectrometers. Chemical shifts are given
as &#948; values against tetramethylsilane as internal standard and <italic toggle="yes">J</italic> values are given in Hz. Mass spectra were obtained on
a Varian MAT-711 instrument. High-resolution mass spectra were obtained
on an Autospec Micromass spectrometer.</p><p>The purity of all tested
compounds was determined to be &gt;95% using analytical HPLC [Water
Breeze
2 system (binary pump 1525, detector UV/Visible 2489, 7725i Manual
Injector Kit 1500 Series)] using a Luna 5 &#956;m Silica (2) 100
&#197;, LC Column 150 &#215; 4.6 mm column with gradient elution using
the mobile phases dichloromethane, isopropanol, and a flow rate of
1 mL/min. The stereochemical purity of described compounds was analyzed
and confirmed (e.e. &gt;97%) by chiral HPLC. A detailed description
of
the experimental protocols, equipment and techniques used in the synthesis
of targeted ligands, as well as the structural and spectroscopic data
obtained for all the compounds described is given in the <ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">Supporting Information</ext-link>.</p><sec id="sec4.1.1"><title>General Procedure for the Synthesis of Esters <bold>15a</bold>&#8211;<bold>p</bold> and <bold>16a</bold>&#8211;<bold>p</bold>
</title><p>A mixture of the 1-substituted indole (or indazole)-3-carboxylic
acid (1 mmol) (<bold>19</bold>), the corresponding cyclic amino ester
(<bold>20</bold>) (1.5 mmol), HATU (1.5 mmol) and DIPEA (4 mmol) in
CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was stirred with orbital stirring
at room temperature for 24 h</p><p>After completion of the reaction,
water was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic phase was dried over MgSO<sub>4</sub>, filtered, and concentrated. The resulting product was purified
by column chromatography on silica gel. The purity of all prepared
compounds was established by high-performance liquid chromatography
(HPLC) and showed to be &gt;95%.</p></sec><sec id="sec4.1.2"><title>General Procedures for the Synthesis of Amides <bold>17a&#8211;p</bold> and <bold>18a&#8211;sp</bold>
</title><p>A mixture of the corresponding
ester (<bold>15</bold> or <bold>16</bold>), and a solution 4 M of
ammonia (4 mmol) in MeOH (2 mL) was stirred at room temperature for
24 h. After completion of the reaction, solvent was evaporated. The
resulting product was purified by column chromatography on silica
gel using MeOH/CH<sub>2</sub>Cl<sub>2</sub>. The purity of all prepared
compounds was established by high-performance liquid chromatography
(HPLC) and showed to be &gt;95%.</p></sec></sec><sec id="sec4.2"><title>Circular Dichroism (CD)</title><p>CD spectra of ligands (&gt;98%)
were recorded on a Jasco-815 system equipped with a Peltier-type thermostatic
accessory (CDF-426S, Jasco). Measurements were carried out at 20 &#176;C
using a 1 mm quartz cell in a volume of 300&#8211;350 &#956;L. Compounds
(0.1 mg) were dissolved in MeOH (1.0 mL). The instrument settings
were bandwidth, 1.0 nm; data pitch, 1.0 nm; speed, 500 nm/min; accumulation,
10; wavelengths, 400&#8211;190 nm.</p></sec><sec id="sec4.3"><title>Binding Assays</title><p>Radioligand binding competition assays
of CB<sub>1</sub> receptors were carried out in polypropylene 96-well
plates by incubating 5 &#956;g of membranes from Chinese hamster
ovary (CHO)-CB<sub>1</sub> C3 cell line (PerkinElmer) with 1 nM [<sup>3</sup>H]-CP55940 (PerkinElmer) and test compounds in binding buffer
(50 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, 1 mM EDTA, 0.5% BSA. pH: 7.4).
Nonspecific binding was determined in the presence of 10 &#956;M
Surinabant. The reaction mixture was incubated at 30 &#176;C for 60
min, then 200 &#956;L were transferred to GF/C 96-well plate (Millipore,
Madrid, Spain) and washed four times with 250 &#956;L wash buffer
(50 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, 1 mM EDTA, 0.5% BSA. pH: 7.4).
Radioactivity was detected in a microplate &#946; scintillation counter
(Microbeta Trilux, PerkinElmer, Madrid, Spain). Radioligand binding
competition assays of CB<sub>2</sub> receptors were carried out in
polypropylene 96-well plates by incubating 5 &#956;g of membranes
from Human embryonic kidney 293 cells (HEK)-CB<sub>2</sub> cell line
with 0.2 nM [<sup>3</sup>H]-CP55940 (PerkinElmer) and test compounds
in binding buffer (50 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, 2.5 mM EGTA,
0.1% BSA. pH: 7,4). Nonspecific binding was determined in the presence
of 10 &#956;M <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="GW405833">GW405833</ext-link>. The reaction mixture was incubated at 30
&#176;C for 90 min, then 200 &#956;L were transferred to GF/C 96-well
plate (Millipore, Madrid, Spain) and washed four times with 250 &#956;L
wash buffer (50 mM Tris-HCl, 5 mM MgCl<sub>2</sub>, 2.5 mM EGTA, 1%
BSA. pH: 7,4). Data was fitted to 4-parameter logistic equation by
employing GraphPad Prism software (V7.0) and <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> data was calculated with the equation: <italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> = IC<sub>50</sub>/(1 + (<italic toggle="yes">F</italic>/<italic toggle="yes">K</italic>
<sub>D</sub>)); where IC<sub>50</sub> was the concentration of the ligand that displaced the specific
binding of the radioligand in a 50%; <italic toggle="yes">K</italic>
<sub>D</sub> is the dissociation constant of the radioligand, and <italic toggle="yes">F</italic> is the concentration of the radioligand employed in the assay.</p></sec><sec id="sec4.4"><title>Functional Experiments</title><sec id="sec4.4.1"><title>Cell Culture and Transient Transfection</title><p>HEK-293T cells
were grown in Dulbecco&#8217;s Modified Eagle&#8217;s Medium (DMEM)
medium (Gibco, Paisley, Scotland, United Kingdom) supplemented with
2 mM <sc>l</sc>-glutamine, 100 U/mL penicillin/streptomycin, MEM Non-Essential
Amino Acids Solution (1/100) and 5% (v/v) heat inactivated Fetal Bovine
Serum (FBS) (Invitrogen, Paisley, Scotland, United Kingdom). Cells
were maintained in a humid atmosphere of 5% CO<sub>2</sub> at 37 &#176;C.
Cells were transiently transfected with the PEI (Polyethylenimine,
Sigma, St. Louis, MO, United States) method as previously described<xref rid="ref71" ref-type="bibr"/> and used for functional assays 48 h later.</p></sec><sec id="sec4.4.2"><title>Neuronal Primary Cultures</title><p>To prepare primary neurons,
brains from fetuses of pregnant CD1 mice were removed (gestational
age: 19 days). Neurons were isolated as described in Hradsky et al.<xref rid="ref72" ref-type="bibr"/> Briefly, after removal of the meninges, samples
were dissected and digested with 0.25% trypsin (20 min at 37 &#176;C).
The effect of trypsin was stopped by adding an equal volume of culture
medium (supplemented DMEM). A single-cell suspension was obtained
by repeated pipetting followed by passage through a 100 &#956;m-pore
mesh. Pelleted (7 min, 200<italic toggle="yes">g</italic>) cells were resuspended
in 2 mL of supplemented DMEM and seeded at a density of 3.5 &#215;
10<sup>5</sup> cells/mL in 6-well plates. After 24 h, the medium was
replaced by neurobasal medium supplemented with 2 mM <sc>l</sc>-glutamine,
100 U/mL penicillin/streptomycin and 2% (v/v) B27 medium (GIBCO, Waltham,
MA, USA). Primary neurons were assayed after 14 days in culture. Using
NeuN as a marker, the percentage of neurons in the culture was &gt;90%.</p></sec><sec id="sec4.4.3"><title>cAMP Determination</title><p>Signaling experiments have been
performed as previously described.<xref rid="ref73" ref-type="bibr"/> Two
hours before initiating the experiment, HEK-293T cell-culture medium
was replaced by serum-starved DMEM medium. Then, cells were detached,
resuspended in growing medium containing 50 mM zardaverine (Tocris,
Bristol, U.K.) and placed in 384-well microplates (2500 cells/well).
Cells were pretreated (15 min) with cannabinoid compounds (1 nM to
100 &#956;M) -or vehicle- before adding 0.5 mM forskolin (Tocris,
Bristol, U.K.) to induce cAMP accumulation. Readings were performed
after 15 min incubation at 25 &#176;C. Homogeneous Time Resolved Fluorescence
(HTRF) energy transfer measures were performed using the Lance Ultra
cAMP kit (PerkinElmer, Waltham, MA, United States). Fluorescence at
665 nm was analyzed in a PHERA star Flagship microplate reader equipped
with an HTRF optical module (BMG Lab Technologies, Offenburg, Germany).</p></sec><sec id="sec4.4.4"><title>Viability Assay</title><p>Primary cultures of striatal neurons
were treated for 24 h with selected SCRAs (100 nM). Afterward, cells
were scrapped from the plate and resuspended in neurobasal medium
supplemented with 2 mM <sc>l</sc>-glutamine, 100 U/mL penicillin/streptomycin
and 2% (v/v) B27 (GIBCO). Trypan blue staining was performed mixing
1 part of 0.4% trypan blue and 1 part of cell suspension in a plastic
tube. After &#8764;3 min of incubation at room temperature, 10 &#956;L
of the mixture were sampled in a Neubauer chamber and counted with
a Countess II FL (Life Technologies, California, CA, USA). The unstained
(viable) and stained (nonviable) cells were counted separately, and
the percentage of viability was calculated as total number of viable
cells/total number of cells &#215; 100.</p></sec><sec id="sec4.4.5"><title>Human Microsomal Stability</title><p>The human microsomal stability
of selected compounds was evaluated by following a previously described
method.<xref rid="ref74" ref-type="bibr"/> The human microsomes employed
were purchased from Tebu-Xenotech. The compound was incubated with
the microsomes at 37 &#176;C in a 50 mM phosphate buffer (pH = 7.4)
containing 3 mM MgCl<sub>2</sub>, 1 mM NADP, 10 mM glucose-6-phosphate
and 1 U/mL glucose-6-phosphate-dehydrogenase. Samples (75 &#956;L)
were taken from each well at 0, 10, 20, 40, and 60 min and transferred
to a plate containing 4 &#176;C 75 &#956;L acetonitrile and 30 &#956;L
of 0.5% formic acid in water were added for improving the chromatographic
conditions. The plate was centrifuged (46,000<italic toggle="yes">g</italic>, 30
min) and supernatants were taken and analyzed in an UPLC-MS/MS (Xevo-TQD,
Waters) by employing a BEH C18 column and an isocratic gradient of
0.1% formic acid in water: 0.1% formic acid acetonitrile (60:40).
The metabolic stability of the compounds was calculated from the logarithm
of the remaining compounds at each of the time point studied.</p></sec><sec id="sec4.4.6"><title>Solubility Determinations</title><p>The solubility of selected
compounds was evaluated by following a previously described method.<xref rid="ref74" ref-type="bibr"/> A 10 mM stock solution of the compound was serially
diluted in 100% DMSO and 2.5 &#956;L of this solution was added to
a 384-well UV-transparent plate (Greiner) containing 47.5 &#956;L
of PBS (pH = 7). The plate was incubated at 37 &#176;C for 4 h and
the light scattering was measured in a Nephelostar plus reader (BMG
LABTECH). The data was fitted to a segmented linear regression for
measuring the compound solubility.</p></sec><sec id="sec4.4.7"><title>Drug Transport Experiments</title><p>Caco-2 cells were grown
in Dulbecco&#8217;s high-glucose modified eagle medium, composed
of 10% fetal bovine serum, 2 mM of glutamine, 100 U/mL of penicillin,
and 0.1 mg/mL of streptomycin (all components purchased from Corning,
Milan, Italy) in a humidified incubator at 37 &#176;C with a 5% CO<sub>2</sub> atmosphere. The experiment started with the preparation of
the Caco-2 monolayer, which occurred by seeding the cells (20,000/well)
in Millicell plates (Millipore, Milan, Italy). Its growth was followed
for 21 days by changing the medium occasionally and measuring its
transepithelial electrical resistance (TEER) daily using an epithelial
voltohmmeter (Millicell-ERS) until a TEER value &gt;240 ohms &#215;
cm<sup>2</sup> was reached. After 21 days, the plate was washed twice
with
Hank&#8217;s balanced salt solution (HBSS) (Invitrogen). After the
second wash, the wells were filled with buffer, and the plate was
kept at 37 &#176;C for 30 min. After the incubation time, the HBSS
buffer was replaced with the solutions of the compounds to be tested
at a concentration of 1 &#215; 10<sup>&#8211;4</sup> M. The plates
were placed in an incubator at 37 &#176;C for 120 min. The apparent
permeability (<italic toggle="yes">P</italic>
<sub>app</sub>), in units of nm s<sup>&#8211;1</sup>, was calculated as previously reported.<named-content content-type="bibref-group">
<xref rid="ref75" ref-type="bibr"/>,<xref rid="ref76" ref-type="bibr"/>
</named-content>
</p></sec><sec id="sec4.4.8"><title>Calcein-AM Experiment</title><p>This experiment was carried out
as described by Contino et al. with minor modifications.<xref rid="ref77" ref-type="bibr"/> Each cell line (30,000 cells per well) was seeded
into black CulturePlate 96/wells plate with 100 &#956;L medium and
allowed to become confluent overnight. 100 &#956;L of test compounds
were solubilized in culture medium and added to monolayers, with final
concentrations ranging from 0.1 to 100 &#956;M. 96/Wells plate was
incubated at 37 &#176;C for 30 min. Calcein-AM was added in 100 &#956;L
of Phosphate Buffered Saline (PBS) to yield a final concentration
of 2.5 &#956;M and plate was incubated for 30 min. Each well was
washed 3 times with ice cold PBS. Saline buffer was added to each
well and the plate was read with Victor3 (PerkinElmer) at excitation
and emission wavelengths of 485 and 535 nm, respectively. In these
experimental conditions Calcein cell accumulation in the absence and
in the presence of tested compounds was evaluated and fluorescence
basal level was estimated with untreated cells. In treated wells the
increase of fluorescence with respect to basal level was measured.
EC<sub>50</sub> values were determined by fitting the fluorescence
increase percentage versus log&#173;[dose].</p></sec><sec id="sec4.4.9"><title>Anti-Inflammatory and Pro-Inflammatory Cytokine Detection</title><p>The amount of cytokines was measured in 5 &#956;L of supernatants,
derived from 1 &#215; 104 cells, using the ProQuantum immunoassays
kits for TNF-&#945;, IFN-&#947;, IL-1&#946;, IL-6, IL-10, and IL-4
[all from ThermoFisher Scientific (Waltham, MA)] according to the
manufacturer&#8217;s instructions. The results were expressed as
pg/mL based on the titration curved of each kits.</p></sec><sec id="sec4.4.10"><title>Cell Culture and Differentiation of SH-SY5Y Cells</title><p>SH-SY5Y
human neuroblastoma-derived cells (ECACC, 94030304) were cultured
and differentiated in black 384-well plates (Revvity, 6057300). Plates
were treated with laminin (1:500 dilution in PBS; Merck, L2020) by
adding 25 &#956;L per well and incubated for 2 h at room temperature.
Subsequently, plates were washed three times with PBS. Cells were
seeded at a density of 6.6 &#215; 10<sup>3</sup> cells per well (in
50 &#956;L) in culture medium. The base culture medium consisted
of RPMI-1640 (Gibco, 61870) supplemented with 2% (v/v) fetal bovine
serum (FBS; Merck, F7524), 1% (v/v) penicillin-streptomycin (P/S;
Merck, P0781), and 0.1% (v/v) gentamicin (Merck, G1397).</p><p>Differentiation
was initiated 24 h after plating. The culture medium was replaced
with a differentiation medium composed of RPMI-1640 supplemented with
2% (v/v) FBS, 1% (v/v) P/S, 0.1% (v/v) gentamicin, and 10 &#956;M
all-trans retinoic acid (RA; Merck, R2625). Medium changes were performed
every 3 days, and the plates were kept covered with aluminum foil
to protect retinoic acid from light exposure. Six days later, cells
were transfected with expression plasmids encoding <italic toggle="yes">MAPT</italic> P301L and <italic toggle="yes">APP</italic> V717I mutations employing Lipofectamine
LTX (Thermo Fisher, 15338100) at a 1:2 proportion in Opti-MEM (Gibco,
11058-021) following the instructions of the manufacturer. After 6
h, the transfection medium was replaced with a differentiation medium
composed of RPMI-1640, B27 supplement (1:50; Gibco, 17504), 1% (v/v)
P/S, 0.1% (v/v) gentamicin, and 100 nM GLP-1 (Merck, G9416). 24 h
later, test compounds were added using an Echo 650T acoustic dispenser
(Labcyte) from a 10 mM stock solution in DMSO (Merck, D8418).</p></sec><sec id="sec4.4.11"><title>Fixation and Immunostaining</title><p>48 h after compound dispensation,
cells were fixed with 4% paraformaldehyde (50 &#956;L per well, Santa
Cruz BT, sc-281692) for 20 min at 4 &#176;C. Wells were then washed
twice with HBSS (50 &#956;L per wash, Merck, H8264) and incubated
with 50 &#956;L of blocking buffer for 30 min at room temperature.
The blocking buffer consisted of HBSS supplemented with 5% BSA (w/v)
(Merck, 10775835001) and 0.1% (v/v) Triton X-100 (Merck, T8787). After
blocking, cells were incubated with an antibeta-tubulin antibody conjugated
to Alexa Fluor 488 (1:500; BD Biosciences, 558605) and Draq5 nuclear
stain (2.5 &#956;M; Abcam, ab108410) diluted in blocking buffer.
After incubation in the dark at room temperature, wells were washed
once with 50&#8239;&#956;L of HBSS and subsequently filled with
50&#8239;&#956;L of blocking buffer prior to imaging.Images were
acquired using an Operetta CLS High Content Screening System (Revvity)
equipped with a 20&#215; water-immersion objective. Fluorescent signals
were detected using specific excitation/emission filter settings for
each fluorophore: Alexa Fluor 488 (&#955;<sub>ex</sub> = 460&#8211;490
nm; &#955;<sub>em</sub> = 500&#8211;550 nm) and Draq5 (&#955;<sub>ex</sub> = 615&#8211;645 nm; &#955;<sub>em</sub> = 655&#8211;760
nm). For each well, nine nonoverlapping fields were captured under
identical acquisition settings. Neurite length and complexity were
quantified using Harmony software (version 4.9.2137.273; Revvity),
applying a predefined analysis algorithm optimized for &#946;-tubulin
immunostaining. For each experiment, data were normalized to the average
neurite length measured in the double-transfected condition (<italic toggle="yes">MAPT</italic> P301L + <italic toggle="yes">APP</italic> V717I) treated with vehicle,
which was assigned a reference value of 100%. All other conditions
were expressed as percentage relative to this baseline. Normalization
was performed independently for each experimental replicate to control
for interassay variability.</p></sec><sec id="sec4.4.12"><title>Data and Statistical Analysis</title><p>
<italic toggle="yes">K</italic>
<sub>
<italic toggle="yes">i</italic>
</sub> and EC<sub>50</sub> values were obtained
by fitting the data with nonlinear regression using Prism 9 software
(GraphPad, San Diego, CA). Results are the mean of four experiments
(<italic toggle="yes">n</italic> = 4), each performed in duplicate. Data are represented
as mean &#177; standard error of mean (SEM) with statistical significance
set at <italic toggle="yes">P</italic> &lt; 0.05. The number of samples (<italic toggle="yes">n</italic>) in each experimental condition is indicated in the corresponding
figure legend. Outliers were assessed by the ROUT method,<xref rid="ref57" ref-type="bibr"/> thus any sample was excluded assuming a <italic toggle="yes">Q</italic> value of 1% in GraphPad Prism 9. Comparisons among experimental
groups were performed by Student&#8217;s <italic toggle="yes">t</italic> test
or one-way analysis of variance (ANOVA) followed by Tukey&#8217;s
multiple comparisons posthoc test using GraphPad Prism 9, as indicated.</p></sec><sec id="sec4.4.13"><title>Molecular Docking</title><p>Compounds <bold>11</bold>, <bold>12</bold>, <bold>17e</bold>, <bold>18e</bold>, <bold>18f</bold>,
and <bold>18o</bold> were docked onto the recently published X-ray
structure of CB<sub>2</sub>R in complex with the agonist AM12033 (co-x)
(3.20 &#197; resolution, PDB code: <ext-link xlink:href="6KPC" ext-link-type="PDB">6KPC</ext-link>).<xref rid="ref46" ref-type="bibr"/> The retrieved
pdb file was prepared using the Protein Preparation Workflow from
the Schrodinger Suite 2024-4,<xref rid="ref78" ref-type="bibr"/> which added
missing hydrogen atoms, reconstructed incomplete side chains, assigned
favorable protonation states at physiological pH, and performed a
force field-based minimization of the three-dimensional (3D) protein
structure. Ligands were prepared using the LigPrep tool<xref rid="ref78" ref-type="bibr"/> generating all the possible ionization states
and tautomers at a pH of 7.0 &#177; 2.0. These prepared files were
used for docking simulations carried out with the Grid-based Ligand
Docking with Energetics (GLIDE) tool.<xref rid="ref78" ref-type="bibr"/> Docking simulations employed SP mode with default settings, constructing
a cubic grid centered on co-x, with an inner box size of 10.5 &#197;
&#215; 10.5 &#197; &#215; 10.5 &#197; and an outer box size of 24.7
&#197; &#215; 24.7 &#197; &#215; 24.7 &#197;. To ensure thorough sampling
of the ligands&#8217; conformational space, we retained 50,000 poses
per ligand during the initial docking phase (default value: 5000)
and selected the top 4000 poses (default value: 400) per ligand for
energy minimization. This protocol was evaluated by redocking the
cognate ligand into the binding site. Satisfactorily, it returned
to the original positions with a root-mean-square deviation (RMSD)
of 0.71 &#197;, considering only heavy atoms. MM-GBSA Calculations.
To account for potential conformational rearrangements in the protein
binding site during molecular recognition and improve the accuracy
of protein&#8211;ligand binding energy predictions, the top-ranked
docking complexes were subjected to MM-GBSA calculations.<xref rid="ref47" ref-type="bibr"/> The MM-GBSA method calculates the protein&#8211;ligand
binding free energy for the obtained docking poses using the following
equation:<disp-formula id="ueq1"><alternatives><graphic position="float" orientation="portrait" xlink:href="jm5c00604_m001.jpg"/><mml:math id="d1e6208" display="block"><mml:mi mathvariant="normal">&#916;</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mi>Bind</mml:mi></mml:msub><mml:mi>MMGBSA</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>Complex</mml:mi></mml:msub><mml:mo>&#8722;</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>Receptor</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>E</mml:mi><mml:mi>Ligand</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></alternatives></disp-formula>Where <italic toggle="yes">E</italic>
<sub>Complex</sub> represents the energy contribution of the optimized ligand&#8211;receptor
complex, and <italic toggle="yes">E</italic>
<sub>Receptor</sub> and <italic toggle="yes">E</italic>
<sub>Ligand</sub> are the energy contributions of the optimized free
receptor and free ligand, respectively. More negative &#916;<italic toggle="yes">G</italic>
<sub>Bind</sub> values indicate stronger binding affinities.
This method was applied using default dielectric constants, the OPLS4
force field,<xref rid="ref79" ref-type="bibr"/> and the VSGB solvation model<xref rid="ref80" ref-type="bibr"/> and allowed flexibility for residues within
3 &#197; of the ligand.</p></sec></sec></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="sifile1" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00604_si_001.pdf" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile2" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00604_si_002.csv" position="float" orientation="portrait"/></supplementary-material><supplementary-material id="sifile3" position="float" content-type="local-data" orientation="portrait"><media xlink:href="jm5c00604_si_003.zip" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack id="ACK-d14e4814-autogenerated"><p>This work
was financially supported by the Conseller&#237;a
de Cultura, Educaci&#243;n e Ordenaci&#243;n Universitaria of
the Galician Government: (grant: ED431B 2020/43), Centro Singular
de Investigaci&#243;n de Galicia accreditation (2023&#8211;2027,
ED431G 2023/03) and the European Regional Development Fund (ERDF),
Ministerio de Ciencia e Innovaci&#243;n&#58872;Agencia Estatal de
Investigaci&#243;n-FEDER-UE (PID2020-118511RB-I00, PID2023-146870OB-I00,
PID2020-113430RB-I00 and PID2021-124010OB-100), Xunta de Galicia (ED431C
2018/21, ED431C 2022/20 and ED431G 2019/02) and European Regional
Development Fund (ERDF) in the frame of the Recovery Assistance for
Cohesion and the Territories of Europe (REACT-EU) funds. This research
program has been developed in the frame of the European COST action
ERNEST (CA 18133).</p></ack><notes id="notes-3" notes-type="si"><p>The Supporting Information
is available free of charge at <ext-link xlink:href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00604?goto=supporting-info" ext-link-type="uri">https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c00604</ext-link>.<list list-type="simple" id="silist"><list-item><p>Spectroscopic and analytical data for all compounds
described, HPLC enantiomeric separations, X-ray crystallography assays,
supplementary figures, supplementary tables and HPLC traces for lead
compounds (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_001.pdf" ext-link-type="uri">PDF</ext-link>)</p></list-item><list-item><p>Molecular formula strings (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_002.csv" ext-link-type="uri">CSV</ext-link>)</p></list-item><list-item><p>Atomic coordinates and experimental data
upon article
publication (<ext-link xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acs.jmedchem.5c00604/suppl_file/jm5c00604_si_003.zip" ext-link-type="uri">ZIP</ext-link>)</p></list-item></list>
</p></notes><notes id="notes-1" notes-type="author-contributions"><label>&#8711;</label><p>The authors C.G.-G. and S.O. contributed equally to this work and
share first authorship.</p></notes><notes id="notes-2" notes-type="conflict-of-interest"><p>The authors
declare no competing financial interest.</p></notes><glossary><def-list specific-use="delimiter-char:, " id="dl1"><title>Abbreviations Used</title><def-item><term>ABFE</term><def><p>absolute binding free energies</p></def></def-item><def-item><term>ADMET</term><def><p>absorption, distribution,
metabolism, excretion and toxicity</p></def></def-item><def-item><term>Ado</term><def><p>adenosine</p></def></def-item><def-item><term>AGT</term><def><p>O<sup>6</sup>-alkylguanine-DNA alkyltransferase</p></def></def-item><def-item><term>AR</term><def><p>adenosine receptor</p></def></def-item><def-item><term>AUC</term><def><p>area under curve</p></def></def-item><def-item><term>cAMP</term><def><p>cyclic adenosine monophosphate</p></def></def-item><def-item><term>CD</term><def><p>circular dichroism</p></def></def-item><def-item><term>CFSE</term><def><p>carboxyfluorescein
succinimidyl ester</p></def></def-item><def-item><term>CHO</term><def><p>Chinese hamster ovary</p></def></def-item><def-item><term>Cmpd</term><def><p>compound</p></def></def-item><def-item><term>Cmpds</term><def><p>compounds</p></def></def-item><def-item><term>DMEM</term><def><p>Dulbecco&#8217;s modified Eagle&#8217;s medium</p></def></def-item><def-item><term>DMF</term><def><p>dimethylformamide</p></def></def-item><def-item><term>DPCPX</term><def><p>Dipropylcyclopentyl-xanthine</p></def></def-item><def-item><term>FEP</term><def><p>Free Energy Perturbation</p></def></def-item><def-item><term>GPCRs</term><def><p>G protein-coupled
receptors</p></def></def-item><def-item><term>MD</term><def><p>molecular
dynamics</p></def></def-item><def-item><term>MFI</term><def><p>median
fluorescence intensities</p></def></def-item><def-item><term>MPLC</term><def><p>medium pressure liquid chromatography</p></def></def-item><def-item><term>NECA</term><def><p>N-ethoxycarbonyl adenosine</p></def></def-item><def-item><term>NMR</term><def><p>nuclear magnetic resonance</p></def></def-item><def-item><term>P<sub>1</sub>
</term><def><p>class
1 purinergic receptors</p></def></def-item><def-item><term>PAINS</term><def><p>pan-assay interference compounds</p></def></def-item><def-item><term>PBMCs</term><def><p>peripheral blood mononuclear cells</p></def></def-item><def-item><term>R-PIA</term><def><p>R-phenylisopropyl-adenosine</p></def></def-item><def-item><term>RBFE</term><def><p>relative binding
free energies</p></def></def-item><def-item><term>ROESY</term><def><p>Rotating frame Overhauser Effect Spectroscopy</p></def></def-item><def-item><term>SAR</term><def><p>structure&#8211;activity relationships</p></def></def-item><def-item><term>SBC</term><def><p>spherical boundary
conditions</p></def></def-item><def-item><term>SCAAS</term><def><p>surface-constrained all-atom solvent</p></def></def-item><def-item><term>SSR</term><def><p>structure-selectivity relationships</p></def></def-item><def-item><term>THF</term><def><p>tetrahydrofuran</p></def></def-item><def-item><term>Veh</term><def><p>vehicle</p></def></def-item></def-list></glossary><ref-list><ref id="ref1"><element-citation publication-type="journal" id="cit1"><name name-style="western"><surname>Di
Marzo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>A.</given-names></name><article-title>Endocannabinoid Signalling
and the Deteriorating Brain</article-title><source>Nat. Rev. Neurosci.</source><year>2015</year><volume>16</volume><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/nrn3876</pub-id><pub-id pub-id-type="pmid">25524120</pub-id><pub-id pub-id-type="pmcid">PMC4471876</pub-id></element-citation></ref><ref id="ref2"><element-citation publication-type="journal" id="cit2"><name name-style="western"><surname>Pacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>B&#225;tkai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kunos</surname><given-names>G.</given-names></name><article-title>The Endocannabinoid System as an
Emerging Target of Pharmacotherapy</article-title><source>Pharmacol.
Rev.</source><year>2006</year><volume>58</volume><fpage>389</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1124/pr.58.3.2</pub-id><pub-id pub-id-type="pmid">16968947</pub-id><pub-id pub-id-type="pmcid">PMC2241751</pub-id></element-citation></ref><ref id="ref3"><element-citation publication-type="journal" id="cit3"><name name-style="western"><surname>Busquets-Garc&#237;a</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bola&#241;os</surname><given-names>J. P.</given-names></name><name name-style="western"><surname>Marsicano</surname><given-names>G.</given-names></name><article-title>Metabolic Messengers: Endocannabinoids</article-title><source>Nat. Metab.</source><year>2022</year><volume>4</volume><fpage>848</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1038/s42255-022-00600-1</pub-id><pub-id pub-id-type="pmid">35817852</pub-id></element-citation></ref><ref id="ref4"><element-citation publication-type="journal" id="cit4"><name name-style="western"><surname>Di
Marzo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Piscitelli</surname><given-names>F.</given-names></name><article-title>The Endocannabinoid System and Its
Modulation by Phytocannabinoids</article-title><source>Neurotherapeutics</source><year>2015</year><volume>12</volume><fpage>692</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1007/s13311-015-0374-6</pub-id><pub-id pub-id-type="pmid">26271952</pub-id><pub-id pub-id-type="pmcid">PMC4604172</pub-id></element-citation></ref><ref id="ref5"><element-citation publication-type="journal" id="cit5"><name name-style="western"><surname>Munro</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K. L.</given-names></name><name name-style="western"><surname>Abu-Shaar</surname><given-names>M.</given-names></name><article-title>Molecular
Characterization of a Peripheral
Receptor for Cannabinoids</article-title><source>Nature</source><year>1993</year><volume>365</volume><fpage>61</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1038/365061a0</pub-id><pub-id pub-id-type="pmid">7689702</pub-id></element-citation></ref><ref id="ref6"><element-citation publication-type="journal" id="cit6"><name name-style="western"><surname>Latek</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kolinski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ghoshdastider</surname><given-names>U.</given-names></name><name name-style="western"><surname>Debinski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bombolewski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Plazinska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jozwiak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Filipek</surname><given-names>S.</given-names></name><article-title>Modeling of Ligand
Binding to G Protein Coupled Receptors: Cannabinoid CB1, CB2 and Adrenergic
&#946;2AR</article-title><source>J. Mol. Model.</source><year>2011</year><volume>17</volume><fpage>2353</fpage><lpage>2366</lpage><pub-id pub-id-type="doi">10.1007/s00894-011-0986-7</pub-id><pub-id pub-id-type="pmid">21365223</pub-id></element-citation></ref><ref id="ref7"><element-citation publication-type="journal" id="cit7"><name name-style="western"><surname>Hua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vemuri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shui</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Korde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laprairie</surname><given-names>R. B.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Zvonok</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kufareva</surname><given-names>I.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Bohn</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Makriyannis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.-J.</given-names></name><article-title>Crystal Structure of the Human Cannabinoid
Receptor CB1</article-title><source>Cell</source><year>2016</year><volume>167</volume><fpage>750</fpage><lpage>762.e14</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.10.004</pub-id><pub-id pub-id-type="pmid">27768894</pub-id><pub-id pub-id-type="pmcid">PMC5322940</pub-id></element-citation></ref><ref id="ref8"><element-citation publication-type="journal" id="cit8"><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vemuri</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>J.-H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Popov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Benchama</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zvonok</surname><given-names>N.</given-names></name><name name-style="western"><surname>Locke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Qu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Han</surname><given-names>G. W.</given-names></name><name name-style="western"><surname>Iyer</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Cinar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Coffey</surname><given-names>N. J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Katritch</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kunos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bohn</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Makriyannis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.-J.</given-names></name><article-title>Crystal Structure of the Human Cannabinoid
Receptor CB2</article-title><source>Cell</source><year>2019</year><volume>176</volume><fpage>459</fpage><lpage>467.e13</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.011</pub-id><pub-id pub-id-type="pmid">30639103</pub-id><pub-id pub-id-type="pmcid">PMC6713262</pub-id></element-citation></ref><ref id="ref9"><element-citation publication-type="journal" id="cit9"><name name-style="western"><surname>Atwood</surname><given-names>B. K.</given-names></name><name name-style="western"><surname>Mackie</surname><given-names>K.</given-names></name><article-title>CB2: A Cannabinoid Receptor with
an Identity Crisis</article-title><source>Br. J. Pharmacol.</source><year>2010</year><volume>160</volume><fpage>467</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2010.00729.x</pub-id><pub-id pub-id-type="pmid">20590558</pub-id><pub-id pub-id-type="pmcid">PMC2931549</pub-id></element-citation></ref><ref id="ref10"><element-citation publication-type="journal" id="cit10"><name name-style="western"><surname>Maccarrone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Marzo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gertsch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grether</surname><given-names>U.</given-names></name><name name-style="western"><surname>Howlett</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Hua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Makriyannis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Piomelli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>N.</given-names></name><name name-style="western"><surname>van der
Stelt</surname><given-names>M.</given-names></name><article-title>Goods and Bads of the Endocannabinoid System as a Therapeutic Target:
Lessons Learned after 30 Years</article-title><source>Pharmacol. Rev.</source><year>2023</year><volume>75</volume><fpage>885</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1124/pharmrev.122.000600</pub-id><pub-id pub-id-type="pmid">37164640</pub-id><pub-id pub-id-type="pmcid">PMC10441647</pub-id></element-citation></ref><ref id="ref11"><element-citation publication-type="journal" id="cit11"><name name-style="western"><surname>Matsuda</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Lolait</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Brownstein</surname><given-names>M. J.</given-names></name><name name-style="western"><surname>Young</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Bonner</surname><given-names>T. I.</given-names></name><article-title>Structure
of a Cannabinoid Receptor and Functional Expression of the Cloned
cDNA</article-title><source>Nature</source><year>1990</year><volume>346</volume><fpage>561</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/346561a0</pub-id><pub-id pub-id-type="pmid">2165569</pub-id></element-citation></ref><ref id="ref12"><element-citation publication-type="journal" id="cit12"><name name-style="western"><surname>Turcotte</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blanchet</surname><given-names>M.-R.</given-names></name><name name-style="western"><surname>Laviolette</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flamand</surname><given-names>N.</given-names></name><article-title>The CB2 Receptor and
Its Role as a Regulator of Inflammation</article-title><source>Cell.
Mol. Life Sci.</source><year>2016</year><volume>73</volume><fpage>4449</fpage><lpage>4470</lpage><pub-id pub-id-type="doi">10.1007/s00018-016-2300-4</pub-id><pub-id pub-id-type="pmid">27402121</pub-id><pub-id pub-id-type="pmcid">PMC5075023</pub-id></element-citation></ref><ref id="ref13"><element-citation publication-type="journal" id="cit13"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><article-title>Neuronal Expression of CB2 Cannabinoid Receptor mRNAs
in the Mouse
Hippocampus</article-title><source>Neuroscience</source><year>2015</year><volume>311</volume><fpage>253</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.10.041</pub-id><pub-id pub-id-type="pmid">26515747</pub-id><pub-id pub-id-type="pmcid">PMC4917208</pub-id></element-citation></ref><ref id="ref14"><element-citation publication-type="journal" id="cit14"><name name-style="western"><surname>Zhang</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>G.-H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.-J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.-R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Bonci</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xi</surname><given-names>Z.-X.</given-names></name><article-title>Expression of Functional
Cannabinoid CB2 Receptor in VTA Dopamine Neurons in Rats</article-title><source>Addict. Biol.</source><year>2017</year><volume>22</volume><fpage>752</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1111/adb.12367</pub-id><pub-id pub-id-type="pmid">26833913</pub-id><pub-id pub-id-type="pmcid">PMC4969232</pub-id></element-citation></ref><ref id="ref15"><element-citation publication-type="journal" id="cit15"><name name-style="western"><surname>Navarro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Morales</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Cueto</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Ruiz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jagerovic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>R.</given-names></name><article-title>Targeting Cannabinoid CB2 Receptors
in the Central Nervous System. Medicinal Chemistry Approaches with
Focus on Neurodegenerative Disorders</article-title><source>Front.
Neurosci.</source><year>2016</year><volume>10</volume><fpage>406</fpage><pub-id pub-id-type="doi">10.3389/fnins.2016.00406</pub-id><pub-id pub-id-type="pmid">27679556</pub-id><pub-id pub-id-type="pmcid">PMC5020102</pub-id></element-citation></ref><ref id="ref16"><element-citation publication-type="journal" id="cit16"><name name-style="western"><surname>Vuic</surname><given-names>B.</given-names></name><name name-style="western"><surname>Milos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tudor</surname><given-names>L.</given-names></name><name name-style="western"><surname>Konjevod</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nikolac
Perkovic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jazvinscak Jembrek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nedic Erjavec</surname><given-names>G.</given-names></name><name name-style="western"><surname>Svob Strac</surname><given-names>D.</given-names></name><article-title>Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies:
New Insights and Therapeutic Potential</article-title><source>Biomedicines</source><year>2022</year><volume>10</volume><fpage>3000</fpage><pub-id pub-id-type="doi">10.3390/biomedicines10123000</pub-id><pub-id pub-id-type="pmid">36551756</pub-id><pub-id pub-id-type="pmcid">PMC9775106</pub-id></element-citation></ref><ref id="ref17"><element-citation publication-type="journal" id="cit17"><name name-style="western"><surname>Rom</surname><given-names>S.</given-names></name><name name-style="western"><surname>Persidsky</surname><given-names>Y.</given-names></name><article-title>Cannabinoid
Receptor 2: Potential Role in Immunomodulation
and Neuroinflammation</article-title><source>J. Neuroimmune Pharmacol.</source><year>2013</year><volume>8</volume><fpage>608</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1007/s11481-013-9445-9</pub-id><pub-id pub-id-type="pmid">23471521</pub-id><pub-id pub-id-type="pmcid">PMC3663904</pub-id></element-citation></ref><ref id="ref18"><element-citation publication-type="journal" id="cit18"><name name-style="western"><surname>Ehrhart</surname><given-names>J.</given-names></name><name name-style="western"><surname>Obregon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mori</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shytle</surname><given-names>R. D.</given-names></name><article-title>Stimulation
of Cannabinoid Receptor 2 (CB2) Suppresses Microglial Activation</article-title><source>J. Neuroinflammation</source><year>2005</year><volume>2</volume><elocation-id>29</elocation-id><pub-id pub-id-type="doi">10.1186/1742-2094-2-29</pub-id><pub-id pub-id-type="pmid">16343349</pub-id><pub-id pub-id-type="pmcid">PMC1352348</pub-id></element-citation></ref><ref id="ref19"><element-citation publication-type="journal" id="cit19"><name name-style="western"><surname>Intranuovo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brunetti</surname><given-names>L.</given-names></name><name name-style="western"><surname>DelRe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mangiatordi</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Stefanachi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Laghezza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Niso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leonetti</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loiodice</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ligresti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kostrzewa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Brea</surname><given-names>J.</given-names></name><name name-style="western"><surname>Loza</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Sotelo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saviano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Colabufo</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Riganti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Abate</surname><given-names>C.</given-names></name><name name-style="western"><surname>Contino</surname><given-names>M.</given-names></name><article-title>Development
of N-(1-Adamantyl)&#173;Benzamides as Novel Anti-Inflammatory Multitarget
Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and
Fatty Acid Amide Hydrolase</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>235</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01084</pub-id><pub-id pub-id-type="pmid">36542836</pub-id></element-citation></ref><ref id="ref20"><element-citation publication-type="journal" id="cit20"><name name-style="western"><surname>Graziano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Delre</surname><given-names>P.</given-names></name><name name-style="western"><surname>Carofiglio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Brea</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ligresti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kostrzewa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riganti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gio&#232;-Gallo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Majellaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nicolotti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Colabufo</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Abate</surname><given-names>C.</given-names></name><name name-style="western"><surname>Loza</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Sotelo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mangiatordi</surname><given-names>G. F.</given-names></name><name name-style="western"><surname>Contino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stefanachi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Leonetti</surname><given-names>F.</given-names></name><article-title>N-Adamantyl-Anthranil
Amide Derivatives: New Selective Ligands for the Cannabinoid Receptor
Subtype 2 (CB2R)</article-title><source>Eur. J. Med. Chem.</source><year>2023</year><volume>248</volume><elocation-id>115109</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115109</pub-id><pub-id pub-id-type="pmid">36657299</pub-id></element-citation></ref><ref id="ref21"><element-citation publication-type="journal" id="cit21"><name name-style="western"><surname>Whiting</surname><given-names>P. F.</given-names></name><name name-style="western"><surname>Wolff</surname><given-names>R. F.</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Nisio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A. V.</given-names></name><name name-style="western"><surname>Keurentjes</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Misso</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ryder</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmidlkofer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Westwood</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kleijnen</surname><given-names>J.</given-names></name><article-title>Cannabinoids
for Medical Use: A Systematic Review and Meta-Analysis</article-title><source>JAMA</source><year>2015</year><volume>313</volume><fpage>2456</fpage><lpage>2473</lpage><pub-id pub-id-type="doi">10.1001/jama.2015.6358</pub-id><pub-id pub-id-type="pmid">26103030</pub-id></element-citation></ref><ref id="ref22"><element-citation publication-type="journal" id="cit22"><name name-style="western"><surname>Morales</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hernandez-Folgado</surname><given-names>L.</given-names></name><name name-style="western"><surname>Goya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jagerovic</surname><given-names>N.</given-names></name><article-title>Cannabinoid
Receptor 2 (CB2) Agonists and Antagonists: A Patent Update</article-title><source>Expert Opin. Ther. Pat.</source><year>2016</year><volume>26</volume><fpage>843</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.1080/13543776.2016.1193157</pub-id><pub-id pub-id-type="pmid">27215781</pub-id></element-citation></ref><ref id="ref23"><element-citation publication-type="journal" id="cit23"><name name-style="western"><surname>Kendall</surname><given-names>D. A.</given-names></name><name name-style="western"><surname>Yudowski</surname><given-names>G. A.</given-names></name><article-title>Cannabinoid Receptors in the Central
Nervous System:
Their Signaling and Roles in Disease</article-title><source>Front.
Cell. Neurosci.</source><year>2017</year><volume>10</volume><fpage>294</fpage><pub-id pub-id-type="doi">10.3389/fncel.2016.00294</pub-id><pub-id pub-id-type="pmid">28101004</pub-id><pub-id pub-id-type="pmcid">PMC5209363</pub-id></element-citation></ref><ref id="ref24"><element-citation publication-type="journal" id="cit24"><name name-style="western"><surname>Pertwee</surname><given-names>R. G.</given-names></name><article-title>Targeting
the Endocannabinoid System with Cannabinoid Receptor Agonists: Pharmacological
Strategies and Therapeutic Possibilities</article-title><source>Philos.
Trans. R. Soc., B</source><year>2012</year><volume>367</volume><fpage>3353</fpage><lpage>3363</lpage><pub-id pub-id-type="doi">10.1098/rstb.2011.0381</pub-id><pub-id pub-id-type="pmcid">PMC3481523</pub-id><pub-id pub-id-type="pmid">23108552</pub-id></element-citation></ref><ref id="ref25"><element-citation publication-type="journal" id="cit25"><name name-style="western"><surname>Shafi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>A. J.</given-names></name><name name-style="western"><surname>Sumnall</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Tracy</surname><given-names>D. K.</given-names></name><article-title>New Psychoactive
Substances: A Review and Updates</article-title><source>Ther. Adv.
Psychopharmacol.</source><year>2020</year><volume>10</volume><elocation-id>2045125320967197</elocation-id><pub-id pub-id-type="doi">10.1177/2045125320967197</pub-id><pub-id pub-id-type="pmid">33414905</pub-id><pub-id pub-id-type="pmcid">PMC7750892</pub-id></element-citation></ref><ref id="ref26"><element-citation publication-type="journal" id="cit26"><name name-style="western"><surname>Zapata</surname><given-names>F.</given-names></name><name name-style="western"><surname>Matey</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Montalvo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Garc&#237;a-Ruiz</surname><given-names>C.</given-names></name><article-title>Chemical Classification
of New Psychoactive Substances (NPS)</article-title><source>Microchem.
J.</source><year>2021</year><volume>163</volume><elocation-id>105877</elocation-id><pub-id pub-id-type="doi">10.1016/j.microc.2020.105877</pub-id></element-citation></ref><ref id="ref27"><element-citation publication-type="journal" id="cit27"><name name-style="western"><surname>Abbate</surname><given-names>V.</given-names></name><name name-style="western"><surname>Schwenk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Presley</surname><given-names>B. C.</given-names></name><name name-style="western"><surname>Uchiyama</surname><given-names>N.</given-names></name><article-title>The Ongoing Challenge
of Novel Psychoactive Drugs of Abuse. Part I. Synthetic Cannabinoids
(IUPAC Technical Report)</article-title><source>Pure Appl. Chem.</source><year>2018</year><volume>90</volume><fpage>1255</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1515/pac-2017-0605</pub-id></element-citation></ref><ref id="ref28"><mixed-citation publication-type="book" id="cit28"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Banister</surname>, <given-names>S. D.</given-names></string-name>; <string-name name-style="western"><surname>Connor</surname>, <given-names>M.</given-names></string-name></person-group><article-title>The Chemistry
and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New
Psychoactive Substances: Origins</article-title>. In <source>New Psychoactive
Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology</source>; <person-group person-group-type="editor"><string-name name-style="western"><surname>Maurer</surname>, <given-names>H. H.</given-names></string-name>; <string-name name-style="western"><surname>Brandt</surname>, <given-names>S. D.</given-names></string-name></person-group>, Eds.; <publisher-name>Springer International Publishing</publisher-name>: <publisher-loc>Cham</publisher-loc>, <year>2018</year>; pp <fpage>165</fpage>&#8211;<lpage>190</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/164_2018_143</pub-id><pub-id pub-id-type="pmid">29980914</pub-id></mixed-citation></ref><ref id="ref29"><element-citation publication-type="journal" id="cit29"><name name-style="western"><surname>Gio&#233;-Gallo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ortigueira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brea</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ra&#239;ch</surname><given-names>I.</given-names></name><name name-style="western"><surname>Azuaje</surname><given-names>J.</given-names></name><name name-style="western"><surname>Paleo</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Majellaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loza</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>C. O.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mera</surname><given-names>X.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sotelo</surname><given-names>E.</given-names></name><article-title>Pharmacological Insights Emerging
from the Characterization of a Large Collection of Synthetic Cannabinoid
Receptor Agonists Designer Drugs</article-title><source>Biomed. Pharmacother.</source><year>2023</year><volume>164</volume><elocation-id>114934</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114934</pub-id><pub-id pub-id-type="pmid">37236027</pub-id></element-citation></ref><ref id="ref30"><element-citation publication-type="journal" id="cit30"><name name-style="western"><surname>Moir</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>F.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hibbs</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Kassiou</surname><given-names>M.</given-names></name><article-title>Strategies to Develop
Selective CB2 Receptor Agonists
from Indole Carboxamide Synthetic Cannabinoids</article-title><source>Eur. J. Med. Chem.</source><year>2019</year><volume>180</volume><fpage>291</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2019.07.036</pub-id><pub-id pub-id-type="pmid">31319265</pub-id></element-citation></ref><ref id="ref31"><element-citation publication-type="journal" id="cit31"><name name-style="western"><surname>Claveria-Gimeno</surname><given-names>R.</given-names></name><name name-style="western"><surname>Vega</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abian</surname><given-names>O.</given-names></name><name name-style="western"><surname>Velazquez-Campoy</surname><given-names>A.</given-names></name><article-title>A Look at
Ligand Binding Thermodynamics in Drug Discovery</article-title><source>Expert Opin. Drug Discovery</source><year>2017</year><volume>12</volume><fpage>363</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1080/17460441.2017.1297418</pub-id><pub-id pub-id-type="pmid">28276703</pub-id></element-citation></ref><ref id="ref32"><element-citation publication-type="journal" id="cit32"><name name-style="western"><surname>Freire</surname><given-names>E.</given-names></name><article-title>Do Enthalpy
and Entropy Distinguish First in Class from Best in Class?</article-title><source>Drug Discovery Today</source><year>2008</year><volume>13</volume><fpage>869</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2008.07.005</pub-id><pub-id pub-id-type="pmid">18703160</pub-id><pub-id pub-id-type="pmcid">PMC2581116</pub-id></element-citation></ref><ref id="ref33"><element-citation publication-type="journal" id="cit33"><name name-style="western"><surname>Lovering</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bikker</surname><given-names>J.</given-names></name><name name-style="western"><surname>Humblet</surname><given-names>C.</given-names></name><article-title>Escape from Flatland:
Increasing
Saturation as an Approach to Improving Clinical Success</article-title><source>J. Med. Chem.</source><year>2009</year><volume>52</volume><fpage>6752</fpage><lpage>6756</lpage><pub-id pub-id-type="doi">10.1021/jm901241e</pub-id><pub-id pub-id-type="pmid">19827778</pub-id></element-citation></ref><ref id="ref34"><element-citation publication-type="journal" id="cit34"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>N. S.</given-names></name><article-title>Rational Design of Inhibitors That Bind to Inactive
Kinase Conformations</article-title><source>Nat. Chem. Biol.</source><year>2006</year><volume>2</volume><fpage>358</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1038/nchembio799</pub-id><pub-id pub-id-type="pmid">16783341</pub-id></element-citation></ref><ref id="ref35"><element-citation publication-type="journal" id="cit35"><name name-style="western"><surname>Ghosh</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Chapsal</surname><given-names>B. D.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>I. T.</given-names></name><name name-style="western"><surname>Mitsuya</surname><given-names>H.</given-names></name><article-title>Design of HIV Protease
Inhibitors Targeting Protein Backbone: An Effective Strategy for Combating
Drug Resistance</article-title><source>Acc. Chem. Res.</source><year>2008</year><volume>41</volume><fpage>78</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1021/ar7001232</pub-id><pub-id pub-id-type="pmid">17722874</pub-id></element-citation></ref><ref id="ref36"><element-citation publication-type="journal" id="cit36"><name name-style="western"><surname>van
de Waterbeemd</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gifford</surname><given-names>E.</given-names></name><article-title>ADMET in Silico Modelling: Towards
Prediction Paradise?</article-title><source>Nat. Rev. Drug Discovery</source><year>2003</year><volume>2</volume><fpage>192</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1038/nrd1032</pub-id><pub-id pub-id-type="pmid">12612645</pub-id></element-citation></ref><ref id="ref37"><element-citation publication-type="journal" id="cit37"><name name-style="western"><surname>Daina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name><article-title>SwissADME: A Free Web Tool to Evaluate
Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness
of Small Molecules</article-title><source>Sci. Rep.</source><year>2017</year><volume>7</volume><elocation-id>42717</elocation-id><pub-id pub-id-type="doi">10.1038/srep42717</pub-id><pub-id pub-id-type="pmid">28256516</pub-id><pub-id pub-id-type="pmcid">PMC5335600</pub-id></element-citation></ref><ref id="ref38"><element-citation publication-type="journal" id="cit38"><name name-style="western"><surname>Veber</surname><given-names>D. F.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>H.-Y.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B. R.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>K. W.</given-names></name><name name-style="western"><surname>Kopple</surname><given-names>K. D.</given-names></name><article-title>Molecular Properties That Influence the Oral Bioavailability
of Drug Candidates</article-title><source>J. Med. Chem.</source><year>2002</year><volume>45</volume><fpage>2615</fpage><lpage>2623</lpage><pub-id pub-id-type="doi">10.1021/jm020017n</pub-id><pub-id pub-id-type="pmid">12036371</pub-id></element-citation></ref><ref id="ref39"><element-citation publication-type="journal" id="cit39"><name name-style="western"><surname>Wu</surname><given-names>Y.-r.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Y.</given-names></name><article-title>Rational Drug
Design of CB2 Receptor Ligands: From 2012 to 2021</article-title><source>RSC Adv.</source><year>2022</year><volume>12</volume><fpage>35242</fpage><lpage>35259</lpage><pub-id pub-id-type="doi">10.1039/D2RA05661E</pub-id><pub-id pub-id-type="pmid">36540233</pub-id><pub-id pub-id-type="pmcid">PMC9730932</pub-id></element-citation></ref><ref id="ref40"><element-citation publication-type="journal" id="cit40"><name name-style="western"><surname>Han</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thatte</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buzard</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>R. M.</given-names></name><article-title>Therapeutic Utility
of Cannabinoid Receptor Type 2 (CB2) Selective Agonists</article-title><source>J. Med. Chem.</source><year>2013</year><volume>56</volume><fpage>8224</fpage><lpage>8256</lpage><pub-id pub-id-type="doi">10.1021/jm4005626</pub-id><pub-id pub-id-type="pmid">23865723</pub-id></element-citation></ref><ref id="ref41"><element-citation publication-type="journal" id="cit41"><name name-style="western"><surname>Brandon</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Baginski</surname><given-names>S. R.</given-names></name><name name-style="western"><surname>Peet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dugard</surname><given-names>P.</given-names></name><name name-style="western"><surname>Green</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sutcliffe</surname><given-names>O. B.</given-names></name><name name-style="western"><surname>Da&#233;id</surname><given-names>N. N.</given-names></name><name name-style="western"><surname>Nisbet</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Read</surname><given-names>K. D.</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>C.</given-names></name><article-title>Log D7.4 and Plasma Protein Binding of Synthetic Cannabinoid
Receptor Agonists and a Comparison of Experimental and Predicted Lipophilicity</article-title><source>Drug Test. Anal.</source><year>2024</year><volume>16</volume><fpage>1012</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1002/dta.3621</pub-id><pub-id pub-id-type="pmid">38062938</pub-id></element-citation></ref><ref id="ref42"><element-citation publication-type="journal" id="cit42"><name name-style="western"><surname>Daina</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zoete</surname><given-names>V.</given-names></name><article-title>A BOILED-Egg To Predict Gastrointestinal Absorption and Brain Penetration
of Small Molecules</article-title><source>ChemMedChem</source><year>2016</year><volume>11</volume><fpage>1117</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201600182</pub-id><pub-id pub-id-type="pmid">27218427</pub-id><pub-id pub-id-type="pmcid">PMC5089604</pub-id></element-citation></ref><ref id="ref43"><element-citation publication-type="journal" id="cit43"><name name-style="western"><surname>Wager</surname><given-names>T. T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Verhoest</surname><given-names>P. R.</given-names></name><name name-style="western"><surname>Villalobos</surname><given-names>A.</given-names></name><article-title>Moving beyond Rules: The Development
of a Central Nervous System Multiparameter Optimization (CNS MPO)
Approach To Enable Alignment of Druglike Properties</article-title><source>ACS Chem. Neurosci.</source><year>2010</year><volume>1</volume><fpage>435</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1021/cn100008c</pub-id><pub-id pub-id-type="pmid">22778837</pub-id><pub-id pub-id-type="pmcid">PMC3368654</pub-id></element-citation></ref><ref id="ref44"><mixed-citation publication-type="weblink" id="cit44"><article-title>RDKit: Open-Source Cheminformatics</article-title>. <uri xlink:href="https://www.rdkit.org">https://www.rdkit.org</uri>.</mixed-citation></ref><ref id="ref45"><element-citation publication-type="journal" id="cit45"><name name-style="western"><surname>Caputo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Corbetta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Piccolo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Vigo</surname><given-names>D.</given-names></name><article-title>Seeking for
Selectivity
and Efficiency: New Approaches in the Synthesis of Raltegravir</article-title><source>Org. Process Res. Dev.</source><year>2020</year><volume>24</volume><fpage>1149</fpage><lpage>1156</lpage><pub-id pub-id-type="doi">10.1021/acs.oprd.0c00155</pub-id></element-citation></ref><ref id="ref46"><element-citation publication-type="journal" id="cit46"><name name-style="western"><surname>Hua</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Iliopoulos-Tsoutsouvas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Brust</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Nikas</surname><given-names>S. P.</given-names></name><name name-style="western"><surname>Song</surname><given-names>F.</given-names></name><name name-style="western"><surname>Song</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grim</surname><given-names>T. W.</given-names></name><name name-style="western"><surname>Benchama</surname><given-names>O.</given-names></name><name name-style="western"><surname>Stahl</surname><given-names>E. L.</given-names></name><name name-style="western"><surname>Zvonok</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bohn</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Makriyannis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.-J.</given-names></name><article-title>Activation and Signaling Mechanism
Revealed by Cannabinoid
Receptor-Gi Complex Structures</article-title><source>Cell</source><year>2020</year><volume>180</volume><fpage>655</fpage><lpage>665.e18</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.01.008</pub-id><pub-id pub-id-type="pmid">32004463</pub-id><pub-id pub-id-type="pmcid">PMC7898353</pub-id></element-citation></ref><ref id="ref47"><element-citation publication-type="journal" id="cit47"><name name-style="western"><surname>Genheden</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ryde</surname><given-names>U.</given-names></name><article-title>The MM/PBSA and MM/GBSA
Methods to Estimate Ligand-Binding Affinities</article-title><source>Expert Opin. Drug Discovery</source><year>2015</year><volume>10</volume><fpage>449</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1517/17460441.2015.1032936</pub-id><pub-id pub-id-type="pmcid">PMC4487606</pub-id><pub-id pub-id-type="pmid">25835573</pub-id></element-citation></ref><ref id="ref48"><element-citation publication-type="journal" id="cit48"><name name-style="western"><surname>Kenakin</surname><given-names>T.</given-names></name><article-title>Biased Receptor
Signaling in Drug Discovery</article-title><source>Pharmacol. Rev.</source><year>2019</year><volume>71</volume><fpage>267</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1124/pr.118.016790</pub-id><pub-id pub-id-type="pmid">30914442</pub-id></element-citation></ref><ref id="ref49"><element-citation publication-type="journal" id="cit49"><name name-style="western"><surname>Morales</surname><given-names>P.</given-names></name><name name-style="western"><surname>Scharf</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Bermudez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Egyed</surname><given-names>A.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>O. K.</given-names></name><name name-style="western"><surname>Jagerovic</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jakub&#237;k</surname><given-names>J.</given-names></name><name name-style="western"><surname>Keser&#369;</surname><given-names>G. M.</given-names></name><name name-style="western"><surname>Kiss</surname><given-names>D. J.</given-names></name><name name-style="western"><surname>Kozielewicz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>O.</given-names></name><name name-style="western"><surname>Majellaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mallo-Abreu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Prieto-D&#237;az</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rosenkilde</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Sotelo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Stark</surname><given-names>H.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wingler</surname><given-names>L. M.</given-names></name><article-title>Progress
on the Development of Class A GPCR-Biased Ligands</article-title><source>Br. J. Pharmacol.</source><year>2024</year><volume>182</volume><issue>14</issue><fpage>3249</fpage><lpage>3300</lpage><pub-id pub-id-type="doi">10.1111/bph.17301</pub-id><pub-id pub-id-type="pmid">39261899</pub-id></element-citation></ref><ref id="ref50"><element-citation publication-type="journal" id="cit50"><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W.</given-names></name><name name-style="western"><surname>McCorvy</surname><given-names>J. D.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>J.</given-names></name><article-title>Biased Ligands of G Protein-Coupled
Receptors (GPCRs): Structure&#8211;Functional Selectivity Relationships
(SFSRs) and Therapeutic Potential</article-title><source>J. Med. Chem.</source><year>2018</year><volume>61</volume><fpage>9841</fpage><lpage>9878</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00435</pub-id><pub-id pub-id-type="pmid">29939744</pub-id></element-citation></ref><ref id="ref51"><element-citation publication-type="journal" id="cit51"><name name-style="western"><surname>Kolb</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kenakin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>S. P. H.</given-names></name><name name-style="western"><surname>Bermudez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bohn</surname><given-names>L. M.</given-names></name><name name-style="western"><surname>Breinholt</surname><given-names>C. S.</given-names></name><name name-style="western"><surname>Bouvier</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Kostenis</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martemyanov</surname><given-names>K. A.</given-names></name><name name-style="western"><surname>Neubig</surname><given-names>R. R.</given-names></name><name name-style="western"><surname>Onaran</surname><given-names>H. O.</given-names></name><name name-style="western"><surname>Rajagopal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Roth</surname><given-names>B. L.</given-names></name><name name-style="western"><surname>Selent</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>A. K.</given-names></name><name name-style="western"><surname>Sommer</surname><given-names>M. E.</given-names></name><name name-style="western"><surname>Gloriam</surname><given-names>D. E.</given-names></name><article-title>Community Guidelines for GPCR Ligand Bias: IUPHAR Review
32</article-title><source>Br. J. Pharmacol.</source><year>2022</year><volume>179</volume><fpage>3651</fpage><lpage>3674</lpage><pub-id pub-id-type="doi">10.1111/bph.15811</pub-id><pub-id pub-id-type="pmid">35106752</pub-id><pub-id pub-id-type="pmcid">PMC7612872</pub-id></element-citation></ref><ref id="ref52"><element-citation publication-type="journal" id="cit52"><name name-style="western"><surname>Li</surname><given-names>A. P.</given-names></name><article-title>In Vitro
Approaches to Evaluate ADMET Drug Properties</article-title><source>Curr. Top. Med. Chem.</source><year>2004</year><volume>4</volume><fpage>701</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.2174/1568026043451050</pub-id><pub-id pub-id-type="pmid">15032683</pub-id></element-citation></ref><ref id="ref53"><element-citation publication-type="journal" id="cit53"><name name-style="western"><surname>Pardridge</surname><given-names>W. M.</given-names></name><article-title>Drug Transport
across the Blood&#8211;Brain Barrier</article-title><source>J. Cereb.
Blood Flow Metab.</source><year>2012</year><volume>32</volume><fpage>1959</fpage><lpage>1972</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.2012.126</pub-id><pub-id pub-id-type="pmid">22929442</pub-id><pub-id pub-id-type="pmcid">PMC3494002</pub-id></element-citation></ref><ref id="ref54"><element-citation publication-type="journal" id="cit54"><name name-style="western"><surname>Feng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Doran</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Di</surname><given-names>L.</given-names></name><name name-style="western"><surname>West</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Osgood</surname><given-names>S. M.</given-names></name><name name-style="western"><surname>Mancuso</surname><given-names>J. Y.</given-names></name><name name-style="western"><surname>Shaffer</surname><given-names>C. L.</given-names></name><name name-style="western"><surname>Tremaine</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liras</surname><given-names>J.</given-names></name><article-title>Prediction
of Human Brain Penetration of P-Glycoprotein and Breast Cancer Resistance
Protein Substrates Using In Vitro Transporter Studies and Animal Models</article-title><source>J. Pharm. Sci.</source><year>2018</year><volume>107</volume><fpage>2225</fpage><lpage>2235</lpage><pub-id pub-id-type="doi">10.1016/j.xphs.2018.03.018</pub-id><pub-id pub-id-type="pmid">29608887</pub-id></element-citation></ref><ref id="ref55"><element-citation publication-type="journal" id="cit55"><name name-style="western"><surname>Zhou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>Y.-X.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>R.-T.</given-names></name><article-title>Astrocyte Morphology:
Diversity,
Plasticity, and Role in Neurological Diseases</article-title><source>CNS Neurosci. Ther.</source><year>2019</year><volume>25</volume><fpage>665</fpage><lpage>673</lpage><pub-id pub-id-type="doi">10.1111/cns.13123</pub-id><pub-id pub-id-type="pmid">30929313</pub-id><pub-id pub-id-type="pmcid">PMC6515705</pub-id></element-citation></ref><ref id="ref56"><element-citation publication-type="journal" id="cit56"><name name-style="western"><surname>Andr&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gonthier</surname><given-names>M.-P.</given-names></name><article-title>The Endocannabinoid System: Its Roles in Energy Balance
and Potential as a Target for Obesity Treatment</article-title><source>Int. J. Biochem. Cell Biol.</source><year>2010</year><volume>42</volume><fpage>1788</fpage><lpage>1801</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2010.06.002</pub-id><pub-id pub-id-type="pmid">20541029</pub-id></element-citation></ref><ref id="ref57"><element-citation publication-type="journal" id="cit57"><name name-style="western"><surname>Hanu&#353;</surname><given-names>L.</given-names></name><name name-style="western"><surname>Breuer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tchilibon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shiloah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Goldenberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Horowitz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pertwee</surname><given-names>R. G.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Mechoulam</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fride</surname><given-names>E.</given-names></name><article-title>HU-308: A Specific
Agonist for CB2, a Peripheral Cannabinoid Receptor</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><year>1999</year><volume>96</volume><fpage>14228</fpage><lpage>14233</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.25.14228</pub-id><pub-id pub-id-type="pmid">10588688</pub-id><pub-id pub-id-type="pmcid">PMC24419</pub-id></element-citation></ref><ref id="ref58"><element-citation publication-type="journal" id="cit58"><name name-style="western"><surname>Ross</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Brockie</surname><given-names>H. C.</given-names></name><name name-style="western"><surname>Stevenson</surname><given-names>L. A.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>V. L.</given-names></name><name name-style="western"><surname>Templeton</surname><given-names>F.</given-names></name><name name-style="western"><surname>Makriyannis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pertwee</surname><given-names>R. G.</given-names></name><article-title>Agonist-Inverse Agonist Characterization
at CB1 and CB2 Cannabinoid Receptors of L759633, L759656 and AM630</article-title><source>Br. J. Pharmacol.</source><year>1999</year><volume>126</volume><fpage>665</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0702351</pub-id><pub-id pub-id-type="pmid">10188977</pub-id><pub-id pub-id-type="pmcid">PMC1565857</pub-id></element-citation></ref><ref id="ref59"><element-citation publication-type="journal" id="cit59"><name name-style="western"><surname>Mlost</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kostrzewa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Borczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bryk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chwastek</surname><given-names>J.</given-names></name><name name-style="western"><surname>Korosty&#324;ski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Starowicz</surname><given-names>K.</given-names></name><article-title>CB2 Agonism Controls Pain and Subchondral
Bone Degeneration Induced by Mono-Iodoacetate: Implications GPCR Functional
Bias and Tolerance Development</article-title><source>Biomed. Pharmacother.</source><year>2021</year><volume>136</volume><elocation-id>111283</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2021.111283</pub-id><pub-id pub-id-type="pmid">33482616</pub-id></element-citation></ref><ref id="ref60"><element-citation publication-type="journal" id="cit60"><name name-style="western"><surname>Soethoudt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grether</surname><given-names>U.</given-names></name><name name-style="western"><surname>Fingerle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Grim</surname><given-names>T. W.</given-names></name><name name-style="western"><surname>Fezza</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Petrocellis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ullmer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rothenh&#228;usler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Perret</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Gils</surname><given-names>N.</given-names></name><name name-style="western"><surname>Finlay</surname><given-names>D.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chicca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gens</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mastrangelo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Alachouzos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Baggelaar</surname><given-names>M. P.</given-names></name><name name-style="western"><surname>Martella</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mock</surname><given-names>E. D.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Heitman</surname><given-names>L. H.</given-names></name><name name-style="western"><surname>Connor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Marzo</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gertsch</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lichtman</surname><given-names>A. H.</given-names></name><name name-style="western"><surname>Maccarrone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pacher</surname><given-names>P.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Stelt</surname><given-names>M.</given-names></name><article-title>Cannabinoid CB2 Receptor Ligand Profiling Reveals Biased
Signalling and Off-Target Activity</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><elocation-id>13958</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms13958</pub-id><pub-id pub-id-type="pmid">28045021</pub-id><pub-id pub-id-type="pmcid">PMC5216056</pub-id></element-citation></ref><ref id="ref61"><element-citation publication-type="journal" id="cit61"><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>S. W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>N.</given-names></name><article-title>Involvement
of &#946;-Arrestin-2
and Clathrin in Agonist-Mediated Internalization of the Human Cannabinoid
CB2 Receptor</article-title><source>Curr. Mol. Pharmacol.</source><year>2015</year><volume>7</volume><fpage>67</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.2174/1874467207666140714115824</pub-id><pub-id pub-id-type="pmid">25023974</pub-id></element-citation></ref><ref id="ref62"><element-citation publication-type="journal" id="cit62"><name name-style="western"><surname>Cabral</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Griffin-Thomas</surname><given-names>L.</given-names></name><article-title>Emerging Role
of the Cannabinoid Receptor CB2 in Immune
Regulation: Therapeutic Prospects for Neuroinflammation</article-title><source>Expert Rev. Mol. Med.</source><year>2009</year><volume>11</volume><elocation-id>e3</elocation-id><pub-id pub-id-type="doi">10.1017/S1462399409000957</pub-id><pub-id pub-id-type="pmid">19152719</pub-id><pub-id pub-id-type="pmcid">PMC2768535</pub-id></element-citation></ref><ref id="ref63"><element-citation publication-type="journal" id="cit63"><name name-style="western"><surname>Bala</surname><given-names>K.</given-names></name><name name-style="western"><surname>Porel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aran</surname><given-names>K. R.</given-names></name><article-title>Emerging
Roles of Cannabinoid Receptor
CB2 Receptor in the Central Nervous System: Therapeutic Target for
CNS Disorders</article-title><source>Psychopharmacology</source><year>2024</year><volume>241</volume><fpage>1939</fpage><lpage>1954</lpage><pub-id pub-id-type="doi">10.1007/s00213-024-06683-w</pub-id><pub-id pub-id-type="pmid">39264450</pub-id></element-citation></ref><ref id="ref64"><element-citation publication-type="journal" id="cit64"><name name-style="western"><surname>Benito</surname><given-names>C.</given-names></name><name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tol&#243;n</surname><given-names>R. M.</given-names></name><name name-style="western"><surname>Carrier</surname><given-names>E. J.</given-names></name><name name-style="western"><surname>R&#225;bano</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hillard</surname><given-names>C. J.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>J.</given-names></name><article-title>Cannabinoid CB2 Receptors and Fatty
Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated
Glia in Alzheimer&#8217;s Disease Brains</article-title><source>J.
Neurosci.</source><year>2003</year><volume>23</volume><fpage>11136</fpage><lpage>11141</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-35-11136.2003</pub-id><pub-id pub-id-type="pmid">14657172</pub-id><pub-id pub-id-type="pmcid">PMC6741043</pub-id></element-citation></ref><ref id="ref65"><element-citation publication-type="journal" id="cit65"><name name-style="western"><surname>Yang</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.-T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.-Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.-R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.-F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.-D.</given-names></name><article-title>The Neurotrophic Function of Glucagon-Like Peptide-1
Promotes Human Neuroblastoma Differentiation via the PI3K-AKT Axis</article-title><source>Biology</source><year>2020</year><volume>9</volume><issue>11</issue><fpage>348</fpage><pub-id pub-id-type="doi">10.3390/biology9110348</pub-id><pub-id pub-id-type="pmid">33105690</pub-id><pub-id pub-id-type="pmcid">PMC7690389</pub-id></element-citation></ref><ref id="ref66"><element-citation publication-type="journal" id="cit66"><name name-style="western"><surname>Barbereau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yehya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Silhol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cubedo</surname><given-names>N.</given-names></name><name name-style="western"><surname>Verdier</surname><given-names>J.-M.</given-names></name><name name-style="western"><surname>Maurice</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rossel</surname><given-names>M.</given-names></name><article-title>Neuroprotective
Brain-Derived Neurotrophic
Factor Signaling in the TAU-P301L Tauopathy Zebrafish Model</article-title><source>Pharmacol. Res.</source><year>2020</year><volume>158</volume><elocation-id>104865</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104865</pub-id><pub-id pub-id-type="pmid">32417505</pub-id></element-citation></ref><ref id="ref67"><element-citation publication-type="journal" id="cit67"><name name-style="western"><surname>Al
Kabbani</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zempel</surname><given-names>H.</given-names></name><article-title>Effects of P301L-TAU
on Post-Translational Modifications of Microtubules in Human iPSC-Derived
Cortical Neurons and TAU Transgenic Mice</article-title><source>Neural
Regen. Res.</source><year>2025</year><volume>20</volume><fpage>2348</fpage><lpage>2360</lpage><pub-id pub-id-type="doi">10.4103/NRR.NRR-D-23-01742</pub-id><pub-id pub-id-type="pmid">38934386</pub-id><pub-id pub-id-type="pmcid">PMC11759014</pub-id></element-citation></ref><ref id="ref68"><element-citation publication-type="journal" id="cit68"><name name-style="western"><surname>Guyon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rousseau</surname><given-names>J.</given-names></name><name name-style="western"><surname>B&#233;gin</surname><given-names>F.-G.</given-names></name><name name-style="western"><surname>Bertin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lamothe</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tremblay</surname><given-names>J. P.</given-names></name><article-title>Base Editing Strategy
for Insertion of the A673T Mutation
in the APP Gene to Prevent the Development of AD in Vitro</article-title><source>Mol. Ther. - Nucleic Acids</source><year>2021</year><volume>24</volume><fpage>253</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1016/j.omtn.2021.02.032</pub-id><pub-id pub-id-type="pmid">33815938</pub-id><pub-id pub-id-type="pmcid">PMC7985668</pub-id></element-citation></ref><ref id="ref69"><element-citation publication-type="journal" id="cit69"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fourriere</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gleeson</surname><given-names>P. A.</given-names></name><article-title>Advances in the Cell Biology of the
Trafficking and Processing of Amyloid Precursor Protein: Impact of
Familial Alzheimer&#8217;s Disease Mutations</article-title><source>Biochem. J.</source><year>2024</year><volume>481</volume><fpage>1297</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.1042/BCJ20240056</pub-id><pub-id pub-id-type="pmid">39302110</pub-id><pub-id pub-id-type="pmcid">PMC11555708</pub-id></element-citation></ref><ref id="ref70"><mixed-citation publication-type="book" id="cit70"><person-group person-group-type="allauthors"><string-name name-style="western"><surname>Barro-Fern&#225;ndez</surname>, <given-names>M.</given-names></string-name></person-group><article-title>Development
of a Novel Neuronal-like Phenotypic in Vitro Model of Familial Alzheimer&#8242;s
Using the Human Neuroblastoma-Derived Immortalized Cell Line SHSY-5Y</article-title>. Poster presented in: 41st National Meeting of the Spanish Pharmacological
Society; <publisher-loc>Palma (Spain)</publisher-loc>, <year>2024</year>; October 3rd-5th.</mixed-citation></ref><ref id="ref71"><element-citation publication-type="journal" id="cit71"><name name-style="western"><surname>Navarro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cordom&#237;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brugarolas</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>E.</given-names></name><name name-style="western"><surname>Aguinaga</surname><given-names>D.</given-names></name><name name-style="western"><surname>P&#233;rez-Benito</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ferre</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cort&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casad&#243;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mallol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Canela</surname><given-names>E. I.</given-names></name><name name-style="western"><surname>Llu&#237;s</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>L.</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>R.</given-names></name><article-title>Cross-Communication
between Gi and Gs in a G-Protein-Coupled Receptor Heterotetramer Guided
by a Receptor C-Terminal Domain</article-title><source>BMC Biol.</source><year>2018</year><volume>16</volume><elocation-id>24</elocation-id><pub-id pub-id-type="doi">10.1186/s12915-018-0491-x</pub-id><pub-id pub-id-type="pmid">29486745</pub-id><pub-id pub-id-type="pmcid">PMC6389107</pub-id></element-citation></ref><ref id="ref72"><element-citation publication-type="journal" id="cit72"><name name-style="western"><surname>Hradsky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Raghuram</surname><given-names>V.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P. P.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hupe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casado</surname><given-names>V.</given-names></name><name name-style="western"><surname>McCormick</surname><given-names>P. J.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kreutz</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>Mikhaylova</surname><given-names>M.</given-names></name><article-title>Post-Translational
Membrane Insertion of Tail-Anchored
Transmembrane EF-Hand Ca2+sensor Calneurons Requires the TRC40/Asna1
Protein Chaperone</article-title><source>J. Biol. Chem.</source><year>2011</year><volume>286</volume><fpage>36762</fpage><lpage>36776</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.280339</pub-id><pub-id pub-id-type="pmid">21878631</pub-id><pub-id pub-id-type="pmcid">PMC3196075</pub-id></element-citation></ref><ref id="ref73"><element-citation publication-type="journal" id="cit73"><name name-style="western"><surname>Navarro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferr&#233;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cordomi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mallol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Casad&#243;</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cort&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ortiz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Canela</surname><given-names>E. I.</given-names></name><name name-style="western"><surname>Llu&#237;s</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pardo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Franco</surname><given-names>R.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>A. S.</given-names></name><article-title>Interactions
between Intracellular Domains as Key Determinants
of the Quaternary Structure and Function of Receptor Heteromers</article-title><source>J. Biol. Chem.</source><year>2010</year><volume>285</volume><fpage>27346</fpage><lpage>27359</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.115634</pub-id><pub-id pub-id-type="pmid">20562103</pub-id><pub-id pub-id-type="pmcid">PMC2930733</pub-id></element-citation></ref><ref id="ref74"><element-citation publication-type="journal" id="cit74"><name name-style="western"><surname>Prieto-D&#237;az</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gonz&#225;lez-G&#243;mez</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fojo-Carballo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Azuaje</surname><given-names>J.</given-names></name><name name-style="western"><surname>El Maatougui</surname><given-names>A.</given-names></name><name name-style="western"><surname>Majellaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loza</surname><given-names>M. I.</given-names></name><name name-style="western"><surname>Brea</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Due&#241;as</surname><given-names>V.</given-names></name><name name-style="western"><surname>Paleo</surname><given-names>M. R.</given-names></name><name name-style="western"><surname>D&#237;az-Holgu&#237;n</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garcia-Pinel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mallo-Abreu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Est&#233;vez</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>And&#250;jar-Arias</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garc&#237;a-Mera</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gomez-Tourino</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ciruela</surname><given-names>F.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>C. O.</given-names></name><name name-style="western"><surname>Guti&#233;rrez-de-Ter&#225;n</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sotelo</surname><given-names>E.</given-names></name><article-title>Exploring the Effect
of Halogenation in a Series of Potent and Selective A2B Adenosine
Receptor Antagonists</article-title><source>J. Med. Chem.</source><year>2023</year><volume>66</volume><fpage>890</fpage><lpage>912</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.2c01768</pub-id><pub-id pub-id-type="pmid">36517209</pub-id><pub-id pub-id-type="pmcid">PMC9841532</pub-id></element-citation></ref><ref id="ref75"><element-citation publication-type="journal" id="cit75"><name name-style="western"><surname>Miciaccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Centonze</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cavallaro</surname><given-names>G.</given-names></name><name name-style="western"><surname>Contino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Armenise</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baldelli</surname><given-names>O. M.</given-names></name><name name-style="western"><surname>Solidoro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ferorelli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scarcia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Agrimi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zingales</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cimetta</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ronsisvalle</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sipala</surname><given-names>F. M.</given-names></name><name name-style="western"><surname>Polosa</surname><given-names>P. L.</given-names></name><name name-style="western"><surname>Fortuna</surname><given-names>C. G.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Scilimati</surname><given-names>A.</given-names></name><article-title>Harmaline
to Human Mitochondrial Caseinolytic Serine Protease Activation for
Pediatric Diffuse Intrinsic Pontine Glioma Treatment</article-title><source>Pharmaceuticals</source><year>2024</year><volume>17</volume><fpage>135</fpage><pub-id pub-id-type="doi">10.3390/ph17010135</pub-id><pub-id pub-id-type="pmid">38276008</pub-id><pub-id pub-id-type="pmcid">PMC10821046</pub-id></element-citation></ref><ref id="ref76"><element-citation publication-type="journal" id="cit76"><name name-style="western"><surname>Braconi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dei</surname><given-names>S.</given-names></name><name name-style="western"><surname>Contino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riganti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bartolucci</surname><given-names>G.</given-names></name><name name-style="western"><surname>Manetti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Romanelli</surname><given-names>M. N.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Colabufo</surname><given-names>N. A.</given-names></name><name name-style="western"><surname>Guglielmo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Teodori</surname><given-names>E.</given-names></name><article-title>Tetrazole and Oxadiazole Derivatives
as Bioisosteres of Tariquidar and Elacridar: New Potent P-Gp Modulators
Acting as MDR Reversers</article-title><source>Eur. J. Med. Chem.</source><year>2023</year><volume>259</volume><elocation-id>115716</elocation-id><pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115716</pub-id><pub-id pub-id-type="pmid">37573829</pub-id></element-citation></ref><ref id="ref77"><element-citation publication-type="journal" id="cit77"><name name-style="western"><surname>Contino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guglielmo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Riganti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Antonello</surname><given-names>G.</given-names></name><name name-style="western"><surname>Perrone</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Giampietro</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rolando</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fruttero</surname><given-names>R.</given-names></name><name name-style="western"><surname>Colabufo</surname><given-names>N. A.</given-names></name><article-title>One Molecule Two
Goals: A Selective P-Glycoprotein
Modulator Increases Drug Transport across Gastro-Intestinal Barrier
and Recovers Doxorubicin Toxicity in Multidrug Resistant Cancer Cells</article-title><source>Eur. J. Med. Chem.</source><year>2020</year><volume>208</volume><fpage>112843</fpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2020.112843</pub-id><pub-id pub-id-type="pmid">33007664</pub-id></element-citation></ref><ref id="ref78"><mixed-citation publication-type="other" id="cit78"><article-title>Schr&#246;dinger
2024&#8211;4: Protein Preparation Wizard; Epik; Prime; LigPrep; Glide</article-title>, <year>2024</year>.</mixed-citation></ref><ref id="ref79"><element-citation publication-type="journal" id="cit79"><name name-style="western"><surname>Lu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ghoreishi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Damm</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>G. A.</given-names></name><name name-style="western"><surname>Dahlgren</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Russell</surname><given-names>E.</given-names></name><name name-style="western"><surname>Von Bargen</surname><given-names>C. D.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Friesner</surname><given-names>R. A.</given-names></name><name name-style="western"><surname>Harder</surname><given-names>E. D.</given-names></name><article-title>OPLS4: Improving
Force Field Accuracy on Challenging Regimes of Chemical Space</article-title><source>J. Chem. Theory Comput.</source><year>2021</year><volume>17</volume><fpage>4291</fpage><lpage>4300</lpage><pub-id pub-id-type="doi">10.1021/acs.jctc.1c00302</pub-id><pub-id pub-id-type="pmid">34096718</pub-id></element-citation></ref><ref id="ref80"><element-citation publication-type="journal" id="cit80"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Friesner</surname><given-names>R. A.</given-names></name><article-title>The VSGB 2.0 Model: A next Generation Energy Model
for High Resolution Protein Structure Modeling</article-title><source>Proteins: Struct., Funct., Bioinf.</source><year>2011</year><volume>79</volume><fpage>2794</fpage><lpage>2812</lpage><pub-id pub-id-type="doi">10.1002/prot.23106</pub-id><pub-id pub-id-type="pmcid">PMC3206729</pub-id><pub-id pub-id-type="pmid">21905107</pub-id></element-citation></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>